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Preface 
Symptomatic muscle weakness resulting from inflammation of the muscles is 
considered the clinicopathological essence of inflammatory myopathies (myo­
sitis) [1]. Traditionally these disorders have been divided into those associated 
with known environmental exposures (viruses, bacteria, drugs) and those wit­
hout, the so-called idiopathic forms. The first description of the idiopathic 
forms of myositis dates from more than 100 years ago [2,3]. Polymyositis, der-
matomyositis, and inclusion body myositis are the most frequently occurring 
syndromes in this group. Athough they may have a temporal association with 
the exposure of external agents, notably viruses, as yet these disorders show no 
evident cause-effect relationship between exposure and the pathophysiologic 
mechanisms involved in the development of the inflammation [1]. 
In the idiopathic forms of myositis an autoimmune origin is strongly suggested 
by various lines of evidence: the presence of various autoantibodies, the evi­
dence of myotoxicity mediated by cytotoxic Τ cells (polymyositis) or comple­
ment-mediated microangiopathy (dermatomyositis), their response to immu­
nosuppressive or immunomodulating therapies, and their association with 
diseases of which the autoimmune character has been established more firmly. 
In polymyositis a pathogenic role of cytotoxic Τ cells, acting against a hitherto 
unknown antigen, is generally agreed upon, whereas the possible contribution 
of humoral mechanisms to muscle injury is less clear. As to the initiation of the 
autoimmune processes, serological studies have implicated the enterovirus 
and cardiovirus subgroup of picomaviruses in poly- and dermatomyositis. It 
has been suggested that persistence of viral RNA in muscle occurs in poly- and 
dermatomyositis, in accordance with the hypothesis of virus-induced autoim­
munity. 
In mice viruses have been known to induce autoimmunity. Inoculation of 
various serotypes of Coxsackie В (CB) virus may induce chronic inflammatory 
organ-specific disorders, like СВЗ-induced myocarditis and CB4-induced dia­
betes. Inoculation of the Tucson strain of CB1 virus in neonatal CD1 Swiss mice 
induces chronic inflammatory changes in hind leg muscles, leading to progres­
sive weakness: CBl-induced myositis (CB1 myositis). Since virus can no longer 
be cultured from affected muscles in the chronic phase, CB1 myositis is consi­
dered a virus-induced autoimmune disorder. It does not develop in the absen­
ce of Τ cells, suggesting Τ cell mediated mechanisms to be operative. Given the 
progressive character of hindleg weakness, and the electromyographic and 
histological abnormalities, CB1 myositis is considered a model for polymyosi­
tis. 
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In the first part of this work we describe studies that used the model of CB1 
myositis to study the role of viral persistence and of virus-induced humoral 
and cellular immune responses in the development of chronic inflammatory 
muscle disease. A sensitive polymerase chain reaction (PCR) technique was 
used to determine whether in CB1 myositis chronic inflammation is associated 
with persistence of enteroviral RNA (Chapter 1). As to humoral immune 
mechanisms in CB1 myositis, we examined the role of the virus dose, antiviral 
antibodies, myositis-specific auto-antibodies, circulating immune complexes, 
and complement in the development and maintenance of CB1 myositis 
(Chapters 2 and 3). Then, to obtain histological clues regarding the pathogene-
sis of CB1 myositis, we performed a detailed qualitative and quantitative ana-
lysis of acute and chronic muscle lesions (Chapter 4). To further clarify the con-
tribution of cellular and humoral mechanisms on tissue level we 
immunohistochemically characterized the inflammatory muscle changes, 
paying special attention to lymphocytes subsets and immunoglobulin and 
complement deposits (Chapter 5). In view of a suggested asymmetric hind leg 
involvement in CB1 myositis, we then set ourselves to confirm in a quantitati-
ve way the reported hind leg asymmetry and studied its histopathological 
basis (Chapter 6). Finally, we reviewed the data at present available on CB1 
myositis, discussed possible pathogenic mechanisms and re-assessed the role 
of CB1 myositis as a model for inflammatory muscle disease (Chapter 7). 
In this century neurologists, rheumatologists, internists, dermatologists and 
pediatricians have witnessed the proliferation of important knowledge on the 
various forms of myositis. Yet, we still have no answers to fundamental 
questions, e.g. regarding the antigen(s) against which the immune responses 
are directed. Likewise, in spite of reasonably workable diagnostic criteria and 
treatment schemes, clinicians often cannot offer their patients adequate solu-
tions to specific diagnostic or therapeutic problems. Therefore, the second part 
of this work (human studies) pertains to (a) the possible role of persistent viral 
RNA as an antigenic trigger in polymyositis and dermatomyositis, (b) a further 
refinement of the diagnostic tools in patients suspicious of inflammatory mus-
cle disease, and (c) the study of new treatment modalities in patients resistent 
to conventional immunosuppressive approaches. 
Parallel to the murine study in CB1 myositis, where we looked for enteroviral 
RNA in affected muscles, we performed a PCR on muscle biopsies from poly-
myositis and dermatomyositis patients using primers with high specificity for 
enterovirus and encephalomyocarditis RNA (Chapter 8). 
Abnormalities on electromyography, including changes in motor unit action 
potentials, are a major diagnostic criterium in all forms of myositis. To circum-
vent the pitfalls of subjective assessment of the EMG signal, automatic decom-
position electromyography (ADEMG) has been described by others, enabling 
an objective measurement of large numbers of motor unit action potentials. 
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Although the ADEMG software package is readily available, studies on the 
clinical applicability of ADEMG were lacking. So, we studied the diagnostic 
usefulness of ADEMG in idiopathic inflammatory myopathies (Chapter 9). 
The second diagnostic study dealt with the differential diagnosis of inclusion 
body myositis (IBM). Diagnosis of IBM greatly depends on two characteristic 
pathological features: rimmed basophilic vacuoles on light microscopy, and 
nuclear or cytoplasmic inclusions of 15-24 nm filaments in electron microsco­
pic observation. These abnormalities may, however, also occur in various other 
neuromuscular disorders. Since their incidence in non-IBM disorders was not 
exactly known, their diagnostic significance could be disputed. Therefore, to 
obtain a quantitive morphological criterium for differentiating inclusion body 
myositis from other neuromuscular disorders, we systematically studied the 
rimmed basophilic vacuoles and filamentous inclusions in neuromuscular dis­
orders other than inclusion body myositis (Chapter 10). 
An unfortunate minority of polymyositis patients are very difficult to treat. In 
such patients resistence to immunosuppressive treatment may result in a chro­
nic course with step-wise or relentlessly slow progression. At closer look these 
patients may have the pathological features of inclusion body myositis, whe­
reas patients lacking these morphological abnormalities keep fulfilling the dia­
gnostic criteria of polymyositis. In an attempt to stop gradual impairement we 
treated three of the latter type of patients with cyclosporine A, an immunomo-
dulating agent specifically acting on Τ cell mediated immune reactions. The cli­
nical effects are described in detail (Chapter 11). 
Finally, if in a patient with idiopathic inflammatory muscle disease immuno­
suppressive treatment is not followed by improvement of muscle strength 
after about 3 months, it is common policy to stop the drug. Recent literature 
suggests that, as far as IBM is concerned, this treatment period may be too 
short. Therefore, we treated a patient with IBM and unresponsiveness to 
various cytotoxic drugs with chlorambucil for 3 years, and quantified the effect 
on muscle strength and serum CK concentration. We report the results in 
Chapter 12. 
The experimental work here described was carried out between January 1990 
and July 1994 in the Research Laboratory for Morphological Neurology, 
Department of Neurology and in the Laboratories of the Section Virology, 
Department of Medical Microbiology of the University Hospital Nijmegen, 
and in the Central Animal Laboratory of the Faculty of Medical Sciences of the 
University of Nijmegen. The clinical studies were carried out between 1988 and 
1992 in the Departments of Neurology and of Clinical Neurophysiology of the 
University Hospital Nijmegen. All studies were performed in fulfillment of the 
requirements for the Ph.D. degree. 
I wish to express my gratitude to my advisors prof. Fons Gabreels, prof. Leo 
van de Putte, Henk ter Laak Ph.D., and Jochem Galama Ph.D. for their encou-
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ragement and support, and for their willingness to entrust so much of the deve-
lopment of the project to my judgement, and to prof. Jo Berden for his indis-
pensable help to get the experimental work started. I am greatly indebted to 
Inge Bergmann, Ans Reynen, Freek van Workum, Lilian Eshuis, and Jan 
Koedam for their excellent practical assistence and to Frans Heessen Ph.D. for 
his great expertise and readiness to help. 
Special thanks to the nurses of the neurological out-patient department for 
their pivotal role in the clinical studies, to Henk van Lier M.Sc. for the manifold 
statistical contributions, and to the personal of the Medical Library, who so 
generously provided me with literature. I also thank all other workers and col-
leagues of the abovementioned départements, who are not expressly named 
here, but who contributed to these studies. 
Finally, and above all I am grateful to the patients with inflammatory muscle 
disease for their willingnes to participate and for constantly askmg 'simple' 
questions, thus being my motivation in both the experimental and clinical stu-
dies. 
Nijmegen 
August 1995 
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PARTI 
MURINE STUDIES 

Chapter 1 
Coxsackievirus Bl-induced murine myositis: 
no evidence for viral persistence 
J Zoll, PJH Jongen, JMD Galama, 
F van Kuppeveld, W Melchers 
(Journal of General Virology 1993,74 2071-2076) 
CHAPTTR 1 
Summary 
The persistence of Coxsackievirus Bl in the muscles of mice with 
Coxsackievirus Bl induced chronic myositis was investigated. Neonatal CD1 
Swiss mice were inoculated with a myositis causing variant of Coxsackievirus 
Bl (Tucson strain). Hamstring muscle samples of diseased mice obtained at 
various times after inoculation were examined for the presence of infectious 
virus, viral RNA and histological abnormalities. Viral RNA was detected up to 
4 weeks after initiation of infection, whereas virus could be isolated from ham­
string muscles for up to 2 weeks. Thereafter no sign of infection was demon­
strated although histological abnormalities remained present for the entire 
observation period of 16 weeks. That viral RNA was detectable only for 2 
weeks after tissues became negative for infectious virus suggests that the infec­
tion slowly waned rather than the viral RNA persisting. Hence, it is concluded 
that Coxsackievirus Bl plays an essential role in the initiation of myositis but 
not in the maintenance of the chronic phase. 
Introduction 
Enteroviruses are thought to be involved in the development of chronic disea­
ses such as insulin dependent diabetes mellitus, dilated cardiomyopathy, poly-
myositis/dermatomyositis and postviral fatigue syndrome. It has been sugge­
sted that these diseases are caused by an autoimmune reaction possibly 
triggered by a transient enteroviral infection (Dalakas, 1991; Woodruff, 1980). 
However, during the last decade, several papers have described the detection 
of enteroviral RNA in muscle tissues of patients suffering from dilated cardio­
myopathy (Jin et al., 1990; Kandolf et al., 1987), polymyositis/dermatomyosi-
tis (Bowles et al., 1987), and postviral fatigue syndrome (Youssef et al., 1988), 
after the virus could no longer be isolated. They suggest that persistence of 
viral RNA might be involved in the pathogenesis of these diseases. 
Several animal models have been developed, in which pancreatitis (Velia et al., 
1992), cardiomyopathy (Gauntt et al., 1979) and myositis (Ray et al., 1979) are 
induced by infection with specific strains of Coxsackie В viruses. 
Ray et al. (1979) described a murine model for myositis induced by a 
Coxsackievirus Bl infection of suckling mice. Studies with that model revealed 
evidence that immunological reactions cause the chronic myositis 
(Strongwater et al., 1984; Ytterberg, 1987). However, in recent studies using the 
same murine model it was found that although viral RNA was still present in 
affected muscle fibres no infectious virus could be isolated from these samples 
(Tarn et al., 1991). From this observation it was concluded that Coxsackievirus 
Bl persisted after the acute phase of infection. 
Recently, however, Koide et al. (1992) investigated the role of viral persistence 
during the development of murine cardiomyopathy. In this study the viral 
RNA could not be detected at more than 4 weeks after inoculation. 
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To investigate whether viral persistence indeed plays a pathogenic role in 
Coxsackievirus Bl induced myositis, we examined muscle samples from infec­
ted mice for the presence of infectious virus, viral RNA, and histological abnor­
malities. 
Materials and methods 
Virus strain 
A myotropic Coxsackievirus Bl strain (Tucson strain) causing myositis in CD1 
Swiss mice was kindly provided by L. Minnich and G. Ray, University of 
Arizona, Tucson, Arizona (Ray et al., 1979). The virus was propagated in 
Buffalo Green Monkey kidney (BGM) cells and subsequently stored in aliquots 
at -80°C. 
Animal model 
Pregnant CD1 Swiss mice that were specific pathogen free and random bred 
were purchased from Charles River Wiga GmbH, Sulzfeld, Germany. 
Neonates were randomly chosen from different litters and inoculated intrape-
ritoneally within 24 hours after birth with 1000 plaque forming units (pfu) 
virus in 0.1 ml PBS (P. Jongen, unpublished results). 
Infected mice were randomly divided among the mothers in groups of 10 to 14 
animals. At two weeks after inoculation, infected mice were examined for cli­
nical signs of myositis as abnormal posture and a waddling gait. Animals 
appearing healthy at two weeks after inoculation were excluded from further 
experiments. At 1, 2, 4, 8 and 16 weeks after inoculation, infected mice were 
sacrificed for histological and virological examination. Gluteus, hamstring, 
and quadriceps muscles from both hindlimbs were removed and divided into 
three equal parts each. For histological examination and in situ hybridisation 
one part was placed in buffered formalin, paraffin embedded and sectioned at 
6 ц т . For PCR analysis examination one part was immediatedly frozen into 
liquid nitrogen and stored at -80°C until use. Another part was placed into 1 ml 
of Hanks medium supplemented with 0.1% yeast extract, 0.5% lactalbumine 
hydrolysate, and 0.5% gelatin and stored at -80°C until use for virus isolation. 
Histological examination 
From every muscle sample transverse sections were stained with hematoxylin-
phloxin-saffron (HPS) and examined using a light microscope (magnification 
250x). Sections were read under code. Degrees of mononuclear cell infiltration, 
necrosis, central nuclei, and muscle fibre atrophy were scored using a five-
grade scale (Table 1). 
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Table 1 Semi-quantitative score for histological abnormalities in transverse sections of 
hamstring muscles 
Infiltrating cells 
Necrotic muscle fibres 
Central nuclei 
Atrophic muscle 
0 
0 
0 
0 
0 
1 
<10 
1-5 
< 25% 
< 25% 
Score 
2 
10-50 
5-15 
25-50% 
25-50% 
3 
50-100 
15- 25 
50- 75% 
50- 75% 
4 
>100 
> 25 
75-100% 
75-100% 
In situ hybridisation 
Deparaffinized muscle sections were hybridized as described (Kandolf et al., 
1987). Briefly, before hybridisation the slides were treated with 0.2 N HCl for 
20 min., 2 χ SSC at 70°C for 30 min., 20 mM Tris-HCl pH 7.4,2 mM CaCl,, and 
1 μg/ml proteinase К at 37°C for 15 min. Slides were washed in distilled water 
and dehydrated. 
An infectious Coxsackievirus Bl cDNA clone (kindly provided by Dr. A. 
Nomoto, University of Tokyo, Japan) (Iizuka et al., 1991) was digested with 
Sail. A 7.5 kb fragment representing the entire Coxsackievirus Bl genome was 
purified by agarose gel electrophoresis and subsequently labeled with [x-
fSJthioJ-dCTP by nick translation (Sambrook et al., 1989). Radiolabeled DNA 
fragments of 100 to 400 bp were generated. 
Hybridisation was performed using a mixture containing 200 ng/ml denatu­
red ^-labeled DNA probe in 10 mM Tris-HCl pH7.4, 50% (v/v) formamide, 
0.6 M NaCl, ImM EDTA, 0.02% polyvinylpyrrolidone, 0.02% ficoll, 0.05% bovi­
ne serum albumin, 10% dextransulfate, 10 mM dithiotreitol, 200 μg/ml salmon 
sperm DNA, and 100 μg/ml rabbit liver tRNA. After incubation at 25°C for 36 
h slides were washed at 30°C for 18 h in 10 mM Tris-HCl pH 7.4,2 χ SSC, 50% 
formamide, and 1 mM EDTA followed by 2 χ SSC at 55°C for 1 h. Hybridized 
muscle preparations were autoradiographed as described (Kandolf et al., 1987) 
and Giemsa stained. 
PCR 
RNA was extracted from muscle samples using a single extraction with guan-
idiniumthiocyanate-phenol-chloroform according to the method of 
Chomczynski and Sacchi (1987). Reverse transcriptase reaction and PCR were 
performed according to Zoll et al. (1992). Briefly, cDNA was synthesized in a 
20-μ1 reactions mixture containing 75 mM KCl, 50 mM Tris-HCl (pH 8.3), 3 mM 
MgCl2, 10 mM dithiotreitol, 0.2 mM (each) deoxynucleoside triphosphates 
(Boehringer Mannheim), 50 pmol of antisense oligonucleotide primer (5'-ATT-
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Table 2 Histological and virological examination of hamstring muscles from infected 
mice. 
Weeks after 
infection 
1 
2 
4 
8 
16 
Mouse 
i l l . 
1 
2 
3 
4 
5 
1 
2 
3 
4 
5 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
1 
2 
3 
4 
5 
PCR 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Virus 
titer 
TCIDM 
108.2 
104 0 
104.0 
105.5 
106.5 
-
102.7 
-
101.0 
102.0 
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
infiltrating 
cells 
4 
4 
4 
4 
4 
4 
4 
3 
4 
4 
2 
2 
3 
3 
3 
4 
3 
1 
1 
4 
1 
2 
1 
2 
2 
2 
1 
3 
2 
3 
1 
2 
2 
1 
2 
Histology 
necrosis atrophy 
4 
4 
2 
3 
4 
4 
4 
4 
4 
4 
1 
2 
2 
4 
3 
4 
3 
0 
1 
4 
1 
1 
1 
1 
1 
1 
1 
2 
1 
4 
1 
2 
1 
1 
2 
3 
3 
2 
1 
3 
3 
4 
2 
3 
2 
1 
2 
2 
2 
2 
2 
2 
1 
3 
2 
2 
1 
1 
2 
1 
1 
3 
2 
3 
3 
1 
1 
1 
2 
1 
central 
nuclei 
1 
2 
1 
1 
2 
3 
-
2 
2 
3 
0 
3 
2 
1 
3 
2 
1 
0 
2 
2 
2 
2 
1 
2 
1 
1 
3 
2 
3 
2 
11 
CHAPTER 1 
GTCACCATAAGCAGCCA-3'), 5 units of avian myeloblastosis virus reverse 
transcriptase (Promega), and extracted RNA. After incubation at 37°C for 60 
min., 80 μΐ of the PCR mixture was added. The PCR mixture contained 50 mM 
KCl, 10 mM Tris-HCl (pH 8.9), 3.6 mM MgCl2,0.2 mM (each) deoxynucleoside 
triphosphates, 100 μg of bovine serum albumine per ml, 80 pmol of sense oli­
gonucleotide primer (5'-TCCTCCGGCCCCTGAATGCG-3'), 40 pmol of antis-
ense oligonucleotide primer, and 0.2 units of SuperTaq DNA polymerase (HT 
Biotechnology Ltd, Cambridge, England). RNA-cDNA hybrids were denatu­
red at 94°C during 5 min. The amplification was performed in 40 cycles con­
sisting of denaturation for 1 min at 94°C, primer annealing for 1 min at 42°C 
and elongation for 2 min at 72°C. The reactions were analyzed by electropho­
resis in 2% agarose gels and Southern blot hybridisation. A 32P end-labeled oli­
gonucleotide (5'-AAACACGGACACCCAAAGTA-3') was used as internal 
probe (Zoll et al., 1992). 
Virus isolation 
Muscle samples were homogenized using sterile sand, suspended in 1 ml of 
Earle's medium and titrated in ten-fold dilutions on BGM monolayers in tri­
plicate in a volume of 100 μΐ (Schmidt, 1979). TCID„, values were calculated 
according to Reed and Muench (1938). 
Results 
Animal model 
Neonatal CD1 Swiss mice from 10 litters were intraperitoneally inoculated 
with 1000 pfu Coxsackievirus Bl (Tucson strain) in 0.1 ml PBS. Within the first 
two weeks mortality was 40%, and morbidity, expressed as the percentage of 
surviving animals demonstrating abnormal gait and posture, was 60%. 
Animals appearing healthy at two weeks after inoculation were excluded from 
further experiments. 
As a control, mice from two different litters were inoculated with 0.1 ml PBS 
only. 
At each time-point after inoculation five to ten mice were sacrificed. Skeletal 
muscles from both hindlegs were removed for further histological and virolo-
gical examination. 
Histological examination 
Preliminary examination (P. Jongen, unpublished results) revealed that histo­
logical abnormalities were most extensive in the hamstring muscles. Therefore, 
hamstring muscles were used for further investigations. Table 2 gives the his­
tological score and representative pictures are shown, in Figure 1 (a to d). 
The number of mononuclear infiltrating cells, necrotic fibers and atrophic 
fibers reached a maximum within the first two weeks after inoculation. At least 
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Figure 1 Hamstring muscle. Haematoxylin-phloxin staining 
A: Massive infiltration of mononuclear cells (centre), muscle fiber atrophy, necrotic fibers, and loss of 
fibers 2 'weeks after inoculation. Bar represents 100 μιη. 
1 %
 * J V · 
Φ ш Л"е f* *-*-. 
В: Numerous mononuclear cells surrounding and partially invading necrotic muscle fibers 4 weeks after 
inoculation. Bar represents 50 μιη. 
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С: Endomysial infiltrate of mononuclear cells 8 weeks after inoculation. Bar represents 50 μη 
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Ό: Muscle fibers irith internal nuclei, fat cell replacement, and sporadic myophagia, reflecting ongoing 
myopathy 16 weeks after inoculation. Bar represents 100 μιη. 
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until 16 weeks after infection, infiltrating cells, necrosis, and atrophy can be 
seen. The maximum number of fibers with central nuclei is reached at 8 weeks 
after infection. 
Mice inoculated with PBS developed no histological abnormalities. 
Detection of virus and viral RNA 
Muscle sections obtained one week after inoculation were hybridized with a 
^S-labeled DNA probe. The viral infection displays a focal character as shown 
in Figure 2. Viral RNA is present in single muscle fibers whereas neighbouring 
fibers are not affected. Hamstring muscles were examined by virus isolation 
and PCR (Table 2). 
One week after inoculation all hamstrings tested contained viable virus and 
viral RNA. Two weeks after inoculation viral RNA was detected in 5 of 5 ham-
string muscles tested. Three of these 5 samples also contained viable virus as 
shown by virus isolation. The mean log10 virus titer in these three muscles, 
however, was decreased from 5.6 to 1.2. Four weeks after inoculation all of 10 
mice tested contained viral RNA in the hamstring muscles of one or both hind-
legs whereas viable virus could no longer be isolated. Viral RNA was not 
detected in muscle more than four weeks after inoculation. Figure 3 shows the 
hybridisation results of PCR products for some muscle samples obtained at 4 
and 8 weeks after inoculation. 
Figure 2 In situ detection of Coxsackievirus Bl RNA in a sections from a hamstring 
muscle 1 week after inoculation. 
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Figure 3 Southern blot hybridisation of Coxsackievirus ΒΊ-specific products of 
RNA isolated from right hamstring muscle samples, (a): 4 weeks after infection; (b): 8 
weeks after infection. Numbers indicate the different mice. Lanes indicated by +: 
Muscle sample obtained from an infected mouse one week after infection; Lanes indi­
cated by -: Muscle sample from an uninfected mouse; lanes D: Coxsackievirus Bl 
cDNA clone; lanes R: Coxsackievirus Bl (Tucson) RNA. Size markers are indicated on 
the left. 
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Polymyositis is an inflammatory disease of the skeletal muscle. It is the most 
frequently aquired muscular disease in adults and has a chronic progressive 
character. The pathogenesis of polymyositis is not well understood. In gener­
al, it is regarded as an autoimmune disease, possibly induced by a preceding 
enteroviral infection. On the other hand, several papers have been published 
which describe the detection of enteroviral RNA in skeletal muscle of patients 
in the absence of infectious virus (Bowles et al., 1987). These findings suggest 
that the virus persists after the acute phase of infection and that the virus itself 
may actually contribute to the maintainance of disease. However, several other 
groups could not confirm that the viral RNA was indeed still present in the 
chronic stage of disease, and questioned the idea that persistence of enterovi­
ruses played an etiological role (P. Jongen, unpublished results; Leff et al., 
1992). 
We have used Coxsackievirus Bl induced murine myositis as a model to inves-
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tigate whether enteroviral persistence might play a role in the pathogenesis of 
myositis. Histological findings clearly showed a myositis continuing for at 
least 16 weeks that resembled polymyositis in man (Table 1, Figure 1). In situ 
hybridisation on affected hamstring muscle showed a focal distribution of the 
viral RNA, which is also described in human polymyositis (Bowles et al., 1987), 
and which is also found in viral murine myocarditis (Kandolf et al., 1987; 
Klingel et al., 1992). Infectious virus was isolated from the affected muscles 
until 14 days after infection. Beyond this time the virus can no longer be isola-
ted, although viral RNA could still be detected by PCR up to 4 weeks after 
infection. These results are in agreement with Tarn et al. (1991) who were also 
able to detect viral RNA up to about 31 days after infection in this animal 
model. However, although histologically an ongoing myositis was found, viral 
RNA was not present anymore beyond 4 weeks after infection. Thus, it appe-
ars that the maintainance of disease in this model is not associated with the per-
sistence of enteroviral RNA. Until now most studies on persistence of picorna-
viruses in murine models revealed similar results. Using an 
encephalomyocarditis virus variant, Cronin et al. (1988) induced myositis in 
mice. Virus was isolated at high titers 1 week after infection, but only at low 
titers 2 weeks after infection. Viral RNA was detected in skeletal muscle up to 
3 weeks and only sporadically as late as 4 weeks after infection. Koide et al. 
(1992) detected viral RNA in a murine model of Coxsackievirus B3 induced 
myocarditis, up to the 28th day after inoculation. They described a decreasing 
number of positive animals with time: at day 14 after infection, five out of six 
animals, and at day 28 after infection, only two out of six animals were found 
positive for viral RNA. Thereafter, the viral RNA could no longer be detected 
in myocardial cells. A similar observation was made by Klingel et al. (1992). 
They described an ongoing myocarditis in the same animal model. Although 
the virus could not be isolated later than 15 days after infection, the viral RNA 
was still detectable up to 30 days after infection. However, in the acute phase 
of disease 13% of the myocardial cells were found to be infected, whereas in the 
chronic phase at day 30 after infection, only 0.01% of the myocardial cells were 
found positive for enteroviral RNA. 
In a previous study the sensitivity of the PCR was determined to be 100 geno-
mic RNA molecules (Zoll et al., 1992). Although the presence of smaller 
amounts can not be detected it seems unlikely that only a few RNA molecules 
persist in a limited amount of cells, in contrast with the more extensive necro-
sis observed at more than 4 weeks after inoculation. Thus, in the mouse models 
of myositis and myocarditis, the viral RNA can be detected for about 4 weeks 
after infection. Since virus can be isolated for 2 weeks after infection, it means 
that the virus persists for only 2 additional weeks. 
Enteroviruses cause a lytic infection. The lytic infection is controlled by the 
immune system which will become active within 5-7 days. For reasons which 
are not fully understood, the lytic infection can be limited to a chronic produc-
tive one with focal necrosis and expression of viral antigens in both surviving 
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and necrotic cells (Velia et al., 1992). Therefore, it may be that the virus can be 
trapped in a few cells which do nog immediately lyse, probably due to defec­
tive virus replication. Several reports have described an abnormal production 
of equal amounts of positive and negative strands of enteroviral RNA in 
patients with the post viral fatigue syndrom as well as in Coxsackievirus B3 
induced myocarditis in the mouse (Cunningham et al., 1990; Klingel et al., 
1992). The presence of a 1:1 molar ratio of the (+) and (-) strand RNA suggests 
the remaining presence of highly stabilized double stranded RNA intermedia­
tes which resist RNA degradation. The RNA will eventually be eliminated. 
Presumably this is what occurs in the murine model after approximately 4 
weeks. This means that the infection is waning. 
Ytterberg and coworkers studied the murine myositis model extensively, espe­
cially the role of Τ cell activity (Ytterberg et al., 1987b; Ytterberg et al., 1988). 
These studies revealed that active virus and Τ cell activity were essential for the 
development of myositis. Mice with Τ cell deficiency, like nude and athymic 
mice, did not develop myositis. This suggest that a chronic myositis may be 
caused by an immunologically mediated mechanism. In fact, a striking feature 
of all these different animal models is the necessity of infectious virus and in 
most cases Τ cell activity to induce a chronic inflammation. The ongoing inf­
lammation is demonstrated by histological parameters such as mononuclear 
infiltrating cells, necrosis, atrophy, etc. Histological abnormalities are visible in 
affected muscles for several months. However, in this model numbers of mon­
onuclear infiltrates decrease by time indicating that the duration of the virus-
induced chronic myositis is limited. Nonprogressive gait abnormality obser­
ved several months after infection may be caused by the inflammation and 
corresponding loss of muscle tissue during the first two weeks of the infection. 
The presence of mononuclear infiltrating cells at 16 weeks after infection indi­
cates that the myositis is still ongoing at this time. 
Post-infectious autoimmunity has been postulated by many investigators and 
remains an important issue to be studied (Craighead et al., 1990). From studies 
in the murine cardiomyositis model it became clear that anti-heart antibody is 
generated in the myocarditic mouse (Paque & Miller, 1991), and that autoreac­
tive cytotoxic Τ lymphocytes are generated, which can cause cardiac damage 
after adoptive transfer to uninfected mice (Loudon et al., 1991). In addition, 
several epitopes have been described that show crossreactivity between 
Coxsackie В viruses and cardiac myocytes (Paque & Miller, 1991). The strain of 
Coxsackie В virus used, as well as genetic factors of the host, are found to be of 
crucial importance. What makes a strain myocarditic or not is still poorly 
understood. The difference might reside in the type of immuneresponse moun­
ted by the various strains (Chow et al., 1991). It is exciting to speculate that 
molecular characteristics of the virus are involved in the immunopathology. 
Although the viral infection appears to be essential for the initiation of inflam­
mation (Ytterberg, 1987), a permanent presence of the viral RNA does not con­
tribute to the maintenance of the disease. 
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CHAPTER 2 
Summary 
Inoculation of Coxsackie Bl virus (CB1) in newborn CD1 Swiss mice induces a 
chronic myositis of proximal hindlimb muscles (CB1 myositis). To study the 
possible role of the virus dose and of antiviral antibodies in the development 
of CB1 myositis, we infected groups of newborn mice with six CB1 doses, ran­
ging from 30 to 10,000 plaque forming units (pfu); after 4 and 8 weeks we deter­
mined morbidity and antiviral antibody titer, and quantified histopathological 
changes. At 4 weeks, morbidity and mononuclear cell infiltration differed sig­
nificantly for the various groups, with the most prominent changes in 300 pfu 
animals. At 4 and at 8 weeks diseased animals had significantly higher antibo­
dy titers than clinically unaffected animals, and at 4 weeks myopathic and infil­
trative changes correlated positively with the serum antibody titer. Our data 
indicate that the virus dose plays a pathogenic role in CB1 myositis, and they 
suggest further study on the role of humoral immune mechanisms in the early 
phase of CB1 myositis. 
Introduction 
Viruses belonging to the enterovirus and encephalomyocarditis-virus (EMC) 
subgroup of picornaviruses may induce chronic myositis in mice [1]. Ray and 
coworkers infected newborn mice of several outbred and inbred strains with 
several isolates of Coxsackie В, and established the importance of the host and 
the virus strain in the induction of chronic disease [2,3]. Inoculation of the 
Tucson strain of Coxsackie Bl virus (CB1) in neonatal CD1 Swiss mice induces 
a chronic inflammatory myopathy of the proximal hindlimb muscles (CB1 
myositis) [2]. In CB1 myositis, clinical, electromyographic, and histological fin­
dings closely resemble those in human polymyostis [4]. 
The EMC-221A virus induces a chronic myositis in adult BALB/c mice (EMC-
221A myositis) [5]. To induce EMC-221A myositis in female BALB/c mice not 
only viral and host genetic factors, but also the dose of the virus is essential [5]. 
In CB1 myositis inoculation doses range from 100 to 2000 plaque forming units 
(pfu) [6-8]. Although it is known that in CB1 myositis low doses yield a low 
morbidity, and high doses result in a high mortality [6], reports of systematic 
studies on the pathogenic effect of the virus dose are lacking. 
In CB1 myositis Τ cells are required for the development of chronic inflamma­
tory lesions [9]. Until now the possible contribution of antibodies to the deve­
lopment of CB1 myositis has received no investigative attention. Yet, in virus-
induced autoimmune disorders various findings suggest a pathogenic role of 
antibodies, including antiviral antibodies [9-10]. 
To study the role of the virus dose and of antiviral antibodies in CB1 myositis 
we infected newborn CD1 Swiss mice with various CB1 doses, ranging from 30 
to 10,000 pfu, and examined morbidity, antiviral antibody response, and his­
tological changes. 
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Materials and Methods 
Vims and cells 
The CBl Tucson strain, known to cause chronic proximal myositis in CD1 
Swiss mice [2-4], was a gift from L. Minnich, M.S., and Dr. C. George Ray, 
University of Arizona, Tucson, AZ Arizona, U.S.A. Buffalo green monkey kid­
ney cells (BGM cells) were used for growth of CBl virus stocks, for plaque 
assays, and for virus neutralisation tests. BGM cells were grown in Eagle's 
Minimum Essential Medium with Earle's salts, 10% fetal bovine serum (FBS), 
penicillin (10,000 U/l), and gentamycin (50 mg/L). Maintenance medium con­
tained 3% FBS. The virus was stored at -70°C. All dilutions of virus used in vivo 
were made in phosphate buffered saline. 
Animals and experimental design 
CD1 Swiss mice were used in all experiments. Specific pathogen-free random-
bred pregnant females were purchased from Charles River Wiga GmbH, 
Sulzfeld, F.R.G., and allowed to deliver. Offspring was randomly selected, ino­
culated, and caged separately in groups of 10-14 animals. Groups of 14-26 mice 
were inoculated intraperitoneally at less than 48 h of age with 30,100,300,1000, 
3000, and 10,000 pfu of CBl in 0.1 ml volume. Control animals were injected 
with 0.1 ml tissue culture supernatant. Animals were coded and observed 
daily for clinical evidence of muscle weakness, manifest by abnormal posture 
and gait. In each dose group, the number of animals that died after inoculation 
was expressed as a percentage of the total number of animals in that group 
(mortality). The number of animals with clinical evidence of muscle weakness 
was expressed as a percentage of the number of surviving animals (morbidity). 
At 4 weeks after inoculation every second animal in each group was killed by 
cardiac puncture under ether anesthesia for histological and serological exa­
mination. The remaining animals were killed at 8 weeks for the same exami­
nations. Serum samples were processed individually. All serum samples were 
stored at -20°C. 
Histological examination 
Immediately after killing, quadriceps, hamstring, and gluteus muscles were 
removed in toto and placed in buffered formalin. In view of a possible predo­
minance of pathology in one side [1,2], right- or left-sided muscles were remo­
ved alternately. Muscles were paraffin-embedded and sectioned at 6 μπ\. From 
every muscle transverse séchons were stained with hematoxylin-phloxin-saf-
fron, and examined light microscopically (magnification χ 250). On prelimina­
ry examinations the most extensive inflammatory and myopathic changes 
were found in hamstring muscles. Therefore, transverse sections of hamstring 
muscles were used for further investigations. It was also found that cross-sec­
tions at 4 and 8 weeks did not differ significantly. The degree of mononuclear 
cell infiltration, muscle fiber necrosis, muscle fiber atrophy, and central nuclei 
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was quantified using a five grade scale, as follows; infiltrating mononuclear 
cells per section: absent (0), less than 10 (+1), 10-50 (+2), 50-100 (+3), more than 
100 (+4); necrotic fibers per section: absent (0), 1-5 (+1), 5-15 (+2), 15-25 (+3), 
more than 25 (+4); atrophic fibers: 0 or 1 per visual field (0), less than 25% per 
section (+1), 25-50% (+2), 50-75% (+3), 75-100% (+4); fibers with central nuclei: 
0 or 1 per visual field (0), less than 25% per section (+1), 25-50% (+2), 50-75% 
(+3), 75-100% (+4). Addition of the values for necrosis, atrophy and central 
nuclei yielded the so-called Myopathy Sum Score (MSS). Sections were read 
under code. 
Antiviral antibody determinations 
The functional ability of serum to neutralize CB1 was studied by a microneu-
tralization assay. Briefly, to 125 μΐ of doubling serum dilutions in maintenance 
medium, starting from 1:10, an equal volume of virus suspension was added 
containing 50 TCID^, of CB1 virus. After incubation at 36°C for 45 min in a 5% 
CO, atmosphere, 100 μΐ of each dilution was transferred in duplicate to micro-
titer wells containing a subconfluent monolayer of BGM cells. Inoculated cul­
tures were incubated and read after 3 days. Neutralizing antibody titers were 
defined as the highest dilution showing intact monolayers, and expressed as 
10log of the reciprocal. 
Statistical analysis 
The Kruskal-Wallis test and the Chi-square test were used to compare the 
results in the various dose groups. Testing between dose groups was perfor­
med using the Wilcoxon test. Values are presented as mean values ± standard 
error of the mean (SEM). The Spearman rank correlation coefficient was com­
puted between histological parameters and the serum antibody titer. In all tests 
a Ρ value of 0.05 or less was considered significant. Animals without detecta­
ble antibodies against CB1 (3 in the 30 pfu group, 1 in the 100 pfu group) were 
excluded from analysis, since in these animals inoculation might have failed to 
cause an infection. 
Results 
Morbidity and virus dose 
Mortality and morbidity caused by the various CB1 doses, as observed 4 weeks 
after inoculation, are given in Table 1. No effects were noted in mice injected 
with control preparations. Mortality ranged from 8% (30 pfu) to 100% (10,000 
pfu). Morbidity ranged from 0% (3000 pfu) to 50% (300 pfu), and it differed sig­
nificantly for the various dose groups (P = 0.039). The morbidity at 300 pfu was 
significantly higher than that at 100 and 3000 pfu (for Ρ values see Table 1). 
Remarkably, at 3000 pfu 57% of the animals survived but none of them showed 
abnormal gait or posture. At 8 weeks, all animals not sacrificed at 4 weeks, 
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were still alive. Those who had shown clinical signs of muscle weakness at 4 
weeks, did so at 8 weeks. Morbidity had not changed. 
Histopathological changes and virus dose 
The pattern of histological abnormalities was similar for the various amounts 
of CBl (Figure ΙΑ-B). However, at 4 weeks the degree of infiltration and the 
MSS differed significantly for the various doses (P = 0.013, and Ρ = 0.025, 
respectively) ( Figure 2A, C). Infiltration was greater at 300 pfu than at 30 pfu 
(P = 0.034) and 1000 pfu (P = 0.047). Necrosis was highest at 300 pfu, but diffe­
rences between the groups failed to be significant (P = 0.066) (Figure 2B). There 
were no apparent differences as to degree of muscle fiber atrophy (P = 0.15) 
and central nuclei (P = 0.20). At 8 weeks neither the degree of infiltration, 
necrosis, atrophy or central nuclei, nor the MSS differed significantly between 
the various dose groups. 
Table 1 Mortality and morbidity for different CBl doses, as observed 4 weeks after 
inoculation. Morbidity is expressed as a percentage of surviving animals. 
Virus dose 
(pfu) 
30 
100 
300 
1000 
3000 
10000 
Number of 
animals 
24 
24 
26 
24 
14 
14 
Mortality 
% 
8 
37 
23 
42 
43 
100 
Morbidity * 
% 
23 
13 
50 
21 
0 
-
Morbidity 
Ρ valuet 
0 05 < Ρ < 0 10 
P = 0 05 
-
0 05 < Ρ < 0 10 
P < 0 0 5 
-
pfu = plaque forming unite 
" Chi-square test, Ρ = 0039 
t Ρ values for the Wilcoxon test, comparing morbidity at 300 pfu with that ofotlier virus doses 
Morbidity and titer of neutralizing antibody 
Animals with clinical evidence of chronic muscle weakness had significantly 
higher neutralising antibody titers, than ammals with normal appearance. This 
was found at 4 weeks (2.17 ± 0.10 vs 1.67 ± 0.16, Ρ = 0.038), and at 8 weeks (2.57 
± 0.21 vs 1.68 ± 0.15, Ρ = 0.006). 
Histopathogical changes and titer of neutralizing antibody 
At 4 and at 8 weeks the antibody titers were highest in the 300 pfu group, but 
differences between the various dose groups were not statistically significant 
(4 weeks, Ρ = 0.26; 8 weeks, Ρ = 0.92). For a given dose titers at 4 weeks after 
inoculation did not differ from those at 8 weeks. 
At 4 weeks, animals with a higher degree of mononuclear cell infiltration or 
muscle fiber necrosis were found to have higher anti-CBl antibody titers (P = 
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Figure IA Perivascular infiltration of mononuclear cells, loss of muscle 
fibers, fat cell replacement (right), and fiber atrophy (left) 4 weeks after inocu­
lation. Hamstring muscle. Bar represents 100 μιτι. 
, "i Г Г" " Ш * ^ ÊT Е.* 
Figure IB Necrotic muscle fibers, myophagia, fat cell replacement, internal nuclei 
and fiber atrophy at 8 weeks. Hamstring muscle. Bar represents 50 mm. 
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Figure 2A Degree of infiltration (mean ± SEM) for different CBl doses 4 weeks 
after inoculation (horizontal lines denote SEM values). 
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Figure 2B Degree of necrosis (mean ± SEM) for different CBl doses 4 weeks after 
inoculation (horizontal lines denote SEM values). 
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0.05, and Ρ = 0.002, respectively) (Figure 3A-B); moreover, the anti-CBl anti­
body titer was positively correlated with degree of infiltration (r = 0.50, Ρ = 
0.001), necrosis (r = 0.58, Ρ = 0.0001) and atrophy (r = 0.53, Ρ = 0.0003). The MSS 
was also significantly correlated with the antibody titer (r = 0.65, Ρ = 0.0001) 
(Figure 3C). 
At 8 weeks, antibody titers in mice showing mononuclear cell infiltration were 
higher than in animals lacking infiltration (2.32 ± 0.28 vs 1.64 ± 0.13, Ρ = 0.02), 
and mice with muscle necrosis had higher titers than those without (2.35 ± 0.27 
vs 1.51 ±0.15, Ρ = 0.006). 
In an additional experiment we inoculated 14 new born animals with 300 pfu 
and sacrificed 10 animals 12 weeks after inoculation. The serum antibody titer 
did not differ between mice with infiltration and those without (P = 0.92). The 
same holds for mice with and without necrosis (P = 0.669). 
Discussion 
We demonstrated that in CB1 myositis severity of disease, as reflected by mor­
bidity and degree of mononuclear cell infiltration, is significantly different for 
various inoculation doses. Compared to both lower and higher amounts of 
CB1, 300 pfu resulted in the highest morbidity and the greatest pathology. 
These findings indicate that in CB1 myositis the induction of chronic disease 
not only depends on the virus strain [4], but also on the virus dose. Miller et al. 
made similar observations: elevations of muscle-associated enzymes in EMC-
221A-myositis in female BALB/c mice were dose dependent [5]. Recently, 
Beck et al. demonstrated that in Coxsackie B3 virus (CB3)-induced myocardi­
tis, secondary CB3 infection after primary Coxsackie B2 virus infection results 
in more severe inflammation in mice receiving 1000 pfu than in those receiving 
100,000 pfu for primary inoculation [12]. Obviously, in virus-induced autoim­
mune diseases in mice, the virus dose may be of pathogenic significance. 
In an attempt to explain this phenomenon, we consider the following. Tissue 
cultures show that the CB1 virus is entirely cleared from the organism within 
2 weeks after inoculation [4]. Therefore, our data implicate that the develop­
ment of chronic disease - at least partly - depends on early immune mecha­
nisms, that permit the virus dose to play a crucial role. It is known that forma­
tion of immune complexes strongly depends on the amount of available 
antigen [13]. In familial canine dermatomyositis, an animal model for human 
dermatomyositis, levels of circulating immune complexes correlate with dise­
ase severity [14], and complexes are involved in the pathogenesis of vasculitic 
changes [15]. In CB1 myositis electron microscopic examination of muscle 
shows occlusions of arterioles with areas devoid of normal capillary network, 
suggesting involvement of microvasculature [16]. Taken together, these data 
argue that in CB1 myositis formation of CBl-antiviral antibody immune com­
plexes might occur early in the disease process, enabling the virus dose to inf­
luence pathogenesis. 
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Figure 2C Myopathy Sum Score (mean ± SEM) for different CBl doses 4 weeks 
after inoculation (horizontal lines denote SEM values). 
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Figure ЗА Neutralizing antibody titers (mean ± SEM) for different degrees of 
infiltration 4 weeks after inoculation (horizontal lines denote SEM values). 
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Figure 3B Neutralizing antibody titer (mean ± SEM) for different degrees of 
necrosis 4 weeks after inoculation (horizontal lines denote SEM values). 
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titer 4 weeks after inoculation. 
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Using in situ hybridisation, Tam et al. demonstrated viral RNA in muscle tis­
sue from mice with CBl myositis 4 weeks after inoculation [17]. Moreover, the 
presence of viral RNA was related to disease severity [17]. In the case of viral 
persistence, sustained synthesis of viral proteins is likely to occur, and in this 
respect viral persistence resembles persistent virus infections. Since persistent 
virus infections are frequently associated with the production and deposition 
of immune complexes [13-18], formation of CBl RNA-antiviral antibody com­
plexes might continue after 2 weeks. 
Despite the absence of quantitative studies on muscle pathology in CBl myo­
sitis, severity of histological changes has been reported to vary among animals 
[4]. Remarkably, at 4 weeks, the height of the neutralizing antibody titer rela­
ted positively to the degree of infiltration and of necrosis, and antibody titers 
were significantly higher in clinically diseased animals. Moreover, at 8 weeks, 
titers in mice showing infiltration or necrosis were higher than in animals lac­
king these pathological changes. It is conceivable that chronic disease and high 
antibody titers both result from viral RNA persistence, without being related 
to each other. However, circumstantial evidence suggests the involvement of 
antiviral antibodies in the pathogenesis of CBl myositis [9-11]; therefore, we 
consider various possibilities. 
Firstly, anti-CBl antibodies might cross react with muscular antigens, causing 
antibody-mediated damage [19]: Huber et al. reported a monoclonal antibody 
which was cross-reactive to different murine tissues and myocarditis-inducing 
CB3 [10], and Notkins et al. described a Coxsackie B4 virus-neutralizing mono­
clonal antibody that reacted with mouse myocardium, but no other organs [9-
20]. Secondly, anti-CBl antibodies could cooperate with cellular effector 
mechanisms. If the monoclonal antibody, on which Huber et al. reported, was 
added to СВЗ-infected myocytes in a cell-mediated cytotoxicity assay, cyto­
toxic activity of sensitized lymphocytes was enhanced [10]. In fact, cooperation 
between antiviral antibodies and cytotoxic Τ cells could explain for the rela­
tionship we found between degree of cellular infiltration and antibody titer. 
Finally, immune complexes containing anti-CBl antibodies might be involved 
in CBl myositis, as suggested above. Interestingly, in some inbred strains of 
mice infection with lymphocytic choriomeningitis virus causes heighthened 
specific antibody responses, which directly correlate with unusually high con­
centrations of circulating immune complexes [21]. Since complex formation 
depends on the availability of both antigen and antibody [13], immune com­
plexes could explain the relationship disease severity has with virus dose and 
antiviral antibody response. 
To summarize, we demonstrated that in CBl-induced myositis, severity of dis­
ease depends on the virus dose. In addition, we found that myopathic and infil­
trative changes 4 weeks after inoculation correlated positively with the anti­
viral antibody response, suggesting the involvement of humoral immune 
mechanisms in an early phase of the disease. 
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Summary 
We investigated the role of humoral factors in the pathogenesis of Coxsackie 
Bl virus-induced murine myositis (CB1 myositis). At 2,4 and 8 weeks after ino­
culation serum was studied for circulating immune complexes (CIC) (Raji cell 
assay), haemolytic complement activity (CH50 titer) and anticytoplasmic auto­
antibodies (Western blotting, immunoprecipitation) in relation to degree of 
mononuclear cell infiltration and muscle fiber necrosis. At 2,4 and 8 weeks cell 
infiltration correlated positively to muscle fiber necrosis. From 2 weeks on 
moderate quantities of CIC were found in nearly all CBl-inoculated mice, but, 
without correlation to histological changes. Except for a positive correlation of 
CH50 titer to muscle necrosis at 4 weeks (r = 0.60; Ρ = 0.02), CH50 titers did not 
correlate to muscle lesions. Anticytoplasmic and other known autoantibody 
specificities were absent. 
In conclusion, first, in CB1 myositis CIC occurred from 2 weeks on, but no cor­
relative evidence was found for their involvemenent in pathogenesis, not for 
that of complement or anticytoplasmic autoantibodies. Secondly, cell infiltra­
tion correlated positively to muscle necrosis, underscoring the importance of 
cellular mechanisms. Thus, our data do not support, nor conclusively exclude 
a role for humoral processes in CB1- myositis. 
Introduction 
Polymyositis is an idiopathic inflammatory myopathy, with weakness and cel­
lular infiltration of skeletal musculature as the major clinical and histological 
findings [1,2]. The pathogenesis of polymyositis involves immunological 
mechanisms, and there is firm evidence that Τ cell-mediated cytotoxicity is ins­
trumental [2]. However, various findings in polymyositis patients indicate 
that, in addition to cellular mechanisms, humoral immune processes may play 
a role: the presence of circulating immune complexes (CIC) [3], the deposition 
of immunoglobulins in blood vessels [4] and on muscle fibers [5,6], comple­
ment consumption [7], the deposition of the membrane attack complex of com­
plement on muscle fibers [8,9], and the presence of В lymphocytes in inflam­
matory infiltrates [10]. Finally, myositis-specific autoantibodies occur in up to 
50% of polymyositis patients, and their levels correlate with disease activity 
[11]. 
Inoculation of the Tucson strain of Coxsackie Bl virus (CB1) in newborn CD1 
Swiss mice induces a chronic myositis of proximal hindlimb muscles (CB1 
myositis), similar to polymyositis [12,13]. Studies in n u / n u mice and in new­
born CD1 Swiss mice after thymectomy showed that development of CB1 
myositis depends on the availability of Τ cells [14,15], thus establishing a 
pathogenic similarity between CBl-induced murine myositis and human poly­
myositis. The possible contribution of humoral factors to the development of 
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CB1 myositis has not been studied so far. Previously, we found that the dose of 
the virus plays a pathogenic role, and that in the early phase of CBl myositis 
the titer of CBl-neutralizing antibody is related to disease severity [16]. The 
formation of antigen-antibody complexes was suggested as a possible expla-
nation [16]. 
To further elucidate the role of humoral processes in CBl myositis, we perfor-
med a correlative analysis of muscle lesions and serological changes. At 
various stages after CBl inoculation CIC, haemolytic complement activity, and 
autoantibody specificities were measured in serum; muscle mononuclear cell 
infiltration and fiber necrosis were quantified. 
Methods 
Virus and cells 
The CBl Tucson strain, known to cause chronic proximal myositis in CD1 
Swiss mice [12-17], was a gift from L. Minnich, M.S., and Dr. C. George Ray, 
University of Arizona, Tucson, Arizona, U.S.A. Buffalo green monkey kidney 
cells (BGM cells) were used for growth of CBl virus stocks, for plaque assays, 
and for virus neutralization tests. BGM cells were grown in Eagle's Minimum 
Essential Medium with Earle's salts, 10% fetal bovine serum (FBS), penicillin 
(100,000 U/l), and gentamicin (50 mg/1). Maintenance medium contained 3% 
FBS. Virus was stored at -70°C. All dilutions of virus used in vivo were made 
in phosphate buffered saline (PBS). 
Animals and experimental design 
CD1 Swiss mice were used in all experiments. Specific pathogen-free random-
bred pregnant females were purchased from Charles River Wiga GmbH, 
Sulzfeld, F.R.G., and allowed to deliver. Offspring were randomly selected, 
inoculated, and caged in groups of 10-14 animals. Mice were inoculated intra-
peritoneally within 48 h after birth with 300 pfu of CBl in 0.1 ml [16]. For the 
experiments on haemolytic complement, CIC, and autoantibody specifities we 
inoculated 91,98, and 56 animals respectively. In each experiment 20 to 28 con-
trol animals were injected with 0.1 ml tissue culture supernatant. Animals were 
coded and observed for clinical evidence of muscle weakness, manifested by 
abnormal posture and gait. At 2,4 and 8 weeks after inoculation animals were 
exsanguinated via the plexus retro-orbitalis under ether anaesthesia. In addi-
tion, at 10 and 12 days after inoculation some animals were killed for detection 
of CIC, and at 12 weeks for detection of autoantibodies. Serum samples were 
processed individually. 
Histological examinations 
Immediately after sacrifice, the left and right proximal hind limb muscles were 
removed in toto and placed in buffered formalin. In agreement with a previous 
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report [12], we found on preliminary examinations the most extensive inflam­
matory and necrotic changes in hamstring muscles, as compared with gluteus 
and quadriceps muscles [16]. Therefore, transverse sections of hamstring mus­
cles were used for further investigations. Muscles were paraffin-embedded 
and sectioned at 6 μιη. From every muscle, transverse sections were stained 
with hematoxylin-phloxin-saffron, and examined light microscopically (mag­
nification 250 x). In view of the reported asymmetric involvement in CB1 myo­
sitis [12-17] it was decided to use the muscle from the clinically (most) affected 
limb for further analysis. Infiltrating mononuclear cells and necrotic muscle 
fibers were counted in a mid-portion section. The degree of cellular infiltration 
was expressed as the number of mononuclear cells per mm2, and the degree of 
muscle necrosis as the number of necrotic muscle fibers per mm2. Thus, in each 
animal, a measure for infiltration and for necrosis was obtained. 
Raji cell test 
Immune complexes were detected and quantified using a slightly modified 
Raji cell assay, as described by Faaber et al.[18]. The assay was performed with 
10" Raji cells, which were incubated for 60 min at 37°C with 10 μΐ serum, in a 
final reaction volume of 200 μΐ PBS containing 0.1% wt/v sodium azide. After 
the incubation the cells were washed three times with 1 ml of PBS. 
Immunoglobulin binding to Raji cells was measured by immunofluorescence. 
The cells were incubated for 30 min at room temperature with 100 μΐ of a 1:50 
dilution in PBS of goat anti-mouse Ig-FITC (Organon Teknika Corp. 
Westchester). The cells were then washed three times in PBS and the brightness 
of the fluorescence was graded on coded slides on a scale from 0 to 4+, as fol­
lows; no cells positive (0), some cells weakly positive (1+), many cells weakly 
positive with or without some cells strongly positive (2+), some cells strongly 
positive and/or all (other) cells weakly positive (3+), many cells strongly posi­
tive (4+). 
Haemolytic complement assay 
The classical pathway complement activity was measured using a sensitive 
microassay, as described by De Waal et al. [19]. For the assay microtitration 
plates with U-shaped wells were used. All titrations were performed in a dex­
trose gelatin veronal buffer (DGVB2*) containing 0.15 mM Ca2+ and 0.5 mM 
Mg2+ (pH 7.35), with 0.13 M NaCl. Sheep red blood cells (SRBC), obtained asep-
tically every week, were collected in an equal amount of Alsever's solution and 
stored at 4°C. Rabbit anti-sheep erythrocyte antiserum was used as ambocep­
tor (Behring Werke GmbH, Germany). For the negative control the ambocep­
tor was replaced by 25 μΐ of DGVB2+ buffer. The plates were read in a multiscan 
ELISA reader at a wavelength of 405 nm. In reference plates control sera of unt­
reated CD1 Swiss mice and congenitally C5-deficient adult B10.D2 mice were 
included as positive and negative controls, respectively. Additionally, 0% and 
100% lysis controls were included, by mixing 25 μΐ of SRBC suspension with 65 
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μΐ of DGVB2* buffer or 65 μΐ H 2 0, respectively. The complement activity was 
expressed as CH50 U/ml serum, 1 U being defined as the amount of comple­
ment giving lysis of 50% of the SRBC. 
Anticytoplasmic autoantibodies 
Autoantibodies directed against intracellular antigens were looked for in 
serum via Western blotting using HeLa nuclear and cytoplasmic extracts [20-
21], and by RNA immunoprecipitation of total cell extracts [22]. 
Statistical analysis 
The Spearman rank correlation coefficient was calculated between the histo-
pathological and the serological findings. The Kruskal-Wallis test, the Mann-
Whitney rank sum test and the Student's t-test were used to compare the 
results obtained in the various groups of animals. Values are presented as 
mean ± standard deviation (SD). In all tests a Ρ value of 0.05 or less was consi­
dered significant. 
Results 
Morbidity and mortality 
In the various experiments 245 animals were inoculated with 300 pfu CBl wit­
hin 48 h after birth. Clinical morbidity ranged from 40 to 55%, and mortality 
ranged from 10 to 30%. 
Histopathological characteristics 
At 2 weeks, hamstring muscle was clearly infiltrated by mononuclear cells. 
Infiltrating cells were localized around blood vessels and between muscle 
fibers, and there was an abundance of fiber necrosis, fiber atrophy, myophagia, 
and internal nuclei (figure 1 A). At 4 weeks the severity of the lesions was dimi­
nished, although cellular infiltration, mainly focal, was still present, as were 
necrosis, atrophy, myophagia, and internal nuclei (figure IB). There was a 
great variability in muscle fiber diameter (figure 1С). At 8 weeks morphologi­
cal changes were grossly similar to those at 4 weeks (figure ID). At 2, 4 or 8 
weeks neither epimyseal nor perimyseal blood vessels showed abnormalities 
suggestive of vasculitis. 
There was a positive correlation between degree of cellular infiltration and the 
degree of fiber necrosis at 2 weeks (r = 0.95; Ρ = 0.0001 ; η = 15) (Figure 2), 4 
weeks (r = 0.78; Ρ = 0.0006; η = 15), and 8 weeks (r = 0.78; Ρ = 0.004; η = 13). 
Circulating immune complexes and histopathological changes 
At various periods after inoculation, 12 to 14 animals were studied for CIC. On 
day 10 there was no evidence for CIC in serum samples from any of the CB1-
inoculated mice. But, at day 12 CIC were detectable in one mouse and from 15 
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days on moderate quantities were found in all or nearly all animals. The num­
bers of CIC positive animals were 1 of 12 (day 12), 10 of 12 (day 15), 12 of 12 
(day 17), 14 of 14 (week 4), and 13 of 14 (week 8). The mean ± SD of CIC quan­
tities in CIC positive animals are given in Figure 3. 
The CIC level did not relate to the number of infiltrating cells or the number of 
necrotic muscle fibers at 2, 4 or 8 weeks (P>0.05). Neither did the number of 
CIC positive animals and the mean CIC quantities differ significantly at 2, 4 
and 8 weeks (P>0.05). Serum samples from control animals were all negative. 
Figure 1Α-Ό Hamstring muscle after CB1 inoculation. At 2 weeks obvious infiltra­
tion of mononuclear cells between muscle fibers, accompanied with many necrotic and 
atrophic fibers, myophagia and fibers with internal nuclei (A). At 4 weeks less promi­
nent but still present cellular infiltration, mainly focally, with fiber necrosis, fiber atro­
phy, myophagia, internal nuclei, muscle fiber calcification (B), and a great variation in 
muscle fiber diameter (C). Similar changes at 8 weeks (D). Cross sections of formalin-
fixed and paraffine-embedded mid-portion of muscles. Haematoxylin-phloxin-saffron 
staining. Magnification 250 x. 
Haemolytic complement activity and histopathological changes 
Hemolytic complement activities were measured in 14 to 16 animals at 2,4 and 
8 weeks after inoculation. Mean haemolytic complement activities were 1597 
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U/ml at 2 weeks (n = 16), 2350 U/ml at 4 weeks (n = 15) and 2144 U/ml at 8 
weeks (n = 14). At 2 and at 8 weeks neither infiltration nor necrosis were rela­
ted to haemolyric complement activity. At 4 weeks the number of necrotic 
muscle fibers per mm2 was correlated to the serum CH50 titer (Figure 4), whe­
reas the number of mononuclear cells per mm2 was not (r = 0.43, Ρ = 0.11). 
Anticytoplasmic autoantibodies 
The presence of serum autoantibodies was tested using immunoblotting [20-
21] as well as RNA immunoprecipitation [22] in 12 to 14 animals at varying 
periods after CBl-inoculation. At 10 and 15 days, and at 4,8 and 12 weeks after 
CBl inoculation, no autoantibodies directed to tRNA synthetases, such as anti-
Jol, -PL7 or -PL12, were detectable. Other known autoantibody activities, as 
judged by immunoblotting [21], were absent as well. 
Figure 2 Positive correlation between the number of mononuclear cells per mm2 and 
the number of necrotic muscle fibers per mm2 in hamstring muscle 2 weeks after CBl 
inoculation. 
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Figure 3 Quantities of circulating immune complexes (CIC) on a five-grade scale (0 to 
4) (mean + SD values) at different stages after CB1 inoculation in CIC-positive ani­
mals. 
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Figure 4 Correlation between the haemolytic complement activity (CH50 titer) and 
the number of necrotic muscle fibers per mm2 (hamstring muscle) at 4 weeks after CB1 
inoculation. 
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Figure 5 Mean and SD values of haemolytic complement activity (CH50 titer) in 
serum from symptomatic (open bar) and asymptomatic mice (shaded bar) at 2,4 and 8 
weeks after CBl inoculation, as compared to controls (hatched bar); * = Ρ < 0.05 as 
compared to controls. 
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Comparison of symptomatic and asymptomatic animals 
Finally, results in symptomatic and asymptomastic animals were compared. 
For each comparison we used six to eight animals per group. There were no 
differences in CIC quantities between animals with and without evidence of 
muscle weakness, at 2,4 or 8 weeks (P>0.05). 
Mean ± SD values for haemolytic complement activities in symptomatic and 
asymptomatic mice, and in controls at 2, 4 and 8 weeks are given in Figure 5. 
Remarkably, as compared to affected and normal animals, unaffected animals 
had lower serum CH50 titers at 4 weeks and higher titers at 8 weeks. 
Discussion 
The pathogenesis of CBl myositis is only partly understood. The major role 
43 
CHAPTER 3 
that Τ cells play has well been established [14,15], and is underscored by the 
positive correlation we found between cellular infiltration and muscle necro­
sis. To our notion, however, the eventual contribution of (auto)antibody- or 
immune complex-mediated mechanisms has not been studied. Previously, we 
found that in CB1 myositis severity of disease depends on the virus dose and 
that muscle necrosis positively correlates with the antiviral antibody response 
[16]; formation of CBl-antiviral antibody complexes [23,24] was suggested as a 
possible explanation [16]. 
Vascular deposits of immune complexes are crucial in human derma tomyosi-
tis [1,2], but evidence has also been obtained in human polymyositis, including 
the presence of CIC [3-7], that deposition of immune complexes in intramus­
cular blood vessels may be relevant to pathogenesis. In this study we demon­
strated that in CB1 myositis CIC occur as early as 12 days after inoculation and 
that moderate quantities persist up to 8 weeks, with a maximum at 17 days. 
These findings are in agreement with the assumption that in CB1 myositis CIC 
are pathogenic. However, other observations we made do not support this 
possibility and rather suggest that the formation of complexes is a non-specific 
response to the viral infection [29]: firstly, CIC occurred equally in symptoma­
tic and asymptomatic animals, and, secondly, inflammatory or necrotic chan­
ges did not relate to CIC quantities. Interestingly, our observations in CB1 
myositis closely parallel the findings by Behan and Behan in human polymyo­
sitis: the occurrence of CIC in most of the patients (10 out of 11), the highest 
proportion in patients with acute and subacute disease, and the absence of a 
correlation between the amount of complexes and the severity of disease [3]. In 
fact, since it is the localized immune complexes that arc relevant to disease pro­
cesses, the lack of correlation between circulating complexes and muscle necro­
sis does not necessarily exclude the role of such complexes in tissue injury, 
both in human polymyositis and in CB1 myositis. 
Polymyositis may occur in patients with immune complex vasculitis [25]. In 
CB1 myositis, light microscopy reveals no vasculitic changes [12], 13], as we 
confirmed, but on electron microscopy Mahowald et al. found occlusions of 
arterioles with areas devoid of normal capillary network, suggesting involve­
ment of the micro vasculature [26]. Given that immunofluorescense microsco­
py revealed complexes in the walls of small blood vessels in patients with poly­
myositis and overlap syndrome [6], the immune complexes we detected might 
contribute to the microvasculopathy in CB1 myositis. 
In human polymyositis, anticytoplasmic autoantibodies directed to various 
tRNA synthetases, such as anti-Jol, occur in up to 50% of the patients and their 
titer relates to disease activity [11]. It is unclear whether these autoantibodies 
are pathogenic. We hypothesised that in CB1 myositis anticytoplasmic antibo­
dies might well occur, since in viral infection polyclonal В cell activation can 
give rise to both specific and non-specific autoantibody production [27]. 
However, we could not detect such autoantibodies, nor other known antibody 
specificities. In fact, in encephalomyocarditis virus-induced myositis anti-Jol 
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antibodies and autoantibodies to other ribonucleoproteines were also found to 
be absent, as tested by immunoprecipitation 2 to 8 weeks after inoculation [28]. 
So, as yet, data from experimental murine myositis do not favour a pathogenic 
role of anticytoplasmic autoantibodies in polymyositis. 
In virus infection, antibodies and immune complexes activate the classical 
complement pathway leading to complement consumption [29]. In this study 
on CBl myositis we found only one correlation between CH50 titers and deg-
ree of cell infiltration or fiber necrosis: a positive correlation between CH50 
titer and muscle necrosis at 4 weeks. This is surprising, since, if complement 
consuming mechanisms are operative in CBl myositis, CH50 titers are expec-
ted to correlate negatively to muscle lesions. Another intriguing observation in 
this respect was that, compared to symptomatic and normal animals, asymp-
tomatic ones had lower serum CH50 titers at 4 weeks and higher titers at 8 
weeks. We suggest the following explanation. Although there is no viral per-
sistence in animals developing CBl myositis [30], we and others detected viral 
RNA up to 4 weeks after infection [30,31 ], thus establishing a relation between 
delayed viral clearance and the induction of CBl myositis. Asymptomatic mice 
have most probally cleared viral RNA effectively, with concomitant consump-
tion of complement. Thus, viral clearance, complement consumption and limi-
ted muscle damage go hand in hand, leading to a positive correlation at 4 
weeks between muscle necrosis and CH50 titer. If so, the elevated CH50 titers 
at 8 weeks in asymptomatic mice are likely to result from compensatory over-
production. 
As stated, in human polymyositis various data indicate that, in addition to cel-
lular mechanisms, humoral immune processes also play a role [3-10]. Our fin-
dings suggest that in CBl myositis this may not be the case, and that therefore 
in this respect the CBl myositis model differs from human polymyositis. 
However, in human polymyositis cell-mediated processes are considered far 
more important than humoral factors [2]. Since previous reports indicated a 
major role for cellular mechanisms in CB myositis [14,15], and as we demon-
strated a positive correlation between cell infiltration and muscle necrosis, the 
negative humoral results do not greatly affect the applicability of CBl myosi-
tis as a model for human polymyositis. On the other hand, our results do not 
contradict the possibility that humoral processes involving antibodies are ope-
rative in CBl myositis, e.g. deposition of immune complexes in the microvas-
culature. In addition, if not through immune complexes, (antiviral) antibodies 
might be pathogenic through such mechanisms as antibody-dependent, cell-
mediated cytotoxicity or antibody-dependent, complement-mediated cyto-
toxicity. So, our data neither support, nor conclusively exclude a role for anti-
bodies in CBl myositis. 
To conclude, first, in CBl myositis we found moderate quantities of CIC from 
2 weeks on, but we obtained no correlative evidence for their involvement in 
pathogenesis, nor for that of the classical complement pathway or anticyto-
plasmic autoantibodies. Second, mononuclear cell infiltration correlated posi-
45 
CHAPTFR 3 
tively to muscle necrosis, underlining the importance of cellular mechanisms 
in CB1 myositis. 
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CHAPTER 4 
Summary 
To study characteristics, severity and duration of muscle changes in CB1 myo­
sitis, we qualitatively and quantitatively examined transverse sections of ham­
string, quadriceps and gluteus muscles at 1,2,4,8, and 16 weeks after inocula­
tion. Mononuclear cell infiltration, muscle fibre necrosis, fibre atrophy, and 
fibres with central nuclei were quantified on a five-grade scale. Findings in 
acute viral myositis (1 to 2 weeks) were compared to those in CB1 myositis (4 
to 16 weeks). Qualitatively, abnormalities were essentially the same from 1 to 
16 weeks: mononuclear cell infiltration, muscle fiber necrosis, fiber atrophy, 
fascicular involvement, and perifascicular atrophy. Mononuclear cells invaded 
necrotic and non-necrotic fibers, but necrotic invaded fibers were clearly more 
frequent than non-necrotic fibers. Quantitative examination showed the follo­
wing: hamstring muscles were in all respects more severely affected than 
quadriceps and gluteus muscles; infiltration and necrosis at 4,8, and 16 weeks 
were less than at 1 and 2 weeks; and on equidistant sections abnormal fascicles 
were involved at their full length, with only small intramuscular variations. 
From these findings we conclude that CB1 myositis has chronic low-grade dis­
ease activity for at least 16 weeks, and that the presence of inflammatory cells 
and fibre necrosis justifies the designation of myositis. The histopathological 
features of CB1 myositis apparently bear more resemblance to those in human 
dermatomyositis than to those in polymyositis, suggesting that humoral 
mechanisms may be operative. Finally, the histological similarities between 
CB1 myositis and the preceding phase of viral myositis may reflect common or 
closely related pathogenic process(es). 
Introduction 
Coxsackie В (CB) viruses are employed in various experimental models in the 
mouse [16,17]. Depending on the virus strain used and the genetic background 
of the host, inoculation of CB virus in new born mice leads to chronic inflam­
matory disease of heart, liver, brain, pancreas, or muscle [16,17,19]. Thus, ino­
culation of the Tucson strain of Coxsackie Bl virus (CB1) in neonatal CD1 
Swiss mice induces a chronic inflammatory myopathy of skeletal muscles: CB1 
myositis [19,22]. Since virus can not be cultured from affected muscles for lon­
ger than 2 weeks after inoculation [22,23,27], secondary autoimmune processes 
are considered causative of CB1 myositis [22]. The observation that the deve­
lopment of CB1 myositis depends on the availability of Τ cells [25,26], suggests 
a pathogenic similarity to human polymyositis, since in polymyositis fibre 
damage is mediated by cytotoxic Τ cells [2,6]. In affected mice abnormalities of 
gait and posture indicate a weakness in the proximal muscle groups of both 
hindquarters [17,19,22,25,26]. Macroscopically, quadriceps, hamstring, gast­
rocnemius and soleus muscles become atrophic [19,22]. On microscopy these 
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muscles show inflammatory, myopathic, and regenerative changes [19]. The 
severity and the extension of the lesions have been reported to vary between 
muscles as well as within a muscle [22], but observations have not been quan-
tified. 
For its clinical, histopathological, and electromyographic features CBl myosi-
tis is considered as a model for human polymyositis [18,22]. However, the 
autoimmune character of CBl myositis has not been established sufficiently. 
Nor has it been demonstrated conclusively that CBl myositis indeed repre-
sents an ongoing myopathy with inflammation as the primary pathogenic pro-
cess. 
Therefore, to obtain histopathological clues regarding the pathogenesis of CBl 
myositis, we assessed the character, severity, and duration of muscle changes 
after CBl inoculation. Histopathological changes in quadriceps, hamstring, 
and gluteus muscles, and the extension and distribution of lesions within mus-
cles were studied qualitatively and quantitatively on light microscopy up to 16 
weeks after infection. 
Methods 
Virus and cells 
The CBl Tucson strain, known to cause chronic proximal myositis in CD1 
Swiss mice [19,22,24] was a gift from L. Minnich, M.S., and Dr. C. George Ray, 
University of Arizona, Tucson, AZ, U.S.A. Buffalo green monkey kidney cells 
(BGM cells) were used for growth of CBl virus stocks and for plaque assays. 
BGM cells were grown in Eagle's Minimum Essential Medium with Earle's 
salts, 10% fetal bovine serum (FBS), penicillin (100,000 U/l), and gentamicin 
(50 mg/1). Maintenance medium contained 3% FBS. Virus was stored at -70°C. 
All dilutions of virus used in vivo were made in phosphate buffered saline 
(PBS). 
Animals and experimental design 
CD1 Swiss mice were used in all experiments. Specific pathogen-free random-
bred pregnant females were purchased from Charles River Wiga GmbH, 
Sulzfeld, Germany, and allowed to deliver. Offspring were randomly selected, 
inoculated, and caged separately in groups of 10-14 animals with a maternal 
animal. Mice were inoculated intraperitoneally at less than 24 hours of age 
with 300 pfu of CBl in 0.1 ml volume [13]. Control animals were injected with 
0.1 ml PBS. Animals were coded and observed for clinical evidence of muscle 
weakness, manifest by abnormal posture and gait. At 1, 2, 4, 8, and 16 weeks 
after inoculation 7 to 15 clinically affected animals were killed by cervical dis-
traction under ether anaesthesia for histological examinations. At each time 
point 5 control animals were also sacrificed. 
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Histological examinations 
Immediately after killing we removed in each animal quadriceps, hamstring 
and gluteus muscles in toto, and placed them in buffered formalin. In view of 
a possible predominance of pathology in one side, right- or left-sided muscles 
were removed alternately [18,19,22]. Muscles were paraffin-embedded and 
sectioned at 6 μτη. Transverse sections were stained with haematoxylin-phloxi-
ne-eosin. Slides were coded and examined light microscopically (magnifica­
tion 250x). 
Sections were assessed qualitatively in detail, with special attention for abnor­
malities known to be characteristic for human inflammatory myopathies [2], 
and abnormalities reported in CB1 myositis [19,22] and other murine CB infec­
tions [16]. 
For quantization of histological changes, mononuclear cell infiltration, muscle 
fibre necrosis, muscle fibre atrophy, and fibres with central nuclei were quan­
tified using a five grade scale, as follows; infiltrating mononuclear cells per sec­
tion: absent (0), less than 10 (+1), 10-50 (+2), 50-100 (+3), more than 100 (+4); 
necrotic fibres per section: absent (0), 1-5 (+1), 5-15 (+2), 15-25 (+3), more than 
25 (+4); atrophic fibres: 0 or 1 per visual field (0), less than 25% of fibres per sec­
tion (+1), 25-50% (+2), 50-75% (+3), 75-100% (+4); fibres with central nuclei: 0 or 
1 per visual field (0), less than 25% of fibres per section (+1), 25-50% (+2), 50-
75% (+3), 75-100% (+4) [13]. Comparison of findings with those in control ani­
mals provided at each time point a frame of reference. To ensure the quality of 
the histological assessment, one of us (HtL) examined random slides throug­
hout the study and compared the scores with those of the principal investiga­
tor (PJ). 
In preliminary studies it was found that whole cross sections of mid-portion 
hamstring muscles at 8 or 12 weeks were not smaller than those at 4 weeks [13]. 
The respective mean ± standard deviation (SD) values for the cross section are­
a's were 7.57 ± 3.20 mm2 (4 weeks), 5.69 ± 2.16 mm2 (8 weeks), and 6.74 ± 2.31 
mm
2
 (12 weeks). Therefore we considered the quantitative scores suitable for 
comparative analyses. 
To study the character and duration of muscle changes after CB1 inoculation, 
mid-portion sections of quadriceps, hamstring, and gluteus muscles were exa­
mined qualitatively at 1, 2,4, 8, and 16 weeks. Based on the qualitative results 
and the results of the intermuscular analysis (see below) we used the ham­
string sections for quantification, to assess the severity of the lesions at these 
stages; 15 animals at each time point. 
To study the degree of involvement of various proximal hind leg muscles we 
quantified muscle changes in mid-portion sections of quadriceps, hamstring, 
and gluteus muscles; 15 animals at each time point. 
To study the extension and distribution of lesions within a muscle, and the 
intramuscular variability of lesions, we performed serial examinations on 
quadriceps, hamstring, and gluteus muscles at 2,4, 8, and 16 weeks; 7 animals 
at each time point. Per muscle 7 equidistant cross sections were made and exa-
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mined qualitatively. Based on the qualitative results and the results of the 
intermuscular analysis (see above) the serial sections of hamstring muscles 
were examined quantitatively at 2,4, 8, and 16 weeks. In every single muscle, 
the intramuscular range for each characteristic (infiltration, necrosis, atrophy, 
central nuclei) was obtained by subtracting the lowest from the highest score 
in that muscle. Thus, per hamstring muscle we obtained 4 ranges, as a measure 
for the variability of changes within a muscle. Ranges of 0 -1 were considered 
to reflect a small intramuscular variability, and ranges of 2 or more a great 
intramuscular variability. 
Statistical analysis 
Quantitative scores of histological changes are given as mean values ± SD. 
Values of different groups were compared using the Kruskal-Wallis test and 
the Wilcoxon signed ranks test. In all tests a Ρ value of 0.05 or less was consi­
dered significant. 
Results 
Character and duration of lesions 
During acute viral myositis, at 1 and 2 weeks, there were massive infiltration 
of mononuclear and polymorphonuclear cells, muscle fibre necrosis and atro­
phy, calcifications, and fascicular involvement, as described by others [19,22]. 
At 4 weeks necrotic fibres and focal calcifications were frequently found; the 
shape and histological context of the latter suggested them to originate from 
necrotic fibres (figure 1 A). Diffuse as well as focal infiltrations of mononuclear 
cells occurred in the endomysium and perivascular, whereas in the perimysi­
um inflammatory cells were sparse. The size of the focal infiltrations varied 
from 5 to more than 100 cells (figure 1A). At times eosinophilic leucocytes and 
plasma cells were present in the infiltrates or isolated in the endomysium. 
Myophagia was regularly observed: mononuclear and eosinophilic leucocytes 
invading degenerating or necrotic muscle fibres (figure IB). At times mononu­
clear cells lined up in the proximity of normally appearing fibres. Mononuclear 
cells invaded necrotic and non-necrotic fibers, but necrotic invaded fibers were 
far more frequent than non-necrotic fibers (figure 1С). Fat tissue, replacing and 
penetrating muscle tissue, was a prominent feature (figure ID). Repeatedly cir-
cumscript infiltrations of mononuclear cells occurred in fat tissue, adjacent to 
blood vessels or surrounding isolated necrotic muscle fibres (figure ID); some­
times there were isolated polymorphonuclear cells. Many muscle fibres were 
atrophic and rounded, sometimes forming 'nests', sometimes appearing as 
perifascicular atrophy (figure ΙΕ-F). Signs of regeneration were basophilia, 
swollen and centralized nuclei, and prominent nucleoli. Fibre splitting also 
occurred. Conspicuously, muscle abnormalities were frequently confined to 
one or more fascicles, whereas neighbouring fascicles had a nearly normal 
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Figure 1 Histopathological findings in hamstring muscles from COI Swiss mice at 4 
weeks after CB1 inoculation (mid-portion transverse sections). Haematoxylin-phloxi-
ne-eosin staining. Bar represents 25 \im (B), 50 \im (C,F), or 100 μιη (A,D,E,G,H). A 
- Necrotizing and calcifying muscle fibres with perivascular cell infiltration. В -
Necrotic muscle fibre invaded by mononuclear and eosinophilic leucocytes (myopha-
gia). С - Mononuclear cells invading a necrotic fibre, but not the surrounding non-
necrotic fibres. D - Replacing fat tissue with focal cell infiltration. E - Perifascicular 
atrophy (top). F - Rounded muscle fibres, fibre atrophy, swollen and centrally located 
nuclei, fibre splitting, and perifascicular atrophy. G - Abnormal fascicle with atrophic 
fibres and central nuclei (left), neighbouring a fascicle with almost normal appearan­
ce. H - Atrophic fascicle surrounded by normal fascicles. 
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appearance (figure IG-Η). Sometimes complete fascicles were replaced by fat 
tissue. Slightly involved fascicles showed diffuse infiltration or, more often, 
only atrophic and rounded fibres with central nuclei. 
At 8 weeks, muscles showed essentially the same changes as at 4 weeks, but 
less impressive. Fibre splitting was more prominent than at 4 weeks. 
Remarkably, occasional necrotic muscle fibres were invaded by eosinophilic 
cells. 
At 16 weeks, mononuclear cell infiltrations were small and sparse, and were 
located adjacent to necrotic muscle fibres. Replacing fat tissue between normal 
muscle fibres was even more prominent than at 4 and 8 weeks. There was also 
evident perifascicular atrophy. 
Severity of lesions 
The scores for mononuclear cell infiltration, fibre necrosis, fibre atrophy, and 
central nuclei in mid-portion sections of hamstring muscles at various stages 
after CBl inoculation are given in Table 1. Cell infiltration and fibre necrosis at 
4,8, and 16 weeks were significantly lower than at 1 and 2 weeks. After 4 weeks 
the degree of infiltration showed a downward trend, but the differences 
between 4, 8, and 16 weeks were not significant. Scores for fibre atrophy and 
central nuclei grossly showed a downward trend throughout the observation 
period, but differences between the 5 time points were not significant 
(Kruskall-Wallis test). 
Table 1 Quantitative scores of histopathological changes in hamstring mid-portion 
sections (five-grade scale). Mean values ± standard deviation as obtained in 15 ani­
mals. 
Weeks 
1 
2 
4 
8 
16 
Infiltration 
4.0 ± 1.9 
3.8 ± 1.8 
2.6 ± 1.4 # 
1 9 ± 0.9 # 
1.6 ± 0.8 # 
Necrosis 
3.4 ± 1.5 
4.0 ± 2.1 
2.4 ± 1.2 # 
1.4 ± 0.7 # 
1.4 ± 0.8 # 
Atrophy @ 
2.4 ±1.1 
2.8 ± 1.5 
1.9 ± 0.9 
1.9 ± 0.8 
1.2 ±0.7 
Central Nuclei @ 
1.4 ± 0.6 
2.5 ± 1.3 
1.6 ± 0.8 
1.9 ±1.0 
1.0 ± 0.6 
@,P> 0,05 for Kruskal-Walhs test comparing mean values at 1,2,4, 8, and 16 weeL·; 
# ,P < 0.05 as compared with 1 and 2 weeks mean values (Wilcoxon signed ranks test). 
Intermuscular analysis 
The character of the lesions in quadriceps and gluteus muscles did not differ 
from that in hamstring muscles. The quantitative scores for quadriceps, ham­
string, and gluteus muscles at 4 weeks are given in Table 2. Obviously, ham­
string muscles had greater abnormalities than quadriceps and gluteus muscles, 
both with regard to myopathic and regenerative changes. 
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Table 2 Quantitative scores ofhistopathological changes in quadriceps, hamstring and 
gluteus muscles (mid-portion sections). Mean values ± standard deviation in 15 ani­
mals at 4 weeks after inoculation. 
Cell Infiltration 
Fibre Necrosis 
Fibre Atrophy 
Central Nuclei 
Quadriceps 
1.2 ± 
1.2 + 
0.6 ± 
0.6 ± 
1.2 
1.7 
0.7 
0.4 
Hamstring 
2.6 ± 1 . 4 * 
2.4 ± 1.2 ** 
1.9 ± 0 . 9 " * 
1.6 ± 0.8 * " 
Gluteus 
1.2 ±1.0 
1.2 ±1.2 
0.4 ± 0.5 
0.5 ± 0.4 
*, Ρ < 0.05 compared to quadriceps and gluteus muscles; 
**, Ρ < 0.05 compared to gluteus muscle; 
**, Ρ < 0.01 compared to quadriceps and gluteus muscles. 
Intramuscular analysis 
Very often the same muscle areas were involved in subsequent cross-sections, 
and often the lesions were located within the borders of one or more fascicles 
(figure IG-Η). Within a muscle diseased fascicles could be identified in most of 
the equidistant sections. So, abnormalities were confined to fascicles and exten­
ded almost through the full length of the muscle. This pattern was seen in both 
the acute stages (1-2 weeks) and in the chronic stages (4 - 16 weeks). 
Quantitative scoring of the 4 histopathological features in serial hamstring sec­
tions at 2, 4, 8, and 16 weeks yielded a total number of 112 ranges (see 
Methods); at each time point 7 animals were examined, one hamstring per ani­
mal. Table 3 shows for each histopathological item the number of animals with 
a range of 0 or 1. So, 98 out of 112 ranges were 0 or 1, indicating that in most 
animals there were only minor quantitative differences between the equidis­
tant sections. Muscles with severe changes (2 and 4 weeks) were slightly less 
homogenous in this respect. There were 14 ranges of 2, fairly distributed over 
infiltration (n=3), necrosis (n=4), atrophy (n=3), and central nuclei (n=4). Twice 
a range of 3 was noted, both with respect to fibre atrophy. In all, the intramus­
cular variability of lesions was small and abnormalities were equally distribu­
ted over the muscle, thus justifying the use of mid-portion sections in quanti­
tative studies. 
Discussion 
The acute viral myositis occurring after CB1 inoculation in new-born CD1 
Swiss mice ends at approximately 2 weeks [22,25,26]. Thereafter myopathic 
changes are considered to result from cell-mediated autoimmune mechanisms 
[18,22,25,26]. In this study we found that from a qualitative point of view the 
abnormalities occurring after 2 weeks - cell infiltration, fibre necrosis, fibre 
atrophy, fascicular involvement, perifascicular atrophy - were essentially the 
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same as in the acute myositis, and that they remained present up to 16 weeks. 
On quantization cell infiltration and fibre necrosis at 4 weeks were significant­
ly less than at 2 weeks, marking the transition from severe acute myositis to 
chronic virus-induced disease with low-grade inflammation. After 4 weeks 
degrees of necrosis and infiltration decreased, but differences were not signifi­
cant. Thus, we provided conclusive evidence, both qualitative and quantitati­
ve, that for at least 4 months after CBl inoculation a myopathy exists with chro­
nic disease activity. The presence of mononuclear cell infiltration and muscle 
fibre necrosis apparently justifies the designation of myositis. 
In human inflammatory muscle disease conventional microscopic criteria for 
distinguishing immune-mediated from other myopathies are identification of 
inflammatory cells, invasion of non-necrotic muscle fibres by mononuclear 
cells in polymyositis, and perifascicular atrophy in dermatomyositis [5,6]. 
Pathological studies demonstrated that in polymyositis invasion of intact 
fibers by cytotoxic Τ cells is the primary pathogenic process [2,6], and that non-
necrotic invaded fibers are equally frequent as necrotic fibers [6]. In contrast, 
we observed that in CBl myositis necrotic invaded fibres were clearly more fre­
quent than non-necrotic fibers. This suggests a limited role for cytotoxic Τ cells 
in the pathogenesis of CBl myositis. In fact, our findings suggest other, not 
mutually exclusive, pathogenic processes. 
Firstly, the chronic myopathy following CBl inoculation might represent nega­
tive long-term effects of the acute myositis on muscle function and metabolism. 
Glucose utilization and enzyme activities in skeletal muscle vary significantly 
in CBl myositis [4], and total lactate generation is increased five-fold compa­
red to normal muscle, indicating decreased mitochodrial function [4]. 
Thereabove, disabled animals most likely overuse the remaining muscle tissue, 
thus predisposing marginally functioning fibres to accelerated death. In nor­
mal human subjects exercise-induced damage in skeletal muscle is accompa­
nied with infiltration of mononuclear cells [20]. Since the appearance of such 
muscle is very similar to that of untreated polymyositis, it has been suggested 
that a proportion of the infiltrating cells in polymyositis is part of a natural 
response to damage, rather than being its cause [20]. Therefore, as in other 
myopathies, in CBl myositis the infiltrating cells adjacent to or invading necro­
tic fibers may constitue a secondary response to fiber damage [3,10,14]. The 
repeated occurrence of perivascular infiltration and multiple necrotic fibers 
with myopaghia in one visual field is in agreement with this assumption (figu­
re 1A). 
Secondly, the chronic myositis might be the protracted resolution phase of the 
acute viral myositis. In CBl myositis viral RNA has been demonstrated in dis­
eased muscle untili 4 weeks after inoculation, not thereafter [23,27]. It is con­
ceivable that after 4 weeks small amounts of RNA molecules persist in a limi­
ted number of fibres, not exceeding the PCR detection threshold of 100 RNA 
molecules [27,28], yet giving rise to scattered fiber necrosis and myophagia. If 
so, the waning character of CBl myositis could result from the steady clearan-
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ce of viral RNA. It could then also be assumed that the selective involvement 
of proximal musculature is caused by tissue tropism of CB1. The more, that tis­
sue tropism depends on distinctive surface characteristics of vascular endot­
helial cells [1], and that selective tropism of CB viruses for particular organs in 
vivo corresponds to the ability to infect vascular endothelial cells of the corre­
sponding organs [Π]. 
Thirdly, CB1 myositis may be mediated by non-cellular autoimmune mecha­
nisms. Like in other Coxsackievirus-induced animal models, Τ cells appear to 
be required for the induction of CB1 myositis [25,26]. They might, however, not 
be a prerequisite for the maintenance of the disease. Although Skemp and 
Ytterberg (1991) found selective muscle inflammation in 1 out of 4 inbred 
CBA/J mice after adoptive transfer of spleen cells from CBA/J mice with CB1 
myositis [21], as yet there is no convincing evidence that Τ cells capable of 
recognizing muscle fibers are generated in CB1 myositis. Recent findings sug­
gest that humoral processes play a role: the presence of circulating immune 
complexes [12] and the positive correlation between degree of muscle patholo­
gy and height of anti-CBl antibody response [13]. To elaborate on this point, 
we compare the histopathology in CB1 myositis with that in two human inf­
lammatory myopathies, in which humoral factors are thought to be decisive. 
On the one hand, Emslie-Smith and Engel described three adult patients with 
a distinct type of inflammatory myopathy, the so-called 'pipestem' myositis 
[5]. The histological features included scattered necrotic and regenerating mus­
cle fibres, sparse cell infiltrates, necrotic fibres invaded by macrophages, but no 
invasion of non-necrotic muscle fibres by mononuclear cells; membrane attack 
complex deposits in capillaries implied that the concomitant microangiopathy 
was mediated by complement-fixing antibodies or by immune complexes. 
These characteristics resemble those in CB1 myositis. In CB1 myositis too there 
is evidence for a microangiopathy of arterioles and capillaries [15]. On the 
other hand, the perifascicular atrophy that we consistently found, and the 
reported microangiopathy [15] resemble features of human dermatomyositis; 
and also in dermatomyositis necrotic invaded fibers are far more frequent than 
non-necrotic fibers. In dermatomyositis perifascicular atrophy results from 
selective capillary loss at the periphery of fascicles, and its presence is almost 
pathognomonic [2,6]. Depletion of capillaries is an early phenomenon, and is 
mediated by a humoral mechanism with the capillary endothelium as possible 
primary target [6]. However, since mice with CB1 myositis have no skin abnor­
malities, including those seen in an animal model for dermatomyositis [8,9], 
CB1 myositis lacks an essential feature of dermatomyositis. 
As far as we know, post-mortem studies on the overall distribution of lesions 
within polymyositis muscles have not been reported. Recently, magnetic reso­
nance imaging (MRI) demonstrated that muscle abnormalities in half of the 
patients with polymyositis had a focal character [7]. In one patient the abnor­
malities occurred all along the length of involved muscles [7]. Our data on the 
intramuscular distribution of muscle changes in CB1 myositis parallel these 
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MRI findings: abnormalities were typically confined to fascicles, and affected 
fascicles were altered all along their length. Interestingly, this pattern of invol-
vement was seen in CBl myositis as well as in the preceding phase of acute 
viral myositis. Since in situ hybridisation has demonstrated viral RNA longi-
tudinally in isolated muscle fibres 1 week after CBl inoculation [27], we sug-
gest that subsequent spread of virus to adjacent fibers cause diffuse inflamma-
tion within the fascicle, and that the connective tissue enveloping the fascicle 
mechanically prevents the virus from further dissemination. 
To conclude, firstly, CBl inoculation induces a chronic myopathy, lasting at 
least 16 weeks, with persistent cellular inflammation and fiber necrosis (CBl 
myositis); secondly, cell-mediated fiber injury seems to play a minor role in 
CBl myositis, since necrotic invaded fibers are evidently more frequent that 
non-necrotic fibers; thirdly, the histological similarities between CBl myositis 
on the one hand, and dermatomyositis and pipestem myositis on the other 
hand, suggest that humoral mechanisms, affecting the microvasculature, are at 
work; fourthly, typical changes in CBl myositis (fascicle-wise involvement, 
predominant involvement of hamstrings, perifascicular atrophy) are identical 
to those in the preceding viral myositis, suggesting common or closely related 
pathogenic processes. 
Table 3 Intramuscular variability of lesions. Seven equidistant cross-sections of ham-
string muscle were quantitatively scored (0-4) for infiltration, necrosis, atrophy, and 
central nuclei. The highest minus the lowest score for a given parameter yielded the 
intramuscular range for that parameter. A range of 0 or I indicate small variability. 
The table gives per parameter the number of animals with a range ofO or 1, divided by 
the number of animals studied. 
Infiltration 
Necrosis 
Atrophy 
Central Nuclei 
2 weeks 
5/7 
5/7 
5/7 
7/7 
4 weeks 
6/7 
5/7 
5/7 
5/7 
8 weeks 
7/7 
7/7 
6/7 
6/7 
16 weeks 
7/7 
7/7 
7/7 
6/7 
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Abstract 
To clarify the immunopathology in Coxsackie Bl virus-induced myositis (CB1 
myositis), we immunohistochemically analysed subsets of mononuclear cells 
by using monoclonal antibodies and identified immunoglobulin (Ig) and com­
plement deposits by using polyclonal antibodies. After inoculation of 300 pla­
que forming units CB1 in neonatal CD1 Swiss mice serial sections of hamstring 
muscles from 7 clinically affected animals were examined at 1, 2, 4, and 8 
weeks. Serial staining was as follows: C3c, IgG, IgM, CD4, CD8a, CD3, CD45R, 
and CD25. At 1 week, there were predominantly CD4+ and CD45R+ cells, 
whereas CD8+ cells were virtually absent. At 4 and 8 weeks CD4+ cells were 
often in immediate proximity to (non)necrotic fibers, at times invading 
(non)necrotic fibers; but necrotic invaded fibers were clearly more frequent 
than non-necrotic fibers. The proportion of endomysial CD8a+ cells increased 
as the inflammation became more chronic, and the CD4+/CD8a+ ratio decre­
ased. Likewise, in perivascular infiltrations the CD8a+ cell proportion was 
higher at 4 than at 2 weeks. Moreover, at 2 and 4 weeks the CD4+ cell propor­
tion was higher in endomysial infiltrates than at perivascular sites, and at 2 
weeks the CD45R+ and IgM+ cell proportions were higher at perivascular than 
at endomysial sites. Once IgM deposition was seen in a venule at 8 weeks. At 
all time points C3c, IgG, and IgM was diffusely deposited on most fibers, but 
more intensely on necrotic ones. In conclusion, immunohistochemical analysis 
of inflammatory changes in CB1 myositis showed that CD4+ Τ cells, and not 
CD8+ Τ cells, most likely play a decisive role in muscle fiber injury. 
Thereabove, our data suggest that immune-mediated vasculopathy might con­
tribute to ischaemic necrosis. 
Introduction 
Coxsackie Bl virus-induced murine myositis (CB1 myositis) is considered to be 
caused by virus-induced auto-immune mechanisms [15,21,22,23]. Studies in 
nude mice and in neonatally thymectomized mice showed that Τ cells are a 
prerequisite for the development of CB1 myositis [22,23]. Thus, a case has been 
made for a T-cell-mediated pathogenesis [22,23]. However, the exact pathoge­
netic role(s) of CD8+ and CD4+ Τ cells are unknown at the moment. Recent fin­
dings suggest that humoral processes may also be concerned: circulating 
immune complexes have been demonstrated in CB1 myositis [7] and the anti­
viral antibody titer correlates positively with tissue damage [8]. 
Histopathological features of CB1 myositis are infiltration of mononuclear 
cells, muscle fiber necrosis, fascicular involvement, and perifascicular atrophy 
[9,15]; mononuclear cells invade both necrotic and non-necrotic fibers, but 
necrotic invaded fibers are evidently more frequent than non-necrotic ones [9]. 
Electron microscopy showed abnormalities of microvasculature with occlu-
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sion of small arterioles and capillaries [13]. Thus, the histopathological charac-
teristics in CBl myositis bear more resemblance to those in human dermato-
myositis than to those in polymyositis [9]. Thereabove, histological similarities 
between CBl myositis and the preceding phase of viral myositis suggest that 
pathogenic process(es) at work in viral myositis may also be operative in CBl 
myositis [9]. 
In human forms of inflammatory muscle disease, distinct immune mechanisms 
are reflected by immunohistochemical abnormalities in muscle biopsies: diffe-
rences in subsets of infiltrating cells, preferential sites of cell accumulation, 
deposition of Immunglobulin (Ig) or complement [1,2,10,19]. Likewise, in CBl 
myositis results of immunohistochemical analysis may indicate cell-mediated 
versus humoral mechanisms, and may even reveal and distinguish among dif-
ferent cell-mediated mechanisms. Moreover, a comparison of findings at 
various stages after inoculation might clarify the transition from acute viral 
myositis to CBl myositis. Therefore, we studied the immunopathogenesis of 
CBl myositis on tissue level by using monoclonal antibodies to identify and 
localize subsets of mononuclear cells, and polyclonal antibodies for Ig and 
complement detection. 
Material and Methods 
Virus and cells 
The CBl Tucson strain, known to cause chronic proximal myositis in CD1 
Swiss mice was a gift from L. Minnich, M.S., and Dr. C. George Ray, University 
of Arizona, Tucson, AZ, U.S.A. [14]. Buffalo green monkey kidney cells (BGM 
cells) were used for growth of CBl virus stocks and for plaque assays. BGM 
cells were grown in Eagle's Minimum Essential Medium with Earle's salts, 10% 
fetal bovine serum (FBS), penicillin (100,000 U/l), and gentamicin (50 mg/1). 
Maintenance medium contained 3% FBS. Virus was stored at -70°C. Dilutions 
of virus used in vivo were made in phosphate buffered saline (PBS). 
Animals and experimental design 
CD1 Swiss mice were used in all experiments. Specific pathogen-free random-
bred pregnant females were purchased from Charles River Wiga GmbH, 
Sulzfeld, Germany, and allowed to deliver. Offspring was randomly selected, 
inoculated, and caged separately in groups of 10-14 animals with a maternal 
animal. Mice were inoculated intraperitoneally at less than 24 h of age with 300 
pfu of CBl in 0.1 ml volume. Control animals were injected with 0.1 ml PBS. 
Animals were coded and observed for clinical evidence of muscle weakness, 
manifest by abnormal posture and gait. At 1,2,4, and 8 weeks after inoculation 
7 clinically affected animals were killed by cervical distraction under ether ana-
esthesia for histological examinations. Since in CBl myositis pathological 
changes have been shown to be most severe in hamstring muscles [9], these 
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musles were studied, and in view of a possible predominance of pathology in 
one side [15], right- or left-sided muscles were removed alternately. For better 
overall assessement of muscle pathology and to facilitate the recognition and 
localisation of mononuclear cells we used hematoxylin-phloxin staining, 
vimentin staining (endothelial cells, satellite cells of regenerating skeletal mus­
cle) [18], and desmin staining (muscle fibers). Slides were coded and examined 
light microscopically (magnification 250x). 
Immunohistochemical procedures 
Hamstring muscles were snap frozen in isopentane precooled with liquid nitr­
ogen at -140°C and 8 um serial cryostate sections were cut. Sections were incu­
bated (one h at 200°C) with a panel of rat-anti-mouse monoclonal bio tin-con­
jugated antibodies (Gibco) for cell surface antigens and a panel of polyclonal 
antibodies for Ig, complement, desmin, and vimentin. The following mono­
clonal antibodies were used [4]. CD3 for Τ cells (T cell receptor, clone YCD3-1, 
diluted 1/40), CD4 for helper/inducer Τ cells and delayed type hypersensiti­
vity Τ cells (L3T4 antigen, clone YTS191.2, diluted 1/80), CD8a for cytotoxic 
and suppressor Τ cells (Ly2 antigen, clone 53-6.7, diluted 1/40), CD45R for pre­
ti cells and В cells (Ly5, B220 antigen, clone RA3-6B2, diluted 1/80), and CD25 
for activated Τ cells, В cells and NK cells (interleukin-2 receptor antibody, clone 
AMT-13, diluted 1/10); the latter staining was only performed in 8 week ani­
mals. After washing in PBS, sections were incubated with Horseradish conju­
gated Avidin (from Vector, diluted 1/50) for 1 h. The following polyclonal anti­
bodies were used. Fc-specific rabbit-anti-mouse IgG (1/200) and IgM (1/100), 
goat-anti-mouse complement C3c (1/25), all from Nordic, rabbit-anti-desmin 
(from Euro Diagnostics, 1/10) for desmin detection in muscle fibers, and rab-
bit-anti-vimentin (from Euro Diagnostics, 1/10) for vimentin detection. After 
washing in PBS, these sections were again incubated with goat-anti-rabbit or 
rabbit-anti-goat peroxidase conjugated antibodies (Dakopatts, 1/50) for 1 h. 
All antibody dilutions were made in PBS to which 1% bovine serum albumin 
was added. After washing with PBS (0,05 M) and TRIS buffer, immunoreacti-
vity was developed by adding a 0.05% diaminobenzidine - 0.01% H 2 0 2 solution 
for 5 min. Finally, sections were washed in destillated water, dehydrated, and 
mounted with Malinol (Chroma). Thus, in each muscle consecutive mid-por­
tion sections were stained in the following sequence: hematoxylin-phloxin, 
desmin, vimentin, СЗс, IgG, IgM, CD4, CD8a, CD3, CD45R, and CD25. For 
positive controls spleens sections from normal mice were used. Negative con­
trols were obtained by omitting first-step incubations in affected muscle sec­
tions. 
Assessment and statistics 
Positive reaction for a surface antigen consisted of a rim of reaction product 
around the cell [1]. Special attention was given to the location of positive cells 
within the infiltrate and to their spatial relation to (non)necrotic muscle fibers 
66 
C B l MYOSITIS: IMMUNOHISTOCHEMICAL ANALYSE 
[1]. Fibers with a pale, fragmented or calcifying appearence were considered 
necrotic. Mononuclear cells accumulating at perivascular and endomysial sites 
were analysed separately; perimysial cells were rare and therefore not inclu­
ded. The sites and their boundaries were defined as follows. Perivascular: a 
compact collection of cells around a blood vessel; endomysial, focal: a compact 
collection of cells between or surrounding muscle fibers, that may or may not 
invade (non)necrotic fibers; endomysial, diffuse: infiltrating cells scattered dif­
fusely. Focal mononuclear cell accumulations were analysed quantitatively, as 
one of the goals of the study was to compare the composition of endomysial 
infiltrations versus that of perivascular infiltrations. 
Since we used 8 \im sections, a particular cell may occur in only two sections at 
best [1]. Therefore, we counted all mononuclear cells of each infiltration 
showing positivity, and divided this number by the total number of cells. In 
this way we obtained the proportion (percentage) of positive cells per infiltra­
tion. In case there were several positive infiltrations in one section, we calcula­
ted the mean percentage, and from these we computed the grand means for the 
animals at each time point. These are given in the tables. Since normal muscle 
incidentally shows infiltrating cells [1], isolated in the endomysium or in small 
groups of one to four cells, only infiltrations of five cells or more were consi­
dered abnormal and included for analysis. 
Covariant analysis was performed to detect whether percentages increased or 
decreased during the period studied. The Student Τ test was used to compare 
two specific subsets, sites of accumulation, or time points. In all tests differen­
ces were considered significant at a Ρ level of <0.05. 
Results 
Qualitative results 
At 1 week infiltrating cells were abundantly present in all animals, and peri­
vascular infiltrates could not be demarcated from endomysial ones. There was 
an obvious predominance of CD4+ cells (Figure 1 A), and, to a lesser degree, of 
CD45R+ cells (Figure 1С), whereas CD8+ cells were very sparse (Figure IB). At 
2 weeks there were severe muscle lesions, with fascicle-wise partition, and evi­
dent infiltration of mononuclear cells, both perivascular and endomysial. At 4 
weeks, the number of inflammatory cells varied considerably between ani­
mals, some showing numerous infiltrations, others being almost negative. 
Overall the inflammation paralleled the degree of necrosis, although isolated 
necrotic fibers occurred repeatedly without adjacent inflammation. The infilt­
rates were generally small and very often restricted to one or more fascicles; in 
a few animals large infiltrations were seen. A remarkable observation was a 
wedge-shaped area with small and necrotic fibers that was intensely infiltra­
ted. CD3+ or CD4+ cells often occurred in immediate proximity to normally 
appearing or necrotic fibers, in contrast to CD8a+ cells. At times CD3+ or CD4+ 
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Figure Î Hamstring muscles at 1 (A,B,C), 4 (D), and 8 (E,F,G) -weeks after CB1 ino-
culation. At 1 week many CD4+ (A) and CD45R+ (C) cells are present, but hardly any 
CD8a+ cells (B, arrow). At 4 weeks IgG+ cells surround and partially invade necrotic 
fibers (D). Small endomysial offshoot of a larg perivascular infiltrate at 8 weeks (E,F; 
arrows) with many CD4+ (E) cells but no CD8a+ (F) cells. IgM deposition in a venu-
le at 8 weeks (G). Bar for all figures: 50 mm. 
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cells invaded (non)necrotic muscle fibers, but necrotic invaded fibers were cle-
arly more frequent than non-necrotic fibers. Regularly, IgM+ or IgG+ cells 
occurred scattered between necrotic fibers or invaded isolated necrotic fibers 
(Figure ID); less often they surrounded normal fibers. Diffusely infiltrating 
IgM+ cells occurred preferentially in areas with perifascicular atrophy. Both 
normal and necrotic fibers stained diffusely for C3c, IgM or IgG, but necrotic 
fibers were more intensely positive than normal ones. At 8 weeks essentially 
the same observations were made as at 4 weeks, although infiltrations were 
sparse and only endomysial sites were numerous enough to be included in the 
comparative quantitative analysis. Remarkably, in one animal a small venule 
showed intramural IgM positivity (figure IG). Diffusely infiltrating CD8a+ or 
CD45R+ cells occurred conspicuously in the vicinity of focal infiltrations, and 
IgG+ or IgM+ cells surrounded necrotic and non-necrotic fibers with central 
nuclei. A remarkable finding was a perivascular infiltration of 160 cells, the 
centre of which contained 27% CD8a+ cells and only few CD4+ cells; at the 
outer border, located endomysially, CD4+ and IgM+ cells were numerous 
(48% and 23%, respectively; figure IE), with some CD4+ cells surrounding and 
invading normal fibers, whereas CD8+ cells were sparse (figure IF). CD25+ 
cells (19 - 32%) were mostly located at the periphery of infiltrations, close to 
normal fibers. 
Quantitative results 
At 2 weeks, in 49 sections (not included the vimentin- and desmin-stained sec-
tions) the total number of positive cells in endomysial and perivascular infilt-
rates were 4265 and 1504, respectively; at 4 weeks, in 35 sections, 1840 and 538, 
respectively; and at 8 weeks, in 27 sections, 1160 and 265, respectively. Results 
of quantitative analysis of endomysial infiltrations are given in Table 1. It 
shows that the proportion of CD8a+ cells increased as the inflammation beca-
me more chronic: at 8 weeks there were more CD8a+ cells than at 4, 2, or 1 
week, and at 4 weeks more than at 1 week. Consequently, the CD4+/CD8a+ 
ratio decreased. The proportion of IgM+ cells at 8 weeks was higher than at 
preceding time points, and the proportion of CD45R+ cells at 1 and 8 weeks 
was greater than at 2 and 4 weeks. 
Table 2 showes the results of quantitative analysis of perivascular infiltrations. 
The inability to discriminate perivascular from endomysial infiltrates at 1 
week, and the low number of perivascular infiltrates at 8 weeks, did not allow 
a quantification at these time points. At 4 weeks the proportion of CD8a+ cells 
was higher than at 2 weeks. Thus, the CD4+/CD8a+ ratio at 4 weeks was lower 
than at 2 weeks. The proportion of IgM+ cells was also lower at 4 weeks than 
at 2 weeks. 
Moreover, at 2 and 4 weeks the CD4+ cell proportion was higher in endomy-
sial infiltrates than at perivascular sites. At 2 weeks the CD45R+ and IgM+ cell 
proportions were higher at perivascular than at endomysial sites. At 4 weeks 
the proprotion of CD8a+ cells tended to be higher perivascular (P = 0.057). 
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Table 1 Quantitative analysis of mononuclear cells at endoi?iysial sites of accumula­
tion in hamstring muscles after CB1 inoculation. For statistically significant differen­
ces see Results. 
Marker 
CD3+ cells 
CD4+ cells 
CD8a+ cells 
CD4+/CD8a+ ratio 
CD45R+ cells 
IgG+ cells 
IgM+ cells 
1 Week 
58 1 ± 11 4 
39 0 ± 15 6 
4 6 ± 3 4 
8 5 ± 6 2 
15 7 ± 7 6 
40 0 ± 9 8 
2 2 7 ± 6 4 
2 Weeks 
58 9 ± 15 9 
45 6 ± 8 7 
8 4 + 5 6 
5 4 ± 4 3 
7 0 ± 2 3 
43 2 ± 10 8 
13 2 ± 3 9 
4 Weeks 
56 7 ± 6 1 
47 7 ± 8 5 
14 3 ± 5 1 
3 3 ± 2 9 
6 6 ± 2 1 
42 1 ± 9 0 
23 7 ± 7 6 
8 Week 
4 7 2 ± 4 3 
39 0 ± 19 1 
271 ± 6 3 
1 5 ± 16 
1 9 0 ± 44 
-
49 5 ± 24 8 
Table 2 Quantitative analysis of mononuclear cells at perivascular sites of accumula­
tion in liamstring muscles after CB1 inoculation. For statistically significant differen­
ces see Results. 
Marker 1 Week 2 Weeks 
CD3+ cells 
CD4+ cells 
CD8a+ cells 
CD4+/CD8a+ ratio 
CD45R+ cells 
IgG+ cells 
IgM+ cells 
63 7 ± 6 0 
21 0 ± 3 6 
6 5 ± 3 7 
3 2 ± 2 6 
15 6 ± 5 9 
43 8 ± 8 1 
36 6 ± 4 0 
62 7 ± 8 3 
11 0 + 5 1 
24 2 ± 9 6 
0 5 ± 0 3 
1 1 7 ± 9 3 
38 0 ± 9 6 
22 1 ± 5 7 
Discussion 
To better understand the immunopathogenesis of CB1 myositis we immunop-
henotypically characterized infiltrating cells and looked for Ig and comple­
ment deposits in muscles from clinically affected animals. In terms of the pos­
sibility of T-cell-mediated pathogenesis we consider the following findings of 
major importance: a positive gradient for CD4+ cells from perivascular to 
endomysial infiltrations, CD4+ or CD25+ cells surrounding and invading 
necrotic and non-necrotic muscle fibers, and the remarkable finding of nume­
rous CD4+ cells at the periphery of a large perivascular infiltrate in the proxi­
mity of myocytes. From these observations we infer that CD4+ Τ cells most 
likely have an effector role in immunopathogenesis with the myocyte as the 
primary target. For comparison, in Coxsackievirus B3-induced murine cardio-
myositis some mice strains show CD4+ dependent immunopathogenic 
mechanisms, involving two distinct CD4+ cytoxic Τ cell populations [5,17]: 
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CD4+ virus-specific cytolytic cells, recognizing virus epitopes, and CD4+ met­
abolic cytolytic cells, recognizing cellular neoantigens induced by the infection 
process. Similar responses might be generated in CBl myositis. As to the pos­
sibility of CD4+ metabolic cytotoxicity, the presence of perifascicular atrophy 
and the fascicular partition of inflammation and necrosis suggest that cell infil­
tration may be secondary to ischaemia and necrosis. In favor of this assump­
tion is evidence suggesting an immmune complex-mediated microvasculopa-
thy in CBl myositis: occlusion of small arterioles and capillaries on electron 
microscopy [13], presence of circulating immune plexes [7], IgM deposit in a 
small vessel, and the observation that CD4+ cells occurred prominently in 
areas with fascicular atrophy. Notably, in СВЗ-cardiomyositis the myocarditic 
potential of viruses correlates with their ability to induce metabolic cytotoxic Τ 
cells [5,6]. Virus-specific cytotoxic CD4+ Τ cells might also develop in CBl 
myositis, reacting with residual viral RNA or cross-reacting with muscular epi­
topes due to molecular mimicry. This latter possibility has gained support by 
the recent finding that in multiple sclerosis viral peptides can activate human 
myelin basic protein-specific Τ cell clones [20]. Moreover, recent evidence 
obtained in several T-cell mediated organ-specific auto-immune diseases in 
mice indicate that selective death of organ-specific cells may be due to a non­
specific inflammatory attack by means of cytokine production by Thl CD4+ 
cells [11,12]. This selective bystander killing is thought to result from an imba­
lance of mediators released by Thl versus Th2 cells [11,12]. 
In general, antigen-specific CD4+ cytotoxic Τ cells are functionally restricted by 
MHC class II (la) gene products. la antigens are not expressed in normal muri­
ne skeletal muscle, but they are in unstimulated myotubes from mice with 
experimental autoimmune myositis [3]. This indicates that diseased murine 
muscle can participate in class II-restricted immune responses. Using a mono­
clonal antibody that recognizes the H-2 haplotypes к and s (clone OX-6, dilu­
ted 1/10) we found all muscle sections, including fibers and vessels, as well as 
control spleen sections to be negative. However, since the CD1 Swiss strain is 
out-bred, H-2 haplotypes other than к and s may have been expressed. So, our 
data do not exclude the possibility of la expression in CBl myositis, and thus 
the possibility of class II restricted autoimmunity. 
Regarding the question whether in CBl myositis humoral factors affect muscle 
fibers, we mention that complement C3c, IgM, and IgG were diffusely deposi­
ted on non-necrotic fibers, regarded as non-specific staining. The more intense 
staining of necrotic-calcifying fibers may also be non-specific, although secon­
dary antibody binding to neoantigens could be a concievable explanation. In 
addition, the diffuse endomysial infiltration of CD45R+ cells and the combined 
endomysial presence of CD45R+ and CD4+ cells suggest the existence of CD4+ 
- В cell cooperativities for local antibody production [1]. 
With respect to the transition from acute viral myositis to CBl myositis, we 
demonstrated that the composition of cell infiltrates changes with the course of 
the inflammation. This can be understood as that the immune processes at 
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work during CBl myositis differ from those in viral myositis. The observation 
that the CD8a+ cell proportion increased as the inflammation became chronic, 
is subject to at least two interpretations. Firstly, it is in agreement with a patho­
genic role for CD8a+ cytotoxic Τ cells, as in polymyositis, where non-necrotic 
fibers are invaded by CD8+ Τ cells [1,10]. Yet, the scarce occurrence of CD8a+ 
cells in the proximity of muscle fibres, and our failure to observe CD8a+ cells 
invading non-necrotic fibers, argue against this explanation. Secondly, the 
increase of CD8a+ cells may reflect a delayed development of anti-viral CD8a+ 
T cell reaction. The finding that CBl inoculation in animals 72 hours or later 
after birth produces no myositis at all (unpublished data), suggests that neo­
natal CD1 mice have an immature immune system, and the presence of viral 
RNA in affected muscles up to 4 weeks after inoculation [16,25] suggests that 
the anti-viral response is indeed inadequate. So, a supportable explanation for 
the gradual increase of CD8a+ cells in muscle may be that at 1 week the CD8a+ 
cells are too low. As a consequence the anti-viral responses may decompensa­
te, acute viral myositis develops [24], and the prolonged presence of viral RNA 
in muscle gives room for the development of virus-specific T-cell-mediated 
immunopathology [24]. 
To further examine pathological resemblances between CBl myositis and 
polymyositis, we compared our data with those obtained by Arahata and 
Engel in human inflammatory myopathies [1]. To that end we computed simi­
lar percentages and ratios from our 8 week findings, - CD3+ (%), CD4+/CD3+ 
(%), CD8+/CD3+ (%), CD4+/CD8+ ratio, CD45R (%), and CD45R/CD3+ ratio 
-, and compared the grand means to those given for polymyositis and derma-
tomyositis [1]. In spite of the methodologie flaws of this approach, we were 
surprised that all CBl myositis values, both endomysial and perivascular, 
came closer to those in dermatomyositis than to those in polymyositis. In fact, 
CBl myositis has some other striking similarities to dermatomyositis: invaded 
necrotic fibers outnumbering non-necrotic fibers, deposition of Ig in intramus­
cular vessels, and fascicular and perifascicular atrophy of muscle fibers [9]. 
In conclusion, immunohistochemical analysis of inflammatory changes in CBl 
myositis showed that CD4+ Τ cells, and not CD8+ Τ cells, most likely play an 
effector role in muscle fiber injury. Thereabove, our data suggest that immune-
mediated vasculopathy might contribute to ischaemic necrosis, that the anti­
viral CD8+ response in neonatal CD1 Swiss mice might be defective, and that 
the composition of infiltrates in CBl myositis grossly corresponds to that in 
dermatomyositis. In all, our findings strongly suggest that the immunopatho-
logical effector mechanisms in CBl myositis bear more similarity to those in 
dermatomyositis than to those in polymyositis. 
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Predominant right leg dysfunction without 
asymmetric muscle inflammation in CD1 Swiss 
mice with Coxsackievirus В1-induced myositis 
PJH Jongen, Ρ Eling, LBA van de Putte 
(Physiology & Behavior, in press) 
CHAPTER 6 
Abstract 
To establish the existence of predominant right leg involvement in 
Coxsackievirus Bl-induced myositis (CB1 myositis) 189 neonatal CD1 Swiss 
mice were inoculated with 300 pfu CB1, and regularly observed for posture, 
mobility, and gait. After 2 and 4 weeks, quantitative comparison of motor dys­
function of right and left leg yielded an asymmetry score; on light microscopy 
mononuclear cell infiltration and muscle fiber necrosis were quantified in bila­
teral hamstring muscles, using a five-grade scale (0-4). Motor asymmetries 
were seen during acute viral myositis as soon as hind leg dysfunction appe­
ared, and animals with a predominant dysfunction of one leg preserved that 
preference throughout the observation period. At 2 weeks, mice with predo­
minant right leg dysfunction (n = 34) significantly outnumbered those with 
predominant left leg dysfunction (n = 11) (P = 0.01). At 2 and 4 weeks, infiltra­
tion and necrosis in hamstrings from legs with predominant dysfunction were 
not higher than in those from contralateral legs; and infiltration in right-sided 
hamstrings was not higher than in left-sided ones, nor was infiltration at 4 
weeks. At 4 weeks right-sided muscles were more necrotic (mean ± SD, 1.8 ± 
1.5) than left-sided muscles (1.1 ± 1.2; P=0.03). In the absence of predominant 
inflammatory disease of the right leg, we interpret the hind leg asymmetry as 
a preferential use of the left leg, due to left-leggedness, and suggest that in CD1 
Swiss mice left-leggednes is associated with increased susceptibility to CB1 
myositis. 
Introduction 
Inoculation of the Tucson strain of Coxsackievirus Bl (CB1) in neonatal CD1 
Swiss mice causes within 1 week after infection an acute viral myositis of the 
hind leg musculature, histologically characterized by widespread necrosis of 
muscle fibers and diffuse infiltration of polymorphonuclear and mononuclear 
cells [22,27,32]. Abnormalities in posture and gait appear a few days later 
[22,27,32]. After 2 weeks the inflammation develops into a chronic phase, CB1-
induced myositis (CB1 myositis), when virus can no longer be cultured from 
muscle tissue [27,32]. CB1 myositis is thougth to have an autoimmune origin 
and only occurs in the presence of Τ lymphocytes [35,36]. For its clinical, elec­
tromyographic, and histological resemblance to human polymyositis [8] CB1 
myositis is considered an experimental model for polymyositis [26,32]. Like 
the preceding acute viral myositis, CB1 myositis principally involves the proxi­
mal hind leg muscles, and weakness shows itself as decreased mobility, abnor­
mal posture and a waddling gait [24,26,27,32]. Severely affected animals deve­
lop a flexion deformity [27,32]. In contrast to other murine models for 
polymyositis [23,26] the motor abnormalities in CB1 myositis have been repor­
ted to be asymmetric, suggesting the predominant involvement of one limb 
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[24,27,32,35,36]. Curiously, the right leg seemed more affected than the left one, 
both on observation and on qualitative microscopy [26,27,32,35]. At present, 
however, no quantified observational data have been reported on predomi-
nant right leg dysfunction in CBl myositis, nor has its morphological basis 
been established on quantitative microscopy [24,26,27,32,35,36], or has a plau-
sible explanation been put forward for the right leg bias. To answer these 
questions, we quantified motor asymmetries in mice with CBl myositis on 
repeated observation and studied mononuclear cell infiltration and muscle 
fiber necrosis in right- and left-sided hamstring muscles on quantitative micro-
scopy. 
Methods 
Virus and cells 
The CBl Tucson strain was a gift from L. Minnich, M.S., and Dr. C. George Ray, 
University of Arizona, Tucson, AZ, U.S.A. [24,27]. Buffalo green monkey kid-
ney cells (BGM cells) were used for growth of CBl virus stocks and for plaque 
assays. BGM cells were grown in Eagle's Minimum Essential Medium with 
Earle's salts, 10% fetal bovine serum (FBS), penicillin (100,000 U/l) , and genta-
micin (50 mg/1). Maintenance medium contained 3% FBS. Virus was stored at 
-70°C. Dilutions of virus used in vivo were made in phosphate buffered saline 
(PBS). 
Animals and experimental design 
Specific pathogen-free random-bred pregnant CD1 Swiss mice were purcha-
sed from Charles River Wiga GmbH, Sulzfeld, F.R.G., and allowed to deliver. 
Offspring was randomly selected, inoculated, and caged with maternal mice in 
groups of 10-14 animals. A total number of 189 mice were inoculated intrape-
ritoneally within 24 hours after birth with 300 pfu of CBl in 0.1 ml PBS 
[18,19,20,27]. Twenty-two control animals were injected with 0.1 ml PBS. 
Animals were housed under normal laboratory conditions of 22 + / - 1 °C on a 
standard lightrdark schedule (12:12; lights on: 0800-2000) and with free access 
to standard laboratory diet and water. 
Observation of hind leg function 
To better recognize abnormal movements and motor patterns, we first perfor-
med a pilot study with other mice, making videos for detailed visual analysis. 
After inoculation mice were coded and observed every day during the first 2 
weeks, thereafter every other day until 4 weeks after inoculation. One experi-
menter (PJ) did all observations. For observation a single mouse was placed in 
the middle of an open square box measuring 25 cm width, 50 cm length, and 
20 cm height, the bottom of which was covered by a sheet of paper with a 
slightly rough surface to provide sufficient grip. The paper was changed regu-
larly to avoid distraction by odors from other mice. 
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After a short period of adaptation to the experimental condition, most animals 
appeared to moved freely inside the box. Mice that were indolent or immobile 
were stimulated mechanically by gently pulling at the base of the tail, to a 
maximum of three times. Observations were made during the light period with 
a room temperature of 22+/-1 °C and at the same time of day. To detect con­
sistent hind leg asymmetries, each animal was observed during 60 seconds for 
posture, spontaneous mobility, pattern of gait (waddling, dragging of a limb, 
flexion deformity), speed of gait, and ability to climb against the wall of the 
box. Having thus obtained an overall assessment of right leg dysfunction and 
left leg dysfunction, quantitative comparison of the two yielded a score for the 
asymmetry of hind leg dysfunction (hind leg asymmetry) as follows: R, right 
leg dysfunction and normal left leg function; R » L , much more right leg dys­
function than left leg dysfunction, with right leg not or hardly contributing to 
locomotion; R>L, more right leg dysfunction than left leg dysfunction, with 
both legs contributing to locomotion; R=L, no difference between right leg dys­
function and left leg dysfunction; R<L, less right leg dysfunction than left leg 
dysfunction, with both legs contributing to locomotion; R « L , much less right 
leg dysfunction than left leg dysfunction, with left leg not or hardly contribu­
ting to locomotion; L, left leg dysfunction and normal right leg function. For 
illustration see Figure 1. Scoring was blinded for the results of the preceding 
observations. It appeared that in the majority of mice at least two of the scores 
of days 13,14, and 15 were identical, and that score was considered the week 2 
score. In the other cases we also took into account the scores of days 11 and 12, 
and the score that occurred most frequently was considered the week 2 score. 
The same procedure was applied to obtain the week 4 score (days 24, 26, and 
28, and days 20 and 22, respectively). Thus, at 2 and 4 weeks animals with dys­
function of one or two hind legs were classified according to direction and deg­
ree of hind leg asymmetry. 
Histological examination 
At 2 weeks after inoculation every second animal (n = 31) was killed by cervi­
cal dislocation under ether anesthesia for histological examinations. The remai­
ning animals (n = 33) were killed at 4 weeks for the same examinations. 
Immediately after killing, quadriceps, hamstring, and gluteus muscles were 
removed in toto and placed in buffered formalin. Muscles were paraffin-
embedded and sectioned at 6 μτη. In a previous study we found that most 
extensive inflammatory and myopathic changes occurred in hamstring mus­
cles, in agreement with previous reports [19,38] and with the fact that these 
muscle were the most atrophic on macroscopy [27,32]. We also demonstrated 
that the histological changes (mononuclear cell infiltration, muscle fiber necro­
sis, central nuclei, fiber atrophy) were evenly distributed over the whole length 
of a muscle [20], and that cross section areas of hamstring muscles at 2 weeks 
did not differ significantly from those at 4 weeks [19]. Therefore, mid-portion 
transverse sections of left and right hamstring muscles were stained with hae-
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Figure ΙΑ-D Normal and abnormal gait in COI Swiss mice 4 weeks after CB1 inocu­
lation, observed from above. Figure 1A; normal hind leg function: right leg stretched 
with fully extended hip joint and semi-extended knee joint, left leg practically invisible 
due to fully flexed hip and knee joints. Figure IB; right leg dysfunction (score R): right 
hip joint partially extended and abducted, knee joint semi-flexed. Figure 1С; less right 
leg dysfunction than left leg dysfunction (score R<L): right leg partially visible due to 
incomplete hip and knee flexion. Figure 3D; more severely affected mouse than in figu­
re 1С (score R<L). For detailed description of scores see Methods. 
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matoxyline-phloxine-saffron and examined light microscopically (magnifica­
tion 250x). Slides were coded. To assess muscle fiber damage - the morpholo­
gical basis of hind leg dysfunction - and cellular inflammation - its underlying 
cause -, we quantitated mononuclear cell infiltration and muscle fiber necrosis 
per section using a five-grade scale, as described previously [18,19,20]. 
Infiltrating mononuclear cells per section: absent (0), less than 10 (+1), 10-50 
(+2), 50-100 (+3), more than 100 (+4); necrotic fibers per section: absent (0), 1-5 
(+1), 5-15 (+2), 15-25 (+3), more than 25 (+4). 
Statistics 
In mice with asymmetric leg dysfunction the McNemar (sign) test for discor­
dant pairs was used to compare the number of mice with predominant dys­
function of the right leg (R>L, R » L , or R) to the number of mice with predo­
minant dysfunction of the left leg (R<L, R « L , or L). Degrees of cell infiltration 
and fiber necrosis are given as mean values ± standard deviation (SD). The 
Wilcoxon test for matched pairs was used to compare values from right-sided 
muscles to those from left-sided muscles, and to compare values from legs with 
predominant dysfunction to those from contralateral legs. In all tests a Ρ value 
of 0.05 or less was considered significant. 
Results 
Observational data 
From 189 CB1 inoculated mice 46 died in the first week after infection from 
generalized viral disease, and five more in the second week, yielding a 2 week 
mortality of 27% . Of the surviving 138 mice, 64 (46%) had a dysfunction of one 
or both hind legs at 2 weeks. Commonly, hind leg dysfunction became detec­
table late in the first untili early in the second week. Asymmetries were seen as 
soon as leg dysfunction became manifest, and they were consistent in that, as 
soon as animals had a predominant dysfunction of one leg, they preserved that 
preference troughout the observation period. In none of the control mice were 
motor asymmetries observed, neither in the fore legs of the CB1 inoculated ani­
mals. 
Figure 2 shows the frequencies of scores for hind leg asymmetry at 2 weeks. 
The number of animals with a predominance of right leg dysfunction (R, R » L , 
R>L) (n = 34; 53%) was significantly higher than the number of animals with 
predominance of left leg dysfunction (R<L, R « L , L) (n = 11; 17%) (P = 0.01). 
Nineteen mice had a symmetric dysfunction (30%). Thirty-three mice were fol­
lowed for 4 weeks. In the additional two weeks no animal died. In some mice 
leg function improved, in 8 animals leading to a decrease of asymmetry, wit­
hout, however, affecting the direction of asymmetry. 
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Figure 2 Scores for hind leg asymmetry, i.e. right leg dysfunction (R) compared to left 
leg dysfunction (L), in 64 COI Swiss mice 2 weeks after CBl inoculation. See Methods 
for details. 
Number of animals 
L>>R L>R L=R L<R L<<R 
Hind leg dysfunction 
Histological data 
Degrees of mononuclear cell infiltration and muscle fiber necrosis in ham-
strings from legs with predominant dysfunction did not differ from those in 
hamstrings from contralateral legs, both at 2 weeks and at 4 weeks (Table 1). 
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Moreover, degree of cell infiltration in right-sided muscles did not differ from 
that in the left-sided muscles at 2 and 4 weeks, neither did the degree of necro­
sis at 2 weeks At 4 weeks right-sided muscles were more necrotic than left-
sided ones 
Table 1 Degrees (mean ± SD) of mononuclear cell infiltration and muscle fiber necro­
sis in CD1 Swiss mice with CB1 myositis at 2 weeks (n = 31) and 4 weeks (n = 33) after 
inoculation Cross sections of hamstring muscles quantified using a five-grade scale 
2 Weeks 4 Weeks 
Mononuclear Cell Infiltration 
Right side 3 3 ± 1 2 
I eft side 3 7 ± 0 7 
Predominant side 3 9 ± 0 8 
Contralateral side 3 6 ± 1 2 
Muscle hber Necrosis 
Right side 2 6 ± 1 5 1 8 ± 1 5 * 
Left side 2 9 ± 14 1 1 ± 12 
Predominant side 3 2 ± 11 2 5 + 13 
Contralateral side 2 4 ± 1 4 2 3 ± 1 7 
* Ρ = 003 Wilcoxon test for matched pairs 
Discussion 
In quantitative observations of motor asymmetries in CD1 Swiss mice with 
CB1 myositis we clearly established a preferential dysfunction of the right hind 
limb at 2 weeks 53% of affected animals had a predominant dysfunction of the 
right leg, being 76% of animals with asymmetric leg dysfunction In contrast, 
we obtained no evidence for a predommant right leg involvement, smce inf­
lammation m right-sided hamstrings was not higher than m left-sided ones, 
nor were inflammation and necrosis in legs with predominant dysfunction 
higher that m contralateral legs Although it cannot be excluded that to a cer­
tain degree asymmetric muscle involvement may play a role m some mice, our 
histopathological data as a whole fail to explain the evident right-bias in leg 
dysfunction Remarkably, motor asymmetries occurred as soon as leg dys­
function became observable, and m an individual animal the direction of 
asymmetry was preserved throughout the observation period Smce CB1 myo­
sitis develops from 2 weeks on [32,35], the asymmetry has to relate to the phase 
of acute myositis, and since there were no histopathological asymmetries, the 
motor asymmeties cannot result from the myositis as such 
1 8 ± 1 3 
1 5 ± 1 3 
2 1 ± 1 2 
2 0 + 10 
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Via the intraperitoneal route inocula may inadvertently be deposited in 
various intra- and extraperitoneal organs. Thus, CBl inoculation might lead to 
damage of retroperitoneal neural structures, and to neurogenic muscle weak­
ness. If so, the handedness of technicians could theoretically predispose to 
right- or left-sided neural damage. However, it is highly unlikely that retrope­
ritoneal deposition occurs in as many animals as we found having predomi­
nant right leg dysfunction. Moreover, histological examination of the perip­
heral nervous system by various investigators was normal [24,27,32], and 
gluteus, hamstring, and quadriceps muscles showed no neurogenic changes 
[19,27,32]. Another explanation for the predominant right leg dysfunction 
might be that in the acute phase of generalized viral disease cerebral hemisp­
heres become slightly inflamed, as has been reported in Coxsackievirus В viral 
myositis [22,24], and that predominant right leg dysfunction results from a left-
sided encephalitis. However, observation gave no signs of spasticity, nor gait 
disturbances suggestive of a cerebral laesion. In addition, on light microscopy 
of cerebral hemispheres no abnormalities were found, neither by us (data not 
shown), nor by others [27,32]. Therefore, we think there is a third and more 
likely explanation. As yet the predominant right leg dysfunction has been 
interpreted as that the right leg functions less than the left one [24,27,32,35]. 
However, our findings justify the alternative view that affected mice preferen­
tially use their left legs, due to left-leggedness. 
Postural and behavioral asymmetries have been documented extensively in 
mice and rats [9,16,30,37], even in their first days of life [1,9]. In experimental 
conditions mice show a pronounced, enduring, and not task specific preferen­
ce for the use of either the right or the left fore-paw [7,31]. Most murine strains 
have a right paw preference, but some preferentially use the left paw [21]. 
Interestingly, the degree of lateralization increases under stress conditions and 
after practice [2,28], especially practice in the postnatal phase [1], and once 
obtained lateralization remains present throughout the animal's life span [1]. 
As to CBl myositis, in neonatally inoculated mice acute and chronic disease 
means a stressful condition and bilateral muscle weakness forces the animal to 
practice in the postnatal days; hence, hind leg lateralization may increase con­
siderably and become manifest. The circumstance that adult mice have less 
potential for increase of lateralization can explain why predominant right or 
left leg dysfunction has not been reported in other animal models for myositis, 
using adult mice [23,26]. 
The fact that at 4 weeks right-sided hamstring muscles were more necrotic than 
left-sided ones, does not contradict our view, since it has recently been demon­
strated in humans that exercise during the active phase of polymyositis impro­
ves muscle strength [11,17]. Likewise, due to their spontaneous mobility, mice 
forcedly train their leg muscles and might induce regeneration. In consequen­
ce of their lesser use, right-sided muscles will undergo less training-induced 
regeneration and show relatively more necrosis. 
In asymmetrically affected CD1 Swiss mice the percentage of left-lateralized 
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animals (76%) is higher than the percentage of left-lateralized animals in 
strains with documented left lateralization, e.g. the ICR strain (68%) 
[9,21,30,37]. In view of the fact that the direction of an individual mouse's side 
preference is genetically determined [1,10,15], we suggest a specific relations­
hip to exist in individual CD1 mice between left-leggedness on the one hand, 
and susceptibility to CB1 viral myositis and CB1 myositis on the other. In line 
with the Geschwind-Galaburda hypothesis on the association between ano­
malous cerebral dominance and immune disorders [14], consistent relations 
were found between left-handedness and autoimmune disorders. Patients 
with allergies, asthma, or colitis ulcerosa have a higher incidence of left-han­
dedness than controls, and colitis ulcerosa and thyreoid! tis are consistently 
more common in left-handers than in right-handers [4]. Likewise, left-handed 
persons have an increased percentage of suppressor-inducer Τ cells [34], non-
right handers show an elevated incidence of circulating autoantibodies [5], and 
non-right-sided individuals have a significantly lower interleukin-2 (IL-2) pro­
duction [6]. Results in animals studies parallel those in humans [10,12,25]. Left-
pawed СЗН/HeNCrMTV mice have a lower natural killer (NK) cell activity 
and mixed leukocyte reaction (MLR) than their right-pawed strain-mates, and 
in the balb/cj strain, left-pawed mice have lower cytotoxic Τ lymphocyte 
response (CTL) and MLR than right-pawed animals [12]. Importantly, NK cell 
activity and CTL are major defence mechanisms against viral disease [3,12,22], 
and for an adequate anti-viral antibody response the positive effect of IL-2 on 
the proliferation of activated Τ cells is essential [29]. Mice with CB1 myositis 
have a prolonged presence of viral RNA in affected muscles (4 weeks), which 
is thought to play a role in the development to CB1 myositis [33,34]. Obviously, 
the delayed clearance of viral RNA indicates that anti-viral immune mecha­
nisms operate inadequately [32,35,36]. Thereabove, a defective CTL may play 
a role in secondary autoimmune reactions [3]. From this we hypothesize that 
left-legged CD1 Swiss mice - in contrast to their right legged strain-mates -
have a genetically determined impairement of immune function, predisposing 
them to develop CB1 myositis. Affected CD1 mice may also have a genetically 
determined high degree of lateralization, since it has been known that a high 
degree of lateralization is associated with decreased immune responsiveness: 
in mice selectively bred for either strong or weak degree of lateralization, only 
mice with a high degree of lateralization had lower immune functions than 
controls, manifest as reduced MLR, CTL, NK cell activity [13]. Finally, the asso­
ciation between immune function and paw-preference is a strain-dependent 
phenomenon [12]. In this respect, we mention that, from various strains tested, 
only left paw balb/c mice had lower NK and MLR [12], and that balb/c mice 
are also the only other strain in which CB1 myositis can be induced, be it to a 
limited degree [22,27]. 
To conclude, we demonstrated that CD1 Swiss mice with CB1 myositis have a 
predominant dysfunction of the right leg, and that, contrary to expectation, 
right-sided muscles are not more inflamed than left-sided ones. We intrepret 
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the observed asymmetry as a preferential use of the left leg, i.e. as a manifesta­
tion of left-leggedness, and suggest that in CD1 Swiss mice left-leggednes is 
associated with impaired immune functions, rendering them susceptible to 
CBl myositis. 
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Introduction 
Acute myositis as a result of Coxsackie В virus (CB) infection in neonatal mice 
has long been recognized [7], but it was not until 1979 that Ray, Minnich, and 
Johnson reported that CB1 infection in neonatal out-bred Swiss mice induced 
a chronic myositis, while virus was no longer detectable [27]. A high-passage 
laboratory strain (Tucson) of CB1 produced an inflammatory myopathy, that 
selectively affected the proximal hind leg muscles [27]. Strongwater et al. 
described CBl-induced myositis in CD1 Swiss in more detail [31]. Virus was 
only recovered during the acute phase of myositis, up to 2 weeks after infec­
tion [28]. On behalf of its clinical, electromyographic, and pathological resem­
blances to human polymyositis, CB1 myositis was coined as a model for poly­
myositis [31]. It was demonstrated that the use of active virus [37] and the 
presence of Τ cells [39,40] are required for the development of CB1 myositis, 
but the pathogenic mechanisms underlying tissue injury were far from clear. 
In recent years work in our laboratory and by the group of Ytterberg has con­
siderably increased our onderstanding of CB1 myositis. It is the purpose of this 
review to present the data now available, to discuss pathogenic mechanisms, 
and to reconsider the use of CB1 myositis as a model for human inflammatory 
muscle disease. 
Clinical characteristics 
On clinical observation muscle weakness becomes evident 7-10 days after 
infection in the proximal muscle groups of both hind legs, predominantly in 
the hamstring (extensor) muscles [27,31]. The bilateral weakness results in a 
waddling gait [31,37]. Due to abnormal posture and gait, or their decreased 
mobility, affected animals are not difficult to recognize. The degree of weak­
ness varies between mice and severely affected animals dragg with one or two 
legs or show hips extremely flexed and rotated forward [31]. Weakness 
progresses until the age of 3 weeks [31]. Thereafter some animals improve, but 
in the majority of cases the hind leg dysfunction remaines unchanged for at 
least 4 months [14,42]. 
Creatine kinase serum concentrations have been reported to be increased in 
CB1 myositis [31]. However, in our experience repeated measurement in indi­
vidual animals shows a great variation, and there is a considerable overlap 
between affected and control animals; we were unable to reproduce significant 
CK elevations in clinically affected animals, as compared to controls (unpu­
blished data). 
After CB1 challenge proximal muscles show fibrillations, positive sharp 
waves, and complex repetitive dyscharges on electromyography (EMG) [31]. 
These abnormalities are most marked in proximal hindquarter muscles early in 
the course of the disease and later become virtually confined to proximal mus-
88 
C B l MYOSITIS: RFVIFW 
culature [31]. Fibrillations and positive sharp waves are detectable up to 24 and 
18 days, respectively [31]. Complex repetitive dyscharges are profuse to mode-
rate in the first 2 weeks, thereafter they are only minimal [31]. 
As to changes of muscle metabolism in CBl myositis, it was demonstrated that 
the biceps femoris muscles from 4 week old animals have significant variation 
in glucose utilization and enzyme activities [2]. Thereabove, the total lactate 
generation by the myositis muscle is increased five-fold compared to controls, 
and the C02 production is increased as a result of pentose shunt activity, a 
pathway not utilized in normal muscle [2]. 
Two more aspects of CBl myositis should be mentioned. First, the decisive role 
of host factors. Minnich and Ray reported that Balb/c or C3H mice similarly 
inoculated showed no myositis, thus establishing differences in susceptibility 
of mouse strains [21]. Secondly, the age at which animals are inoculated is a 
very critical factor in CBl myositis. Mice have to be inoculated within 48 hours 
after birth [31]. Inoculation of animals of 72 hrs. or older does not lead to acute 
viral myositis, nor to CBl myositis [P Jongen, unpublished data]. 
Pathological features 
On macroscopy the extensor muscles of the hind legs are grossly atrophic the 
second week after infection, thereafter they often have a fibrotic and whitish 
appearance [27,31]. The following sequence of histological abnormalities 
reflects the changes observed on light microscopy: earliest changes on day 4, 
consisting of interstitial edema and necrosis of isolated muscle fibers, surroun-
ded by inflammatory cells; on day 6 widespread necrosis of muscle cells, seve-
re interstitial edema, diffuse infiltration with polymorphonuclear cells, lymp-
hocytes, and plasma cells, and phagocytosis of necrotic fiber segments; by day 
8 active regeneration and dystrophic myofiber calcification; by day 14 marked 
variation in fiber size, centralization of myocyte nuclei, rounding of cell con-
tours, and focal round cell infiltrates with occasional eosinophils; on day 21 
adipose tissue begins to replace lost myofibers; the severe atrophy with fatty 
replacement and myopathic changes in residual muscle is also found at 23,30, 
and 42 days; myocyte regeneration remains active as late as 4 months 
[14,27,31]. Thus, overall there appears to be an initial acute generalized inf-
lammatory reaction which progresses to the stage of focal, chronic inflamma-
tion and then may gradually begin to resolve [14,27,31]. Inflammation is not a 
persistent feature [14,27,31]. Overall, inflammation seems to parallel the activi-
ty of the necrosis, although isolated necrotic muscle fibers are a permanent fin-
ding [27,31]. 
As mentioned above, CBl myositis is a selective myositis of proximal hind leg 
muscles. In muscles not belonging to the hind-quarter group changes are mini-
mal and only present in 4 and 6 days old animals [31]. Remarkably, the degree 
of abnormalities vary among different hind quarter muscles, even in the same 
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animal [27,31]. Non-quantifying studies suggested that on macroscopy hip 
extensors (hamstrings) were more affected than hindquarter knee flexors, and 
that microscopically the former muscles show more severe lesions than gast­
rocnemius and soleus muscles [27,31]. In a quantitative microscopic comparis­
on hamstring muscles were indeed significanlty more intensely affected than 
gluteus and quadriceps muscles, both regarding inflammation and necrosis 
[14]. Moreover, there was a conspicuous partition of abnormalities, in that they 
were usually confined to one or more fascicles, and that affected fascicles were 
involved all along their length [14]. Characteristic features of CB1 myositis 
were furthermore perifascicular atrophy, necrotic and non-necrotic fibers inva­
ded by mononuclear cells with necrotic fibers being more frequently invaded 
than non-necrotic ones [14]. 
Electron microscopicy of mice less than 2 weeks old failed to reveal evidence 
of Picornavirus infection [31]. Perfusional electron microscopic studies of hip 
flexors and extensors of normal and myositic 3 month old mice showed that 
normal muscle contains regularly branching arteries and a uniform longitu­
dinal capillary network, surrounding individual muscle fibers [18]. In contrast, 
in myositic mice the muscle microvascular pattern was disrupted and chaotic, 
with occlusions at the second and third branchings of the arterioles, and 
adjacent areas of muscle tissue devoid of the longitudinal capillary network 
[18]. 
The muscle-specificity of CB1 myositis has been firmly established. 
Histological studies of extra-muscular organs were negative for inflammatory 
and necrotic changes [27,31]. The central nervous system, including coronal 
sections of cerebrum at the level of the olphactory bulbs, corpus callosum, cor­
pus striatum, and thalamus, as well as of sections through the pons and all 
levels of the spinal cord, revealed no significant changes [27,31]. No alterations 
were seen in the peripheral nervous system, studied at the level of the dorsal 
root ganglia and proximal and distal nerve trunks in the upper and lower limbs 
[27]. Likewise, heart, pancreas, diaphragm, spleen, and liver show no abnor­
malities on light microscopy (31; Ρ Jongen, unpublished data). 
Asymmetric dysfunction 
A remarkable observation was that most clinically affected animals show an 
asymmetric weakness of their legs, with a preferential predominance of right 
leg weakness [27,31]. On macroscopy the right lower extremity seemed more 
severely affected than the left, since muscle atrophy was often accentuated on 
the right half of the body [27]. On microscopy most severe lesions were repor­
ted in the right hip extensors, as compared to left-side muscles, but findings 
were not quantified [27]. Jongen et al. performed a quantitative comparison of 
motor dysfunction of right and left leg, and quantitative light microscopy of 
mononuclear cell infiltration and muscle fiber necrosis in hamstring muscles 
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[11]. Motor asymmetries occurred during acute viral myositis as soon as hind 
leg dysfunction appeared, and animals with a predominant dysfunction of one 
leg preserved that preference [11]. Moreover, at 2 weeks mice with predomi-
nant right leg dysfunction significantly outnumbered those with predominant 
left leg dysfunction [11]. However, at 2 and 4 weeks infiltration and necrosis in 
legs with predominant dysfunction were not higher than in contralateral legs, 
and infiltration in right-sided hamstrings was not higher than in left-sided 
ones, nor was infiltration at 4 weeks [11]. The authors suggested that the hind 
leg asymmetry in CBl myositis most likely results from a preferential use of the 
left leg, possibly due to left-leggedness [11]. 
Virological aspects 
Not only the genetic background of the host but also the virus strain is crucial 
for the development of CBl myositis. It was found that six different low-pas-
sage field isolates of CBl isolated from infected patients varied considerably in 
their capability to induce myositis [21]. Thereabove, inoculation with active 
virus is mandatory for the induction of CBl myositis. Inactivated virus did 
cause virus-specific antibody production, but acute myositis and CBl myositis 
did not develop, histologically nor clinically [37]. Another viral factor that 
plays a role is the virus dose. Strongwater reported that an infectious dose of 
300 plaque forming units (pfu) was optimal to produce clinical weakness in 70-
80% of challenged animals with an accompanying mortality of less than 30% 
[31]. Jongen et al., using dosages ranging from 30 to 10,000 pfu, found that at 4 
weeks morbidity and mononuclear cell infiltration differed significantly for the 
various dose groups, with the most prominent changes in 300 pfu animals, 
thus establishing that the dose is a pathogenic factor in CBl myositis [13]. 
Virus can be recovered from skeletal muscle 2 days after inoculation, with peak 
titers of infectious virus on the 5th and 6th day [31]. Virus is entirely cleared 
from muscle on day 14 [31,32,42]. Indirect immunofluorescence examination of 
muscle tissue for the presence of CB or CB-associated antigens showed that by 
2 weeks there was no demonstrable evidence of these antigens [31]. However, 
Zhang et al., by using molecular hybridisation and biotynilated probes, detec-
ted enterovirus RNA in paraffine-embedded tissue samples from 2 weeks old 
CBl infected mice [41]. Viral RNA was localised in affected muscle fibers. More 
recently, sensitive polymerase chain reaction (PCR) techniques detected viral 
RNA up to 4 weeks after initiation of infection [41]. Since these data indicate a 
slowy waning infection rather than viral RNA persistence, it was suggested 
that CBl plays an essential role in the initiation of CBl myositis, but not in the 
maintenance of the chronic disease [32,42]. 
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Immunological findings 
Ytterberg and co-workers were the first to demonstrate the importance of Τ 
cells in the pathogenesis of CB1 myositis. After inoculation of Τ cell deficient 
athymic nude (nu/nu) mice and heterozygotes (nu/+) with normal Τ cell func­
tion, clinical weakness and histopathology of CB1 myositis developed only in 
nu/+, whereas anti-viral antibody production was similar in both groups [39]. 
Moreover, reconstitution of infected nude mice with spleen cells from normal 
mice resulted in disease [39]. Likewise, in neonatally thymectomized animals 
only 8% of mice had clinical weakness and histological CB1 myositis, in con­
trast to 43% of sham operated animals [40]. On quantitative light microscopy 
Jongen et al. showed that mononuclear cell infiltration correlates positively to 
muscle fiber necrosis [14]. In an immunohistochemical analysis of inflammato­
ry changes using mono- and polyclonal antibodies these investigators demon­
strated that CD4+ cells, and not CD8+ cells, surround and infiltrate necrotic 
and non-necrotic fibers, and that invaded necrotic fibers are far more frequent 
than non-necrotic ones [15]. These findings are in line with an abstract report, 
stating that deletion of the CD8+ subset in animals does not prevent the deve­
lopment of CB1 myositis [38]. In adoptive transfer experiments Skemp and 
Ytterberg inoculated spleen cells from CB1 inoculated CBA/J mice into 3-
weeks old CBA/J mice: by 2-4 weeks muscle fiber abnormalities associated 
with scant inflammatory cells were seen, but no animals became weak [30]. The 
authors concluded that the occurrence of isolated myositis in inbred CBA/J 
mice supports the hypothesis that immune cells capable of recognizing muscle 
fibers are generated in CBl-induced murine myositis [30]. However, the limi­
ted number of mice studied does not permit far-reaching conlusions. With 
respect to the inflammation in acute viral myositis, muscle tissue contains very 
few CD8+ cells, and although their proportion increases during CB1 myositis, 
it remains low [15]. A related observation was that in CB1 myositis the overall 
composition of endomysial and perivascular infiltrates comes closer to that in 
human dermatomyositis than that in polymyositis [15]. 
A rise in specific serum antibody titer directed against CB (microneutralization 
assay) is first detectable by day 6, by day 12 there is an eightfold increase in 
serum neutralizing capacity, and titers remain elevated for at least 8 weeks 
[31]. It was demonstrated that at 4 and 8 weeks clinically affected animals have 
significantly higher antibody titers than clinically unaffected animals, and that 
at 4 weeks necrosis and infiltration correlates positively with the serum anti­
body titer [13]. Anticytoplasmic and other known autoantibody specificities, 
occurring in human inflammatory muscle disease, are absent in CB1 myositis 
[13]. Interestingly, from 2 weeks on moderate quantities of circulating immu­
ne complexes (Raji-cell assay) occur in nearly all infected mice, without corre­
lation to histological changes [12]. Neither does hemolytic complement activi­
ty (CH50 titre) correlate to muscle lesions, except for a positive correlation at 4 
weeks [12]. On immunohistochemical analysis with polyclonal antibodies 
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most muscle fibers, normal and necrotic, are positive for C3c, IgG, or IgM at 4 
and 8 weeks, but necrotic fibers clearly stain more intensely [15]. Thereabove, 
in a single animal IgM was deposited in a venule [15]. 
Pathogenesis 
Basic concept 
The phase of viral myositis plays a pivotal role in the development of CBl myo­
sitis, as is shown by the fact that CBl myositis only occurs after preceding acute 
myositis due to infection with active virus [37]. But, CBl myositis is not simp­
ly a sequela of acute myonecrosis, since T-cell deprived mice recover from 
acute myositis and do not develop chronic inflammation [39]. The reviewed 
data suggest that various processes may be at work in CBl myositis, and that 
a particular constellation of circumstances leads to a sequence of pathogenic 
events. Based on the presence of viral RNA in muscle 4 weeks after infection, 
we argue that the period between 2 and 4 weeks represents the protracted reso­
lution phase of the acute viral myositis. The prolonged presence of viral RNA 
may be crucial for the induction of processes responsible for the inflammation 
after 4 weeks. In fact, the prolonged presence of viral RNA indicates that in 
neonatal CD1 Swiss mice CBl infection is not totally lytic, leaving room for 
autoimmune reactions to develop. So, we presume that the induction of CBl 
myositis (developmental phase, 2 to 4 weeks) and its maintenance represent 
different pathogenic stages. 
Probably the immune system of neonatal CD1 Swiss mice is not capable of ade­
quate viral clearance. The very few CD8+ Τ cells in acutely inflamed muscle 
suggests that the cellular component in anti-viral response may be deficient 
[15]. Rapid maturation of the immune system could explain for the failure to 
induce acute or chronic inflammation in animals 72 hours of age. In very young 
animals the disbalance between viral challenge and inadequate anti-viral def­
ence has two important consequences: [1] severe acute inflammation and 
necrosis, and [2] prolonged presence of viral RNA. Before discussing the pro­
cesses related to these particularities, we first bring up an other aspect of acute 
CBl infection. 
Vasculopathy 
Like in Coxsackie B3 virus-induced cardiomyositis (CB3 cardiomyositis) [29], 
CBl myositis has electron microscopic evidence of a vasculopathy of small 
arterioles and capillaries [18]. Correspondingly, light microscopy shows fasci­
cular involvement and perifascicular atrophy, indicating ischaemia [14]. The 
occurrence of the latter abnormalities 1 week after infection suggests that the 
vasculopathy originates early [14]. Since it has been known that the selective 
tropism of CB virus for particular organs corresponds to the ability to infect 
vascular endothelial cells [8], it may be assumed that the infection of vascular 
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endothelium not only enables CI31 to pass into muscle, but also induces the 
development of microvasculopathy. E.g. anti-viral antibodies might bind to 
intravascular viral RNA or cross react with endothelial antigens. After 2 weeks, 
the occurrence of circulating immune complexes and vascular IgM deposition 
- albeit a single observation - might have their part in the continuation of the 
microvasculopathy [12,15]. 
The ischaemia clearly affects mitochondrial function, as is demonstrated by the 
five-fold increase of total lactate production in 4 week old mice with CB1 myo­
sitis [2]. The impaired metabolism may contribute to weakness. Probably more 
important in terms of pathogenesis is that severe ischaemia leads to structural 
lesions of muscle fibers (or other muscle constituents), in addition to damage 
caused by the viral infection. So, formation of neo-antigens or revelation of hid­
den antigens is to be expected. Secondary autoimmune mechanisms may lead 
to continuation of CB1 myositis by sustaining inflammation and tissue dama­
ge-
Cellular immunopathology 
Autoimmunity in mice may arise in different ways [9,10,22,23]. In the autoim­
mune reactions in CB1 myositis Τ cells are pivotal, as is demonstrated by stu­
dies in T-cell deprived mice [39,40]. Deletion experiments and immunohisto-
chemical phenotyping of inflammatory cells strongly suggest that CD4+ Τ 
cells, and not CD8+ Τ cells, are decisive in this respect [15,30,38]. In analogy to 
what is known in CB3 cardiomyositis [9,10], we suggest these CD4+ cells to be 
cytotoxic and to include two types: CB1 specific cytotoxic cells, recognizing 
CB1 antigens, and metabolic cytotoxic cells, recognizing muscle neoantigens 
induced by viral infection or ischaemia. In CB3 cardiomyositis, cellular neoan-
tigcn only occurs on cells exposed to infectious virus where cellular metabo­
lism is altered [6]. In case CB1 virus possesses antigenic determinants that 
mimic epitopes found on muscle antigens, a cross reactivity to these latter anti­
gens may arise [34]. 
Provided that cytotoxic CD4+ Τ cells occur, the following sequence of immu­
nological events is conceivable. Peptides from CB1 antigen (or muscle 
[neo]antigens) are presented to Τ cells by macrophages, present in the muscle 
in response to the initial viral infection. Then, activation and proliferation of Τ 
cells result in release of cytokines (e.g. interleukin 2, interferon gamma), and 
locally released cytokines induce aberrant expression of MHC class II antigen. 
MHC class II molecules on muscle fibers then may serve as functional antigen-
presenting cells to CD4+ cytotxic cells. Destruction of muscle fibers begins 
when CD4+ Τ cells encounter their antigens in conjunction with MHC mole­
cules expressed on muscle cells. Moreover, recent evidence obtained in sever­
al T-cell mediated organ-specific auto-immune diseases in mice indicate that 
selective death of organ-specific cells may be due to a non-specific inflamma­
tory attack by means cytokine production by Thl CD4+ cells. This selective 
bystander killing is thought to result from an imbalance of mediators released 
by Thl versus Th2 cells [17]. 
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Humoral immunopathology 
In CB3 cardiomyositis, murine strains that display prolonged myocarditis also 
produce myocard-specific autoantibodies, whereas strains with short disease 
duration do not [36]. Thereabove, relations were found between the duration 
of viremia, titer of neutralizing antibody, and degree of myocardial disease 
[36], and a recent report showed that some anti-СВЗ monoclonal neutralizing 
antibodies can participate in proinflammatory reactions in vitro and induce 
cardiopathologic alterations in vivo [6]. In CBl myositis, the positive correla­
tion of CBl neutralizing antibodies with degree of histopathology [13], sugge­
sts that anti-viral antibodies participate in pathogenesis. In fact, helper CD4+ Τ 
cells might activate В cells to produce CBl-specific antibodies. Synergism on 
effector level between cytotoxic Τ cells and auto-antibodies might also occur in 
CBl myositis: in СВЗ-induced cardiomyositis a monoclonal antibody, cross-
reactively binding heart tissue and virus, was not directly injurious to cardio-
cytes alone or in the presence of complement, but autoreactive Τ cell mediated 
cytotoxicity tripled in the presence of the antibody [35]. The increased deposi­
tion of IgG and IgM on abnormal and necrotic fibers might represent cross 
reactivity of anti-viral antibodies to released muscle antigens or a secondary 
antibody attack against neoantigen [15]. Whether antiviral antibodies react 
with muscular antigens via complement is not clear. On the one hand have 
IgG, IgM, and C3c been found increased on abnormal fibers [15], on the other 
hand, serum CH50 levels were not related to tissue damage [12]. 
It is conceivable that antibodies are also involved in the development of micro­
vascular changes, either via reaction with endothelium or through participa­
tion in immune complexes. Since viral RNA is absent after 4 weeks [32,42], the 
circulating complexes then occuring are unlikey to include a CBl antigen. A 
plausible composition of these complexes would be released muscle (neo)anti-
gen, mimicking CBl determinants, and complexed by CBl-specific antibodies. 
However, since the В cell response after viral inection is polyclonal, other anti­
body specificities may be involved as well. Notably, the inoculation dose-
dependency of CBl myositis may relate to the role of immune complexes, since 
complex formation critically depends on availability of both antigen and anti­
body. Finally, speculating on a possible role of anti-idiotypic antibodies in CBl 
myositis, we refer to a report by Paque and Miller on CB3 cardiomyositis; the 
affinity of anti-idiotypic antibodies to bind myocytes or solubilized myocyte 
proteins of virus-exposed animals, and the presence of an autoantibody capa­
ble of binding idiotypes, suggest that autoanti-idiotypes exhibit mimicry of 
myocyte antigens [24]. However, in spite of the intriguing possibilities of anti­
body and immune complex involvement in CBl myositis, to date the evidence 
favoring suchlike mechanisms is less firm than that on cell-mediated immuni-
ty· 
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Pathogenic scheme 
We think it unlikely that all abnormalities in CB1 myositis can be explained by 
one major pathogenic process or by a single unifying principle. In the above we 
roughly delineated how different factors may synergize for the induction and 
maintenance of CB1 myositis: acute CB1 infection, vasculopathy, ischaemia, 
prolonged presence of viral RNA, T-cell autoimmunity, and possibly antibo-
dy-mediated fiber injury all represent distinct pathogenic processes, which are 
more or less likely to take place, complementing or potentiating one each other 
(figure 1). A central notion is that in neonatal CD1 Swiss mice CB1 infection is 
not completely lytic, a view that is contrary to convention. Thus, we come to 
distinguish three major stages in the pathogenesis of CB1 myositis: [1] the pre-
liminary phase: acute viral myositis (up to 2 weeks after infection), [2] the deve-
lopmental phase: induction of autoimmunity (2 to 4 weeks), and [3] the main-
tenance phase: sustained autoimmunity (4 to at least 16 weeks). Evidence 
supporting this distinction again comes from the CB3 myocarditis model, in 
which the persistence of virus for 5 weeks or longer did not correlate with 
ongoing myocarditis and vice versa [5,26]. Studies in different murine strains 
with CB3 myocarditis indicate that the genetic regulation of susceptibility to 
CB3 infection and the viral inflammation differ from the later autoimmune 
myocarditis [26,36]. 
A model for polymyositis? 
In polymyositis progressive weakness is due to inflammation of skeletal mus-
cles and necrosis of muscle fibers, leading to increased serum CK concentration 
and EMG abnormalities [3,16]. Often the weakness has as a limb-girdle distri-
bution, suggesting that most severe inflammation occurs in proximal muscles. 
Involvement of extra-muscular organs is exceptional. Accordingly, the dia-
gnostic criteria for definite polymyositis are: progressive muscle weakness, 
increased serum CK concentration, EMG abnormalities, and on muscle biopsy 
mononuclear cell infiltration leading to fiber necrosis [3]. It could be claimed 
that, in order to be a model of polymyositis, CB1 myositis should meet these 
diagnostic criteria. In fact, it were the clinical, electromyographic, and patho-
logical similarities to polymyositis that brought Strongwater et al. to consider 
CB1 myositis as a model for polymyositis [231]. 
CB1 myositis selectively affects skeletal muscles, and the predominant invol-
vement of hind-quarter muscles corresponds with the limb-girdle weakness in 
men. Hind leg dysfunction can readily be observed, and most probably results 
from muscle weakness, although it may partly be due to pain and discomfort. 
Weakness progresses for approximately 3 weeks after inoculation, with most 
dysfunction developing in the second week, the phase of viral myositis [27,31]. 
Weakness persists for at least 16 weeks, although function may recover slight-
ly in some animals [124]. So, strictly spoken, progression of weakness during 
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Figure 1 Schematic representation of possible pathogenic mechanisms in CBl 
myositis 
CBl inoculation 
S 4 
Infection of 
Vascular endothelium 
Systemic Infection 
S 4 s ч 
CBl passage 
1 
Microvasculopathy Anti-CBl antibodies 
1 
\ 
1 
Deficient 
CD8+ response 
1 
CBl infection 
muscle fibers 
Ischaemia Immune complexes Prolonged presence 
viral RNA 
1 * 1 
Impaired 
metabolism 
Tissue damage 1 
ч s 
Metabolic 
CD4+ CTL 
CBl-specific 
CD4+ CTL 
97 
CHAPTER 7 
CBl myositis is rather short, about 1 week. Therefore, the motor impairement 
occurring after 3 weeks may be interpreted as being, to a certain degree, the 
permanent sequela of the acute viral myositis. 
Unequivocal evidence of increased serum CK concentrations in CBl myositis 
is lacking. With respect to EMG abnormalities, findings strongly suggestive of 
active myositis are present during acute viral myositis, whereas abnormalities 
during CBl myositis are less impressive [31]. Since, however, CK and EMG 
measurements only indirectly reflect the underlying disease process, biological 
differences between the murine and the human species could partly explain for 
the negative findings. Histological changes are of more importance, since they 
reflect aetio-pathogenic processes more directly. 
The histological characteristics of polymyositis include endomysial infiltrates 
of numerous CD8+ Τ cells and sparse В cells, and CD8+ Τ cells surrounding 
and invading muscle fibers, with non-necrotic fibers being equally frequent as 
necrotic ones [1,16]. In CBl myositis immunophenotyping of inflammatory 
cells showed that CD4+ Τ cells surround and invade non-necrotic fibers, that В 
cells are not rare, and that the great majority of invaded muscle fibers is necro­
tic [15]. Overall, the composition of endomysial and perivascular infiltrates in 
CBl myositis bears more resemblances to findings in dermatomyositis than to 
those in polymyositis [15]. This is in line with the fact that in dermatomyositis 
CD4+ Τ cell and В cell proportions are higher than in polymyositis [1,16]. In 
addition, the occurrence in CBl myositis of perifascicular atrophy [14,15], iso­
lated necrotic fibers [14,31], intravascular IgM deposition (although a single 
observation) [15], and of an abnormal capillary network [18] are similar to 
abnormalities in dermatomyositis. Therefore, from a pathological point of 
view, CBl myositis models dermatomyositis more accurately than polymyosi­
tis. The fact that CBl myositis only develops in neonatal mice suggest a closer 
look at possible similarities between CBl myositis and childhood dermatomy­
ositis. 
Future applications 
At the end of this review we briefly outline potential applications of CBl myo­
sitis. As we concluded, there is little support for the notion that CBl myositis 
is a model for polymyositis, but there is sound evidence for the use of CBl 
myositis as a model for dermatomyositis, in spite of the fact that skin abnor­
malities are absent. Thereabove, this murine disorder has striking clinical simi­
larities with self-limiting viral or virus-induced myopathies with a benign 
course, like pleurodynia and benign acute childhood myositis [28]. From a 
pathological point of view, there are resemblances to a rare myopathy called 
pipe-stem myositis [4,14]. However, in stead of trying to designate CBl myosi­
tis as a model for a particular type of human myositis, we suggest another 
approach, which may be more fruitful. 
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The various human inflammatory myopathies, including those of unknown 
origin, are not clearly demarcated disease entities, but rather clinicopathologic 
syndromes with different pathogeneses and complex immunoregulatory 
abnormalities [20]. Thus, a particular pathogenic factor may be at work in 
various disorders, and a particular clinical disorder may involve different 
pathogenic mechanisms. Consequently, the value to be gained from studying 
CBl myositis may lie in its heuristic potential regarding basic aspects of inf­
lammatory muscle disease: experimental results in CBl myositis might enhan­
ce our understanding of various aspects of different inflammatory muscle dis­
eases. We think that CBl myositis could help to elucidate questions concerning 
the role viruses play in inducing inflammatory muscle disease, the role played 
by vascular factors, and factors making that acute inflammation becomes chro­
nic. Answering these questions will touch the genetic base of CBl myositis. 
Whether an inoculated mouse will develop CBl myositis, as well as the diver­
sity in degree and duration of disease is most likely related to the genetic make­
up of individual animals, implicating MHC and non-МНС genes. Like in CB3 
myocarditis, susceptibility to acute viral myositis and virus-induced myositis 
may be primarily regulated by the MHC [10,36]. T-cell-mediated responses are 
МНС-restricted and the MHC may affect predisposition to chronic autoimmu­
ne myositis by several mechanisms [33]. On the other hand, H-2 congenie mice 
strains with CB3 myocarditis and antibody-mediated immunopathology 
differed in prevalence and titer of autoantibodies, suggesting non-МНС con­
trol of antibody production [10,36]. In the non-obese diabetic mouse, suscepti­
bility genes as well as diabetes-resistent genes exist, with protective alleles 
conferring various degrees of resistance to diabetes [33]. It can be expected that 
such-like genes may be found in CBl myositis, and that they explain variations 
in clinical disease between animals. Findings in other organ-specific autoim­
mune diseases in mice indicate that the genetic basis for developing CBl myo­
sitis might be defined by specific combinations of several predisposing loci on 
multiple chromosomes [33]. 
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CHAPTER 8 
Summary 
A persistent infection of enteroviruses and cardioviruses has been implicated 
in polymyositis and dermatomyositis, but conventional hybridisation studies 
on the presence of enterovirus RNA and encephalomyocarditis-virus (EMC) 
RNA in affected muscle yielded conflicting results. To investigate further the 
possibility of viral persistence, the presence of viral RNA in muscle from 
patients with adult onset polymyositis and dermatomyositis was investigated 
using a polymerase chain reaction (PCR) technique. Muscle tissue was obtai­
ned from 10 patients with polymyositis and five patients with dermatomyosi­
tis, all with adult onset active disease. A PCR was performed using primers 
with high specificity for enterovirus and EMC RNA, followed by Southern blot 
hybridisation with an oligonucleotide probe directed against the internal por­
tion of the amplified product. A PCR directed against the Abelson tyrosine 
kinase mRNA served as an internal control for the presence and quality of 
RNA. A specific amplification for enterovirus or for EMC virus could not be 
seen, despite a sensitivity of about 30 plaque forming units for enterovirus and 
of 100 plaque forming units for EMC virus. Southern blot hybridisation confir­
med the results in that positive controls hybridised with the oligonucleotide 
probe, but no signal was obtained with the muscle specimens. 
Using a sensitive and specific PCR technique no evidence was found for the 
presence of enterovirus or EMC RNA in muscle from patients with polymyo­
sitis or dermatomyositis. These data do not support the proposal that viral 
RNA persistence plays a part in these idiopathic inflammatory myopathies. 
Introduction 
Polymyositis and dermatomyositis are specific diagnoses in the group of inf­
lammatory myopathies [1,2]. In these two disorders an autoimmune origin is 
supported by the presence of various autoantibodies, the evidence of myotoxi-
city mediated by cytotoxic Τ cells or complement-mediated microangiopathy, 
their response to immunotherapies, and their association with diseases of 
which the autoimmune character has been established more firmly [1-3]. The 
agents initiating self-sensitisation and the specific antigens against which the 
immune reactions are directed are unknown, however [1]. 
Viruses can induce autoimmunity in mice [4-6] and, probably, in humans [4,7]. 
Electron microscopic [8] and serological studies [9,10] have implicated the 
enterovirus and cardiovirus subgroup of picornaviruses in polymyositis and 
dermatomyositis, but reports of the isolation of the viruses from muscle tissue 
are rare [1]. Dot spot hybridisation studies of the presence of enterovirus-spe-
cific RNA in affected muscle have yielded conflicting results. Bowles et al 
found Coxsackie В virus-specific RNA in muscle tissue from patients with 
polymyositis or dermatomyositis [11], whereas Bunn and Walport could not 
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detect this virus in patients with polymyositis [12]. Unconfirmed in situ hybri­
disation studies in patients with polymyositis and dermatomyositis have 
found enterovirus-specific [13] or encephalomyocarditis (EMC)-specific RNA 
[14]. 
Persistent infection of enterovirus and EMC virus as a pathogenic factor in 
polymyositis and dermatomyositis is therefore a subject of controversy. To 
investigate further the possibility of viral RNA persistence in polymyositis and 
dermatomyositis, we extracted RNA from muscle biopsy samples from 
patients with active disease, and used a highly specific and sensitive polyme­
rase chain reaction (PCR) technique for the detection of enterovirus and EMC 
RNA. 
Table 1 Diagnosis, age, sex, duration of symptoms, and associated diseases of the 
patients with polymyositis (PM) and dermatomyositis (DM). 
Patient 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
Diagnosis 
PM 
PM 
PM 
PM 
PM 
PM 
PM 
PM 
PM 
PM 
DM 
DM 
DM 
DM 
DM 
Age (yrs) a 
66 
70 
59 
73 
63 
51 
73 
59 
34 
58 
63 
24 
34 
42 
22 
Sex 
F 
F 
M 
M 
M 
M 
F 
F 
M 
F 
F 
F 
F 
F 
F 
Duration a 
4 years 
1 month 
6 weeks 
16 years 
3 months 
1 year 
2 5 months 
13 years 
14 years 
9 years 
1 month 
3 months 
8 years 
5 years 
7 years 
Associated Disease 
. 
Primary Biliary Cirrhosis 
-
Dilated Cardiomyopathy 
-
Adenocarcinoma (site unknown) 
-
-
-
-
Interstitial Lung Fibrosis 
-
-
-
-
a, at time of muscle biopsy 
Patients and methods 
Patients 
We studied 10 patients with adult-onset polymyositis and five patients with 
adult-onset dermatomyositis attending the centre for neuromuscular diseases 
of the University of Nijmegen. All patients fulfilled the diagnostic criteria for 
definite polymyositis or definite dermatomyositis, as formulated by Dalakas 
[1]. Of the patients with polymyositis five were men and five women; their ages 
ranged from 34 to 73 years. The patients with dermatomyositis were all 
women; their ages ranged from 22 to 63 years. The table gives the diagnosis, 
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age, sex, duration of symptoms at time of examination, and associated diseases 
of the patients. Biopsy samples were obtained from a quadriceps muscle for 
diagnostic reasons. At the time of examination all patients had progressive 
muscle weakness and increased serum creatine kinase concentrations. For 
RNA extraction and viral RNA detection, tissue samples of approximately 25 -
30 mm2 were immediately frozen in liquid nitrogen and stored at - 80°C until 
use. Fifteen patients with non-inflammatory non-immune mediated neuro­
muscular disorders were studied as controls. 
Sample processing 
RNA from muscle samples was purified using a single extraction with guan-
idiniumthiocyanate-phenol-chlorophorm according to Chomczynski and 
Sacchi [15]. RNA was dissolved in 50 μΐ water treated with distilled diethylpy-
rocarbonate (DEPC). To all samples, human placenta RNAse inhibitor 
(RNasin; Promega) was added to a concentrationn of 0.4 U/μΙ. The samples 
were stored at - 80°C. The reverse transcriptase PCR and the determination of 
the amplified products was performed as described previously [16]. In brief, 
for enteroviral RNA amplification, the RNA was transcribed in cDNA using 
reverse transcriptase and an antisense primer (3'ATTGTCACCATAAGCAGC-
CA5'). After completing the reverse transcriptase reaction, the buffer condi­
tions were adapted for PCR, and the sense primer (5'TCCTCCGGCCCCT-
GAATGCG3') was added. RNA/cDNA hybrids were denaturated at 94°C for 
five minutes. The thermal profile involved 40 cycles of denaturation at 94°C for 
one minute, primer annealing at 42CC for one minute, and primer extension at 
72°C for two minutes. The reactions were analyzed by electrophoresis on a 2% 
agarose gel stained with ethidium bromide, and by Southern blot analysis 
using an endlabelled oligonucleotide probe (5'AAACACGGACACCCAAAG-
TA3')- A positive PCR generates a fragment of 155 base pairs. The primers were 
selected in the conserved 5'NCR of enterovirus and have been shown to detect 
60 of the 66 different enterovirus types tested [16]. 
For amplification of EMC RNA, we used an antisense primer (5'CACGTG-
GCTTTTGGCCGCAGAGG3') and a sense primer (5'CGAAGCCGCTTG-
GAATA3'), specific for cardioviruses and Theiler's murine encephalomyocar-
ditis virus (TMEV) [Zoll G}, Galama JMD, Melchers WJG, unpublished data; 
17]. For Southern blot analysis we used an EMC/TEMV specific oligonucleoti­
de probe (5'CGTGTTACCAGGTGGGG3') [14]. A fragment of 282 base pairs is 
obtained with positive specimens. 
As an internal control for the presence and quality of RNA, we performed a 
PCR directed against the Abelson tyrosine kinase mRNA, which is expressed 
in muscles [18]. A positive PCR results in a fragment of 218 base pairs. 
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Results 
When a titrated stock of virus was serially diluted and added to negative mus­
cle samples before RNA extraction, we obtained a sensitivity of approximate­
ly 30 plaque forming units for enterovirus (Figure la) and of 100 plaque for­
ming units for EMC (Figure lb). A specific amplification for enterovirus 
(Figure 2a) or for EMC (Figure 2b) was not observed in any of the muscle biop­
sy samples. A specific amplification product of 155 base pairs was seen from 
enterovirus RNA and from enterovirus cDNA, and of 282 base pairs from EMC 
RNA, which were used as positive controls. In all samples, the reverse trans­
criptase PCR on the non-relevant mRNA of the Abelson tyrosine kinase gene 
resulted in a specific amplification product of 218 base pairs, confirming the 
presence of adequate RNA in the tissues. Southern blot hybridisation with an 
oligonucleotide probe directed against the internal portion of the amplified 
product confirmed the results as observed directly upon gel electrophoresis: 
the positive controls hybridized with the oligonucleotide probe but no signal 
was obtained with the muscle specimens. 
Discussion 
The aetiology of polymyositis and dermatomyositis is unknown, but evidence 
is accumulating that viruses belonging to the enterovirus and cardiovirus sub­
group of picornaviruses play a part [8-11,13,14). Immunopathogenic studies in 
experimental murine myositis support the idea of viral persistence: in 
Coxsackie Bl virus-induced myositis [19] and in EMC-induced myositis [20], 
hybridisation studies showed viral RNA in affected muscle, at times when cul­
tures for the virus were negative. In various human disorders viral persistence 
has been established. Conventional hybridisation [21,22] as well as PCR stu­
dies [23] detected Coxsackie В virus RNA in endomyocardial biopsy samples 
from patients with dilated cardiomyopathy and myocarditis. Muscle from 
patients with chronic fatigue syndrome have shown evidence of enterovirus 
RNA on PCR [24]. 
Bowles et al., using quantitative dot spot hybridisation, found Coxsackie В 
virus-specific RNA in muscle tissues from five of nine patients with polymyo­
sitis or dermatomyositis, whereas control biopsies were all negative [11]. With 
an in situ hybridisation technique, Yousef et al. detected enterovirus specific 
RNA in biopsy samples from six of 13 patients with polymyositis or dermato­
myositis [13], and Rosenberg et al. found evidence for an EMC-like virus in 
three patients with dermatomyositis [14]. 
Using a highly specific and sensitive PCR assay [16], we were unable to detect 
enteroviral or EMC RNA in muscle samples from patients with active poly­
myositis or dermatomyositis. Our results are in agreement with some conven­
tional hybridisation studies, which reported the absence of enteroviral RNA in 
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Figure la Sensitivity of the enterovirus polymerase chain reaction. Lane 1, 20* ' plaque 
forming units (pfu); lane 2, Ш"pfu; lane 3,10"' pfu; lane 4,10''"pfu; lane 5, lŒ'pfu; 
lane 6, Wpfu; lane 7, Wpfu; lane 8, Wpfu; lane 9, Wpfu; lane 10, Wpfu; lane 
11, 2015 pfu; lane 12, 20" pfu; lane 13, W> pfu. Lane -: negative control (distilled 
water). Lane M: length marker (pBR322 χ Hinfl). 
M l 2 3 4 5 6 7 8 9 10 11 12 1 3 - - M 
Figure lb Sensitivity of the EMC polymerase chain reaction. Lane 1,20" plaque for­
ming units (pfu); lane 2, 10°" pfu; lane 3, 20" pfu; lane 4, 20"' pfu; lane 5, 2 0 3 pfu; 
lane 6,Wpfu; lane 7, W'pfu; lane 8, Wpfu; lane 9, Wpfu; lane 10, Wpfu; lane 
11, 1015 pfu; lane 12, 10'" pfu; lane 13, 20 м pfu. Lane -: negative control (distilled 
water). Lane M: length marker (pBR322 χ Hinfl). 
M 1 2 3 4 5 6 7 8 9 10 11 12 13 - - M 
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Figure 2a Gel electrophoresis showing the results of polymerase chain reaction analy­
sis for enterovirus RNA in muscle samples from four patients with polymyositis (lanes 
1A - 4A), two patients with dermatomyositis (lanes 5A - 6A), and corresponding 
internal controls (lanes IB- 6B; mRNA of the Abelson tyrosine kinase gene). Lane M, 
length marker (pBR322 χ Hinfl); -, negative controls (distilled water); lane R, positi­
ve control (Coxsackie Bl virus RNA); lane D, positive control (Coxsackie B3 virus 
cDNA). 
1 2 3 4 5 6 
A B A B A B A B A B A B M R D 
2 1 8 b p — 
— 1 5 5 b p 
Figure 2b Gel electrophoresis showing the results of polymerase chain reaction analy­
sis for EMC RNA in muscle samples from four patients with polymyositis (lanes 1 -
4), two patients with dermatomyositis (lanes 5 - 6), one muscle sample from an unin­
fected mouse (lane 7), and one muscle sample from a mouse inoculated with EMC (lane 
8). Lane M, length marker (pBR322 χ Hinfl); lane - , negative controls (distilled 
water); lane R, positive control (EMC RNA). 
M 1 2 3 4 5 6 7 8 - - R M 
- — 2 8 2 b p 
111 
CHAITER 8 
polymyositis and dermatomyositis. Thus, Rosenberg et al. did not detect enter-
oviral RNA in five such patients [14], and Bunn and Walport, using slot blot 
hybridisation, could not find Coxsackievirus RNA in 15 patients with polymy­
ositis [12]. Our results are also in agreement with other PCR studies, which did 
not detect viral RNA for Coxsackie В virus, EMC, mumps virus, adenovirus 
[25], or enteroviral RNA [26] in muscle from adult patients with polymyositis 
or dermatomyositis. 
The discrepancies between these reports, including ours, may result from the 
different methods used, or from differences between patient groups. 
Although the sensitivity of RNA PCR may be limited by the efficiency of RNA 
extraction and reverse transcription, the PCR technique has been described as 
superior compared to conventional hybridisation techniques for the detection 
of enteroviral RNA [17]. In our study the positive Abelson band confirmed the 
quality of the RNA samples for PCR. As all muscle cells express the Abelson 
gene, however, it can not be excluded that negative viral results could be obtai­
ned form Abelson positive samples if virus was present in only few cells. 
We obtained a sensitivity of 30 plaque forming units for enterovirus, and of 100 
plaque forming units for EMC virus, which is within the range of values repor­
ted elsewhere [25,26]. It should be remembered, however, that virus prepara­
tions may contain an excess of non-infectious to infectious particles, and thus 
small amounts of virus not be detected in spite of an apparently high sensitivi­
ty. On the other hand, pathogenic changes, which are clinically relevant, are 
not likely to result from minute amounts of viral RNA. Moreover, our previous 
finding of enterovirus RNA in a cardiac muscle biopsy from a patient with dila­
ted cardiomyopathy and in muscle from mice with Coxsackie Bl virus-indu­
ced myositis indicate an adequate sensitivity of the PCR for the detection of 
persistent viral RNA [16]. 
Our approach does not preclude the possibility that we have missed enterovi­
rus and EMC RNA sequences, not detectable by the primers used. As viral 
RNA without the highly conserved 5'NCR is incapable of translation and repli­
cation, however, a persistent infection wich such RNA sequences is not likely 
to occur. Likewise, picornaviruses not belonging to the enterovirus or cardio­
virus subgroup could have been missed with our primers, due to their type 
specificity. There is little evidence, however, that other Picornavirus subgroups 
are involved in polymyositis or dermatomyositis. 
As has been reported elsewhere [25], most studies of viral persistence in myo­
sitis have been of children. In view of the differences between adult and child­
hood dermatomyositis [1], it cannot be excluded that in childhood myositis 
viral RNA does persist. For comparison, Coxsackie Bl virus induces chronic 
myositis in mice only, if inoculated within 48 hours after birth [27]. It is possi­
ble that immature immune systems do not completely clear the enterovirus, 
and thus predispose to the development of dermatomyositis or polymyositis. 
Another possible explanation for the discrepant results may be genuine 
geographical differences in the aetiopathogenesis in that viruses may play a 
part in patients in some countries or regions, but not in others. 
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To summarise, with the use of a sensitive and specific PCR technique we did 
not detect enterovirus and EMC virus RNA in muscle from adult patients with 
active polymyositis or dermatomyositis. Therefore, our data do not favour the 
proposal that persistent virus RNA plays a part in the maintenance of the adult 
onset forms of these idiopathic inflammatory myopathies. Given the discre­
pancies between serological, conventional hybridisation, and PCR results, stu­
dies in childhood and adult patients are needed to compare the sensitivity and 
specificity of various techniques in detecting viral RNA. Until such data are 
available, this sub]ect is likely to remain controversial. 
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Abstract 
Automatic decomposition electromyography (ADEMG) is a commercially 
available software package with installed reference values that enables the 
objective measurement of motor unit action potentials (MUAPs). To assess the 
diagnostic yield of this package in idiopathic inflammatory myopathies (ИМ) 
we performed biceps brachii ADEMG in 19 patients with polymyositis, der-
matomyositis, and inclusion body myositis. Results were compared with those 
in 12 controls, and with the results of conventional EMG of the biceps and other 
muscles. Decreased mean values for MUAP duration occurred significantly 
more frequently in IIM patients than in controls; other MUAP characteristics 
did not differ. In IIM patients, decreased mean amplitude and increased mean 
number of turns occurred significantly less frequently on ADEMG than did 
corresponding abnormalities on conventional biceps EMG. Decreased mean 
values for duration and amplitude, and increased mean values for number of 
turns were seen significantly less often on ADEMG than corresponding abnor­
malities on conventional EMG of 4 different, individually chosen muscles. 
Overall evaluation of ADEMG resulted in diagnosis of 'possible myopathy' in 
1 and 'probable myopathy' in 8 patients, whereas overall evaluation of con­
ventional EMG led to a diagnosis 'suggestive of IIM' in 13 patients. We con­
clude that, although measurement of mean MUAP duration might be valuable 
in IIM diagnosis, our results do not favour the use of biceps brachii ADEMG 
and the installed reference values in IIM diagnosis. We suggest modifications 
to improve ADEMG's applicability. 
Introduction 
Idiopathic inflammatory myopathies (IIM) are the commonest acquired disor­
ders of muscle to present in adult life [20], with polymyositis, dermatomyosi-
tis, and inclusion body myositis as the major diagnostic entities [3]. 
Characteristic abnormalities on electromyography (EMG) are an important 
diagnostic criterion for IIM [3,17]. The changes consist of fibrillation potentials 
and sharp positive waves, complex repetitive discharges, and changes in 
motor unit action potentials (MUAP) [13]. Typically, abnormalities have a pat­
chy distribution, and the MUAPs are polyphasic with low amplitude and a 
short duration [13]. 
IIM are potentially treatable, but in the absence of specific diagnostic tests 
sometimes difficult to diagnose [3]. Subjective interpretation on conventional 
EMG may cause MUAP abnormalities to go unnoticed, thus diminishing the 
chance of IIM detection. On the other hand, overdiagnosis might result from 
the fact that clinical suspicion of IIM could influence the electromyographer. 
As a consequence, there is a need to further improve electrodiagnosis in IIM. 
Objective quantification of MUAP parameters permits a more consistent inter-
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pretation of EMG findings [7,14]. In previous years various automatic quanti­
tative EMG methods have been described, which, however, have not been 
widely put into clinical practice [9,10,16,18,19]. More recently, automatic 
decomposition electromyography (ADEMG) has been developed, a fully auto­
matic method of decomposing EMG patterns into their constituent MUAPs 
[6,7,11,15]. Potentials from the same motor unit are recognized and averaged, 
so that duration, amplitude, number of turns, and firing rate of the MUAPs are 
measured. A software package with installed reference values is commercially 
available as part of the Nicolet Viking electromyographic system. Major 
advantages of ADEMG are the measurement of large numbers of MUAPs, and 
the analysis of both low- and higher-threshold MUAPs [7,14]. Diagnosis of 
generalized neuromuscular disorders is considered one of its major applica­
tions [7]. However, until now there have been few reports studying the clinical 
usefulness of ADEMG [2,5,6]. Therefore, in an attempt to improve EMG diag­
nosis in ИМ, we evaluated the diagnostic yield of ADEMG, by comparing its 
sensitivity to that of conventional EMG in 17 patients with active IIM. 
Subjects and methods 
Patients and controls 
To validate the data base reference values installed in the ADEMG software 
package, we performed ADEMG in 12 healthy controls (4 male and 8 female) 
with ages ranging between 22 and 56 years. Then we studied 17 patients with 
adult-onset IIM (5 male, 12 female; age 20 - 68 years), who attended the centre 
for neuromuscular diseases of the University of Nijmegen. All patients fulfil­
led the diagnostic criteria for definite polymyositis (9 patients), definite der-
matomyositis (3 patients), or inclusion body myositis (5 patients) [3]. When 
studied, all patients had signs and symptoms of active disease, including 
progressive muscle weakness. In 3 patients the research EMG and ADEMG 
studies were peformed prospectively as part of the diagnostic process; in these 
patients response to subsequent immunosuppressive treatment confirmed the 
initial diagnosis. Fourteen patients were studied in the course of their IIM dis­
ease when having a clinical worsening after previously successful immuno­
suppression. Diagnosis, age, sex, duration of symptoms at time of examina­
tion, serum creatine kinase concentration, and major findings on muscle 
biopsy of individual patients are given in Table 1. 
All persons gave their informed consent prior to inclusion in the study. All stu­
dies were performed in accordance with the ethical standards laid down in the 
1964 Declaration of Helsinki. 
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Table 1 Diagnosis, age, sex, duration of symptoms, serum creatine kinase (CK) con­
centrations, and major findings on muscle biopsy of the patients with idiopathic inf­
lammatory myopathies. 
Patient 
1. 
2. 
3. 
4 
5 
6. 
7 
8 
9. 
10. 
11 
12 
13. 
14 
15 
16. 
17. 
Diagnosis 
PM' 
PM 
PM 
PM 
PM 
PM 
PM 
PM 
PM 
DM 
DM 
DM 
IBM 
IBM 
IBM 
IBM 
IBM" 
Age' 
27 
64 
41 
20 
68 
55 
54 
22 
65 
41 
67 
57 
68 
66 
52 
49 
53 
Sex 
M 
F 
F 
M 
M 
F 
F 
F 
F 
F 
F 
F 
F 
F 
F 
M 
M 
Duration" 
5 months 
6 months 
3 months 
1 month 
2 months 
15 months 
6 years 
4 years 
4 years 
4 years 
4 months 
7 years 
6 months 
7 years 
2 years 
6 years 
9 years 
CK u/i1· 
1550 
1400 
1200 
1700 
5000 
490 
260 
990 
560 
100 
300 
2400 
2200 
240 
1900 
140 
200 
Histology 
Inf, Neer 
Inf, Neer, SwV 
Inf, Neer 
Inf, Neer 
Inf, Neer 
Inf, Neer 
Inf, Neer, SwV 
Inf, Neer 
Inf, Neer 
Inf, Neer, Pen 
Inf, Neer 
Inf, Neer, Pen 
Inf, Neer, RBV 
Inf, Neer, RBV 
Inf, Neer, RBV 
Inf, Neer, RBV 
Inf, Neer, RBV 
PM, polymyositis 
DM, dermatomyosihs 
IBM, inclusion body myositis 
Inf, mononuclear cell infiltration 
Neer, muscle fiber necrosis 
SwV, swollen blood vessels 
Pen, penfascicular atrophy 
RBV, rimmed basophilic vacuoles 
a, at time of examination 
b, normative values for CK < 90 U/l 
c, associated disease Mixed Connective Tissue Disease 
d, associated disease Rheumatoid Arthritis 
Automatic decomposition electromyography 
ADEMG was performed according to the instructions of the manufacturer. 
Great care was taken to follow the procedure used by the inventors of the 
method as described in their original papers [5-7,14,15]. Thus, in our opinion 
the ADEMG examinations were carried out correctly, in that there was no con­
flict between our performance of ADEMG and the available guidelines. The 
right biceps brachii muscle was studied in each normal subject and ИМ patient. 
For recording the subject lay supine with the upper arm resting on the exami­
nation table, the elbow flexed 90°, and the wrist fully supinated. The subject 
pulled against variable weights, attached by a cable to a cuff which encircled 
the distal forearm. Recordings were made using a standard concentric EMG 
electrode inserted into the midportion of the muscle and adjusted to produce 
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crisp sounds when the amplified signal was fed to a loudspeaker. After measu­
ring the maximal voluntary contraction (MVC), at least 10 sites were sampled, 
during 10 seconds per site, at each of three isometric contractile forces: thres­
hold (arm maintained against gravity), 10% of MVC, and 30% of MVC. 
Feedback of % MVC helped subjects to maintain steady and accurate contrac­
tile forces. 
The processing of the ADEMG signal involves digital prefiltering, high-resolu­
tion template matching, interspike-interval analysis, and interference-cancella­
tion averaging [15]. Thus, in each control subject and patient, mean values 
were calculated from the cumulative MUAP properties for duration, amplitu­
de, number of turns, and firing rate. The program automatically compared the 
individual mean values and intra-individual standard deviations (SD) with the 
installed data base reference values. Since the reference values have a normal 
distribution [5, 7,14,15], the software package used a 2-tailed T-test; a Ρ value 
less than 0.05 was considered significant. In addition, IIM patients having at 
least two of the three following MUAP abnormalities - decreased mean dura­
tion, decreased mean amplitude, or increased number of turns - were classified 
by us as 'probable myopathy'. Cases with one of these abnormalities were clas­
sified as 'possible myopathy'. 
Conventional EMG 
In each patient various muscles were investigated with a concentric needle 
electrode by an experienced electromyographer (H.V.). The choice of the mus­
cles depended on symptoms and signs, as is common practice in EMG diagno­
sis of IIM [13]. For the group of IIM patients as a whole, the muscles examined 
were in decreasing frequency: quadriceps, deltoid, biceps brachii, tibialis ante­
rior, gastrocnemius, triceps brachii, erector trunci, interosseus dorsalis, and 
gluteus maximus muscle. The mean number of muscles examined per patient 
was 4. 
MUAPs with short duration, or low amplitude, or polyphasia were detected 
visually, resulting in a qualitative MUAP assessment: presence or absence of 
abnormal amounts of short-duration MUAPs, low-amplitude MUAPs, or 
polyphasic MUAPs. In addition, fibrillation potentials, positive sharp waves, 
and complex repetitive discharges were looked for. Since IIM was clinically 
suspected (n=3) or known as previously established diagnosis (n=14), a patchy 
distribution of abnormalites was anticipated and abnormalities were searched 
for at various sites within a single muscle. 
Finally, in each patient the overall subjective assessment of conventional EMG 
findings (MUAP abnormalities, fibrillation potentials, positive sharp waves, 
complex repetitive discharges, patchy distribution), resulted in one of two pos­
sible EMG diagnoses: 'suggestive of IIM' or 'not suggestive of IIM'. 
Comparisons and statistics 
To validate the ADEMG reference values installed in the software package, 
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mean and SD values of MUAP characteristics in healthy controls were compa-
red with the data base reference values. Then, to assess the diagnostic potential 
of biceps brachii ADEMG in IIM patients, we studied the detection of abnor-
mal mean values in these patients in three different ways: first, we compared 
the detection of abnormal mean values with that in controls; second, we com-
pared the detection of abnormal mean values with that of corresponding 
MUAP abnormalities on conventional biceps EMG in the same patient, where-
by an increased number of turns was considered to correspond to polyphasia 
[8]; third, we compared the detection of abnormal mean values with that of cor-
responding MUAP abnormalities on conventional EMG of multiple muscles in 
the same patient. Finally, in patients who had ADEMG performed at two or 
three contraction levels the diagnostic yield of ADEMG was compared to that 
of conventional EMG, i.e. 'probable myopathy' and 'possible myopathy' ver-
sus 'suggestive of IIM'. 
In the comparison with controls we used the 2x2 Fisher exact test with a one-
tail probability (P), since we expected low-amplitude, short-duration, and 
polyphasic MUAPs to occur in IIM, not in healthy controls. In the comparisons 
between ADEMG and conventional EMG a two-tailed 2x2 Fisher exact test was 
used. 
Results 
Validation of data base reference values for biceps brachii ADEMG 
In the 12 control subjects we obtained a total number of 144 mean values of 
MUAP characteristics, 13 of which by the reference data base were qualified as 
abnormal: 3 at threshold, 5 at 10% MVC, and 5 at 30% MVC. Abnormal mean 
values included a decrease of turns (n=4), firing rate (n=4), amplitude (n=2), 
and duration (n=l); and an increase of duration (n=l) and firing rate (n=l). Of 
the 144 SD values that were computed, 57 were qualified as abnormal: 26 at 
threshold, 22 at 10% MVC, and 9 at 30% MVC. Decreased SD values regarded 
firing rate (n=23), number of turns (n=13), duration (n=ll), and amplitude 
(n=7); an increased firing rate SD was recorded 3 times. 
From these data we concluded that the installed ADEMG normative data for 
mean values of MUAP characteristics could be used reliably, in contrast to the 
SD reference values. Therefore, we only used ADEMG mean values for further 
analysis. 
Biceps brachii ADEMG in IIM patients and controls 
ADEMGs at threshold, 10% MVC, and 30% MVC were recorded in 17,14, and 
13 IIM patients, respectively. The numbers of patients with abnormal mean 
values for MUAP amplitude, duration, number of turns, or firing rate at thres-
hold, 10% MVC, and 30% MVC, compared with controls are given in Table 2. 
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Table 2 Numbers oflIM patients and controls with abnormal mean values of motor 
unit action potentials (MUAP) characteristics on biceps brachii ADEMG at treshold, 
at 10% of maximum voluntary contraction (MVC), and 30% MVC. 
Parameter IIM Controls 
Threshold 
Amplitude decrease 
Duration decrease 
Turns decrease 
Fmng rate increase 
1/17 
7/17 
1/17 
4/17 
1/12 
0/12a 
1/12 
1/12 
Parameter IIM Controls 
10% MVC 
Amplitude decrease 
Duration decrease 
Turns decrease 
Firing rate decrease 
Firing rate increase 
1/14 
3/14 
4/14 
3/14 
2/12 
1/12 
1/12 
0/12 b 
1/12 
2/12 
Parameter IIM Controls 
30% MVC 
Amplitude decrease 
Duration decrease 
Turns decrease 
Firing rate decrease 
Firing rate increase 
1/13 
0/13 
3/13 
2/13 
2/13 
1/12 
1/12 
0/12 
2/12 
1/12 
a. One Tail Probability Fisher's 2x2 Exact Test 0 01 compared to IIM patients 
b. One Tail Probability Fisher's 2д:2 Exact Test 0 06 compared to ¡IM patients 
Biceps brachii ADEMG and conventional biceps brachii EMG in UM patients 
In 8 patients we compared the MUAP characteristics at threshold, 10% MVC, 
and 30% MVC of the biceps brachii muscle with the results of conventional 
EMG in the same muscle (Table 3). Significantly more patients had low-ampli-
tude or polyphasic MUAPs on conventional EMG than abnormal mean values 
for the corresponding parameter on ADEMG, irrespective of contraction level. 
As is shown, there was no difference between ADEMG and conventional EMG 
as far as MUAP duration is concerned. 
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Table 3 Comparison of biceps brachi ADEMG and conventional EMG of biceps bra­
cini muscle in eight UM patients Numbers of UM patients with abnormal MUAP 
characteristics at various contraction levels, and numbers of patients with correspon­
ding abnormalities on conventional EMG. 
Decreased Mean Duration 
Decreased Mean Amplitude 
Increase of Turns 
ADEMG 
Threshold 
4/8 
0/8 
0/8 
10% 
3/8 
0/8 
0/8 
30% 
0/8 
0/8 
0/8 
Total 
5/8 
0/8 * 
0/8 a 
Conventional EMG 
8/8 
5/8 
6/8 
Increase of Short 
Duration MUAPs 
Increase of Low-
Amplitude MUAPs 
Increase of 
Polyphasic MUAPs 
a, Two-tailed Probability Fisher's 2x2 Exact Test <0 01 compared to conventional EMG 
Table 4 Comparison of ADEMG of biceps brachu muscle and conventional EMG of 
various muscles in 17 UM patients Numbers of UM patients with abnormal MUAP 
characteristics on ADEMG and numbers of patients with corresponding abnormalities 
on conventional EMG. 
ADEMG a 
Decreased Mean 
Duration 
8/17 b 
Decreased Mean 
Amplitude 
2/17 c 
Increase of 
Turns 
0/17 c 
Convential EMG 
Increase of 
Short Duration MUAPs 
15/17 
Increase of 
Low Amplitude MUAPs 
14/17 
Increased number 
Polvphasic MUAPs 
15/17 
a, Combined results from threshold, 10% and 30% ADhMG 
b, Ρ = 003 
c,P<0 0001 (Two Tail Probability Fisher's 2x2 Exact Test) compared with conventional EMG 
Biceps brachn ADEMG and conventional EMG of multiple muscles in UM patients 
In 17 patients the MUAP characteristics on biceps brachn ADEMG were com­
pared with corresponding abnormalities as obtained on conventional EMG of 
multiple, individually chosen muscles. The results are given in Table 4. 
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Diagnostic yield of biceps brachii ADEMG and conventional EMG in IIM patients 
In 13 of 17 patients overall evaluation of conventional EMG findings in various 
muscles suggested IIM. The final diagnosis in patients not having an IIM-sug-
gestive EMG was PM (n=3) and inclusion body myotites (IBM) (n=l). In 16 
patients we obtained ADEMG findings at at least 2 contraction levels, leading 
to classification as 'probable myopathy' in one patient (PM), and 'possible 
myopathy' in 8 patients (PM, n=2; DM, n=2; IBM, n=4). One patient (PM) had 
a 'probable myopathy' on ADEMG, whereas the conventional EMG was 'not 
suggestive of IIM'. Table 5. 
Table 5 Diagnostic yield of biceps brachii ADEMG and conventional EMG of various 
muscles in IIM patients. 
Electrodiagnosis Numbers of patients 
ADEMG Possible Myopathy 1/16 
ADEMG Probable Myopathy 8/16 
EMG Suggestive of IIM 13/17 
Discussion 
In this study on the diagnostic usefulness of ADEMG in IIM we made the fol-
lowing observations. On ADEMG only decreased MUAP duration occurred 
more frequently in IIM patients than in controls, and in IIM patients ADEMG 
was less sensitive in detecting relevant MUAP abnormalities than convention-
al EMG. The overall diagnostic yield of ADEMG was not greater than that of 
conventional EMG. In addition, ADEMG appeared to be rather time consu-
ming, so that in the same amount of time we could examine multiple muscles 
conventionnally. With respect to the patient's discomfort, ADEMG was not 
more favourable, since it was as painful as conventional EMG. 
There have been few reports on the use of ADEMG in neuromuscular disor-
ders, including IIM [2,5,6]. Dorfman et al. found in a minimally symptomatic 
IIM patient normal mean MUAP amplitudes and number of turns, but an 
excess of short-duration potentials and increased firing rates; in a treated 
asymptomatic IIM patient, mean MUAP amplitude, duration, and number of 
turns were all reduced and mean firing rate increased. The authors suggested 
that findings on ADEMG not necessarily relate to disease activity [6]. Our 
observation of only few abnormal mean values in 17 patients with active IIM is 
in keeping with this suggestion. 
We found clear discrepancies in the diagnostic yield of conventional EMG and 
ADEMG. On evaluation of an other automatic method of analysing biceps bra-
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chii MUAPs, Fuglsang-Frederiksen found a concordance between automatic 
analysis and visual assessment in 76% of neuropathy patients, but only in 50% 
of myopathy patients [9]. As far as our study is concerned, it may be argued 
that the electromyographer was biased towards IIM diagnosis, since in most 
patients IIM was suspected on clinical grounds. Although this factor undoub­
tedly does play a role, it can not explain the low sensitivity of ADEMG and the 
resulting low diagnostic yield. Moreover, the percentage of 'IIM suggestive' 
EMGs in our patients corresponds to that reported in the literature [3,13]. 
There are various explanations for the somewhat disappointing results on 
ADEMG. Firstly, in IIM some muscles may remain electrically normal [13]. For 
this reason, conventional EMG assessment includes the examination of mul­
tiple muscles, with emphasis on those exhibiting moderate weakness [13]. As 
yet, ADEMG has only been standardized for the biceps brachii muscle, and this 
muscle is not always affected. 
Figure 1 Motor unit action potentials (MUAPs) from six different motor units (1-6) 
are represented in the upper part (middle and left) of the figure. The lower part shows 
that MUAP X is not identified and notably not recognized as a MUAP coming from 
motor unit 4, although shape and interspike interval of MUAP X are identical to those 
of MUAP 4; X - X, interspike interval of MUAP X; 4 - 4, interspike interval of MUAP 
4. 
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Figure 2 Motor unit action potentials (MUAPs)from nine different motor units (Ί-9) 
are represented in the upper part (middle and left) of the figure. In view of their shapes, 
MUAP 1 and MUAP 2 would be identified by most electromyographers as coming 
from the same motor unit. The firing patterns of motor unit 1 and motor unit 2 - indi­
cated by arrows in the lower part of the figure - confirms this interpretation. The 
ADEMG program, however, classifies MUAP 1 and 2 as coming from two different 
motor units. 
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Secondly, one of the inherent difficulties with methods automatically analy­
zing MUAPs, including ADEMG, centers on the selection of the signals [13]. 
On visual analysis of ADEMG recordings, we found that the beginning and the 
end of a MUAP were not always delineated correctly. Likewise, not all MUAPs 
were detected. Notably, the program had difficulties in detecting very small 
MUAPs, and in some patients a substantial number was missed. Sometimes, 
MUAPs with very abnormal configuration went undetected (Figure 1), or a 
given MUAP was 'recognized' as two different ones (Figure 2). In IIM patients 
MUAP characteristics may not only differ considerably between motor units 
[13], but also MUAPs from the same motor unit vary greatly, in that amplitu­
de, duration, and configuration fluctuate from one firing instant to another [4]. 
Therefore, it is likely that MUAPs originating from the same motor are not 
always recognized as such, but instead are interpreted as coming from diffe­
rent units. The resulting low frequency of MUAPs from these 'different' motor 
units causes them not to be accepted by the ADEMG program. As a conse­
quence, precisely motor units with great intra-MUAP variability run the risk of 
not contributing to the ADEMG signal. 
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Thirdly, and perhaps the most important factor, conventional EMG is an inter-
active process between the investigator and the myographic findings, resulting 
in an 'intelligent search' for abnormal MUAPs. Given the patchy distribution 
of abnormalities in IIM, detection of low-amplitude, short-duration or polyp-
hasic MUAPs, though constituting a minority in the whole MUAP population, 
is diagnostically important. In ADEMG, however, the statistical approach pre-
vents abnormal MUAPS from compensating for the prevailing normal ones. In 
consequence, although many of our patients had mean values lying in the 
lower normal range, the values were not abnormal. 
Buchthal has extensively measured motor units that were recruited at very 
slight voluntary contraction, so that MUAPs could be registrated on a smooth 
baseline [1]. Although we did not compare ADEMG to the Buchthal method, 
we mention some basic differences between the methods. First, by means of 
averaging, ADEMG determines the beginning and the end of MUAPs also on 
a non-smooth baseline. Secondly, MUAP duration and amplitude are related 
to excitation threshold [13]; at 10% MVC and 30% MVC motor units with addi-
tional information, are recruited, other than the units measured by the 
Buchthal method. Thirdly, ADEMG also measures MUAPs that are not located 
in the immediate vicinity of the recording electrode. 
It has been suggested that ADEMG will have its most powerful application in 
those early or bordeline cases of neuromuscular disorders in which the eletro-
physiological abnormalities are relatively slight and which might otherwise 
elude diagnosis [7]. However, as yet it has not been demonstrated whether 
automated methods do help in the diagnosis of these patients [13]. Our failure 
to detect MUAP abnormalities in most IIM patients with active clinical disea-
se, argues against a role for biceps brachii ADEMG in the detection of early or 
borderline cases of IIM. 
In conclusion, our results suggest that ADEMG of the biceps brachii muscle 
with the use of the reference values installed in the software package, is not of 
great diagnostic value in IIM, except possibly for the measurement of mean 
MUAP duration. However, we expect that the establishment of reference valu-
es, especially those for SD, per laboratory or in a multi-centre setting [8] might 
increase ADEMG's applicability, as will (we believe) the following modifica-
tions: firstly, the availability of ADEMG for other muscles, which enables the 
investigator to choose a clinically involved muscle; secondly, improvement of 
the program algorithms, both to enhance MUAP detection and to detect out-
liers, since in myopathies the outliers, particularly of amplitude values, are 
more often abnormal than the mean value [12]; thirdly, the use of the MUAP 
area and the area/amplitude ratio as parameters, instead of MUAP duration 
and amplitude, may circumvent problems of delineation [19]. However, only 
blinded and prospective comparisons of the diagnostic yield of ADEMG and 
conventional EMG will establish the usefulness of improved ADEMG techni-
ques. 
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CHAPTER 10 
Summary 
To study the incidence of rimmed basophilic vacuoles (RBV) and 15-21 nm fila-
mentous inclusions in neuromuscular disorders, other than inclusion body 
myositis (IBM), and to determine the diagnostic value of RBV quantitation in 
the differential diagnosis of IBM, we reviewed 1600 muscle biopsies for RBV 
and 750 biopsies for filamentous inclusions. The number of RBV-positive fibers 
per 10 mm2 - the RBV-fiber density - was determined. The incidence of RBV in 
non-IBM biopsies was 8.8 per 1,000. Major diagnostic categories were neur-
ogenic disorders (n = 7) and limb girdle muscular dystrophies (LGMD) (n = 3). 
In IBM (n = 7) the RBV-fiber density ranged from 10.4 to 63.1 and was signifi-
cantly higher than in neurogenic disorders (0.9 - 4.4) and LGMD (1.1 - 2.7). The 
highest value was found in rigid spine syndrome (205.8). Filamentous inclu-
sions were seen in 2.7 per 1,000 non-IBM biopsies, including familial oculop-
haryngeal muscular dystrophy with distal myopathy (OPMD-DM), rigid spine 
syndrome, acid maltase deficiency, and amyloid neuropathy. RBV and fila-
mentous inclusions coexisted in rigid spine syndrome and in familial OPMD-
DM. 
So, RBV as well as filamentous inclusions have a very low incidence in non-
IBM neuromuscular disorders; the RBV-fiber density may help to discriminate 
neurogenic disorders and LGMD from IBM. 
Introduction 
Inclusion body myositis (IBM) is a chronic, mostly distal myositis with slow 
progression and resistence to immunosuppressive treatment [1,2,3]. Diagnosis 
of IBM greatly depends on two characteristic pathological features: rimmed 
basophilic vacuoles (RBV) on light microscopy, and nuclear or cytoplasmic 
inclusions of 15-21 nm filaments in electron microscopic observation [1,3,4]. 
However, it has been known that RBV and filamentous inclusions may occur 
in various other neuromuscular disorders. RBV have been reported in familial 
and sporadic distal myopathies [5,6,7], familial rimmed vacuole myopathy 
sparing the quadriceps [8], familial myopathy associated with periventricular 
leucoencephalopathy [9], oculopharyngeal muscular dystrophy [10], oculop-
haryngeal muscular dystrophy with distal myopathy (OPMD-DM) [11], poly-
myositis [5], rigid spine syndrome [12], congenital myopathy [5], familial limb-
girdle type of muscular dystrophy [5],13, spinal muscular atrophy [5], and 
neurogenic muscular atrophy after poliomyelitis [14]. Filamentous inclusions, 
with or without rimmed vacuoles, have been described in sporadic and fami-
lial distal myopathies [6,15,16], familial myopathy with periventricular leu-
coencephalopathy [9], and rigid spine syndrome [12]. 
The incidence of rimmed vacuoles in non-IBM disorders has not been studied 
systematically. Therefore, their significance in IBM diagnosis may be a matter 
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of debate [17], and is it unknown which non-IBM diseases should be conside­
red in particular when rimmed vacuoles and/or filamentous inclusions are 
found. 
Given the non-specificity of the mere presence of rimmed vacuoles or filamen­
tous inclusions, quantitative criteria might be helpful to support IBM diagno­
sis. According to Lotz et al. at least 1 rimmed vacuole per low-power field is 
required for IBM diagnosis [3]; these investigators, however, did not include 
non-IBM disorders in their study [3]. 
To study systematically the incidence of RBV and filamentous inclusions in 
non-IBM neuromuscular disorders, and to obtain a quantitive RBV criterium 
for differentiating IBM from non-IBM disorders, we reviewed 1600 muscle 
biopsies for the presence of rimmed vacuoles and quantified the muscle fibers 
showing vacuoles; 750 of these biopsies were reviewed for filamentous inclu­
sions as well. 
Materials and Methods 
Between 1982 and 1990, muscle biopsy specimens were obtained for diagnos­
tic reasons in 1600 consecutive patients with neuromuscular signs and symp­
toms, attending the Centre for Neuromuscular Diseases of the University 
Hospital Nijmegen. In the majority of patients tissue was obtained from the 
quadriceps muscle (vastus lateralis). Patients with a neurogenic disorder 
necessitating a sural nerve biopsy, had a biopsy of the soleus muscle taken. In 
few patients a biopsy was taken from the deltoid, biceps, or gastrocnemius 
muscle, depending on the clinical picture. 
For light microscopy, tissues were immediately processed for histological and 
enzyme-histochemical studies according to the technique of Dubowitz and 
Brooke [18]. Specimens were immediately frozen into isopentane previously 
cooled in liquid nitrogen. The usual standard and some special staining tech­
niques and reactions were performed on transverse 8 μτα sections. For this 
study the sections stained with haematoxylin and eosin were used. That sec­
tion in which on preliminary examination overall pathology was most promi­
nent, was chosen for quantitation, since that section was considered to have the 
greatest diagnostic yield. The sections were examined at a magnification of 400 
x, without knowledge of the final diagnosis. In the whole section, fibers with 
RBV were systematically looked for and counted. The cross sectional area was 
quantified using the point method. The number of RBV-positive muscle fibers 
per 10 mm2, the so-called RBV-fiber density, was used as a measure for the 
quantity of rimmed vacuoles. 
In 750 of the 1600 patients, electron microscopic examination of muscle tissue 
was performed, including all patients with clinical suspicion of inflammatory 
myopathy, or with light microscopic evidence of mononuclear cell infiltration 
or rimmed vacuoles. Thin sections of at least 10 randomly chosen tissue blocks 
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were studied systematically for the presence of cytoplasmic and/or nuclear 
filamentous inclusions of 15-21 nm. Great care was taken not to include abnor-
mal filaments present in areas with mainly autophagic lysosomes or desinte-
grating myofibrils with Z-line dérivâtes. 
Clinical records were reviewed for final neuromuscular diagnosis. For IBM 
diagnosis we used the guidelines of Mikol [4]. Each patient's evaluation inclu-
ded a detailed history and neurological examination at the time of initial diag-
nosis and at least once during the follow-up. The diagnosis of a neurogenic dis-
order was based on clinical and electromyographic criteria, and in case of 
peripheral neuropathy also on findings of sural nerve biopsy. 
Groups of patients were compared using the Kruskal-Wallis test and the 
Mann-Whitney test. A P-value of less than 0.05 was considered significant. 
Results 
Light microscopical examination revealed basophilic vacuoles measuring up 
to 30 μπ\; they were partly - with rimmed appearance - or totally filled with 
basophilic granules. Their location was often peripheral, but also more cen­
trally located vacuoles were found. In cases with high numbers of vacuoles 
often more than one vacuole per transverse section were present, while basop­
hilic granules frequently occurred between the vacuoles. Since the rimmed 
basophilic vacuoles (RBV) prevailed and since the 'full' vacuoles nearly always 
occurred in the presence of rimmed ones, we used the term RBV for both these 
vacuoles. 
RBV were found in 21 patients, resulting in an incidence of 12.5 per 1,000. 
Seven patients had IBM as final diagnosis. The incidence of RBV in patients 
with non-IBM diseases was 8.8 per 1,000. In this latter group, major diagnostic 
categories were neurogenic disorders (n = 7), limb girdle muscular dystrophy 
(n = 3), and sporadic cases of distal myopathy with rimmed vacuoles (n = 2). 
Clinico-pathological characteristics and final diagnosis in individual patients 
are given in Tables 1 and 2. 
RBV-fiber density in IBM patients ranged from 10.4 to 63.1 (mean _ SD, 35.1 _ 
19.4) and was significantly higher than in non-IBM patients (range 0.9 to 205.8; 
mean _ SD, 19.5 _ 54.1) (Ρ = 0.005) (Figure 1). With regard to the subgroups of 
non-IBM patients, RBV-fiber densities were higher in IBM patients than in 
patients with neurogenic disorders (range 0.9 to 4.4; mean _ SD, 2.4 _ 1.3) (Ρ = 
0.002), and higher than in patients with limb girdle muscular dystrophy 
(LGMD) (range 1.1 to 2.7) (P = 0.002). For illustration see Figure 2B-D. 
Moreover, values in the IBM group and those in the neurogenic disorder or 
LGMD group did not overlap. The rest group consisted of 4 patients, having 
the following diagnoses: sporadic distal myopathy with rimmed vacuoles (n = 
2), rigid spine syndrome, and familial OPMD-DM. The patient with familial 
OPMD-DM and one patient with sporadic distal myopathy had RBV-fiber den­
sities lying in the range of IBM values. 
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Table 1 Clinical and pathological characteristics of patients with rimmed basophilic 
vacuoles on light microscopy and 15 - 21 nm filamentous inclusions on electron micro­
scopy of quadriceps muscle. 
Pt Age Age Clinical 
Biopsy Onset Features 
Pathological Filamentous Diagnosis 
Features Inclusions 
vD 
H 
О 
vS 
V 
HP 
vSo 
vdH 
D 
70 
59 
65 
76 
42 
55 
49 
39 
20 
67 
47 
60 
58 
41 
53 
45 
28 
2 
Proximal 
weakness 
Weakness, 
proximal 
atrophy 
Proximal 
weakness 
Hip girdle 
weakness 
Shoulder 
girdle 
weakness 
Proximal 
weakness 
Proximal 
weakness 
Ophthalmoplegia, 
bulbar weakness, 
dysarthria 
Prox. weakness 
rigid spine 
feet contractures 
Myopathic, 
infiltration 
Myopathic, 
necrosis, 
infiltration* 
Myopathic, 
necrosis, 
infiltration 
Neurogenic, 
infiltration 
Myopathic, 
necrosis, 
infiltration 
Myopathic, 
necrosis, 
infiltration 
Myopathic, 
necrosis, 
infiltration 
Myopathic, 
necrosis 
Myopathic 
necrosis** 
C + 
N + 
C + + 
C + 
c + 
N + 
C + + 
N + + 
C + 
N + 
C + 
c + 
N + 
IBM 
IBM 
IBM 
IBM 
IBM 
IBM 
IBM 
Familial OPMD 
with Distal 
Myopathy 
Rigid Spine 
Syndrome 
C, cytoplasmic 
N, nuclear 
+,few to moderate 
++, many 
IBM, inclusion body myositis 
* deltoid muscle 
** erector trunci muscle 
OPMD, oculopharyngeal muscular dystrophy 
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Not all biopsies were taken from the quadriceps muscle. In one IBM patient (H) 
a biopsy was taken from the deltoid muscle and the RBV-fiber density, 47 per 
10 mm2, was clearly in the range of values obtained from quadriceps biopsies 
in these patients (Figure 1). Equally, the RBV-fiber density in the quadriceps 
muscle from a patient with a neurogenic disorder (KH), 2 per 10 mm2, did not 
differ from values obtained in 6 soleus muscles (range 1 - 4 per 10 mm2; 
Figure 1). By far the highest RBV-fiber density was found in the erector spinae 
muscle of the patient with rigid spine syndrome (D) (205.8 per 10 mm2; Figure 
2A). 
Figure 1 Numbers of muscle fibers with rimmed basophilic vacuoles (RBV) per 10 
mm'transverse section, the RBV-fiber density (magnification 400x) in inclusion body 
myositis (IBM) and non-IBM neuromuscular disorders. NG, neurogenic disorders; 
LGMD, limb girdle muscular dystrophy. 
RBV-fiber density 
1000 π 
100-
1 0 -
1 -
0,1 
IBM ND LGMD Others 
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Table 2 Clinical and pathological characteristics of patients with rimmed basophilic 
vacuoles on light microscopy and absence of 15 -21 nm filamentous inclusions on elec­
tron microscopy of quadriceps muscle. 
Pt 
V 
в 
vD 
S 
GW 
LN 
LS 
V 
К 
J 
кн 
H 
Age at 
Biopsy 
14 
64 
57 
29 
66 
66 
37 
29 
59 
38 
67 
22 
Age of 
Onset 
5 
30 
34 
24 
51 
65 
37 
28 
53 
36 
59 
6 
Clinical 
Features 
Proximal 
weakness 
Weakness 
legs 
Proximal 
weakness 
Weakness 
lower legs 
Distal 
weakness 
Multiple 
neuropathies 
Acute 
sensorimotor 
polyneuropathy 
Subacute 
sensorimotor 
polyneuropathy 
Chronic 
sensorimotor 
polyneuropathy 
Pathological 
Features 
Dystrophic, 
necrosis 
Dystrophic* 
Dystrophic 
Myopathic, 
necrosis* 
Myopathic, 
necrosis** 
Neurogenic** 
Neurogenic** 
Neurogenic** 
necrosis 
Neurogenic** 
Sensorimotor Neurogenic 
polyneuropathy, 
perceptive deafness, 
ichthyosis, 
retinitis pigmentosa 
Generalized 
weakness 
Central motor 
neuron syndrome 
Neurogenic 
Neurogenic** 
Diagnosis 
Limb Girdle 
Muscular Dystrophy 
Limb Girdle 
Muscular Dystrophy 
Limb Girdle 
Muscular Dystrophy 
Distal Myopathy with 
Rimmed Vacuoles 
Distal Myopathy with 
Rimmed Vacuoles 
Vasculitic Neuropathy 
Vasculitic Neuropathy 
Axonal Polyneuropathy 
Chronic Idiopathic 
Axonal Polyneuropathy 
Hereditary Motor 
Sensory Neuropathy 
Spinal Muscular 
Atrophy Adult Type 
Lateral Sclerosis 
* gastrocnemius muscle 
** soleus muscle 
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Figure 2 Rimmed basophilic vacuoles (RBV) in muscle fibers. A: rigid spine syndro­
me, RBV-fiber density 205.8; B: inclusion body myositis, RBV-fiber density 63.1; C: 
limb girdle muscular dystrophy, RBV-fiber density 2.7; D: vasculitic neuropathy, 
RBV-fiber density 4.4. Bar = 50 μηι. 
In 3 patients more than one muscle biopsy was taken. In one IBM patient (V) 
the quadriceps muscle was examined on a yearly basis on 3 consecutive occa­
sions. The RBV-fiber densities did not change (45, 45, and 48 per 10 mm2, 
respectively). In another IBM patient (vSo) the quadriceps and biceps muscle 
were examined within 6 months; the RBV-fiber densities were exactly the 
same, 37 per 10 mm2. Surprisingly, the patient with the rigid spine syndrome, 
who showed 205.8 RBV-positive fibers per 10 mm2 in the erector spinae biop­
sy, had no vacuoles in a quadriceps biopsy, nor in the quadriceps at autopsy 5 
years later. 
Electron microscopically, abnormal filaments measuring 15 to 21 nm were 
found in the sarcoplasm (6 patients), the nuclei (one patient) or in both (4 
patients). In longitudinal sections these filaments had bended or undulating 
appearance with a periodicity of 2.5 - 3.7 filaments per 100 nm, but also areas 
with intermingled filaments occurred. In the sarcoplasm, groups of filaments 
were often partially surrounded by a membrane. Aggregates of filaments were 
often peripherally located, bordering to areas with membranous whorls. The 
frequency of filamentous inclusions was highest in patient Η and lowest in 
patient HP, both having IBM; the latter patient showed a single cytoplasmic 
inclusion with 15 -21 nm filaments. 
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Cytoplasmic and/or nuclear inclusions were detected in 11 patients, resulting 
in an overall incidence of 14.7 per 1,000. In non-IBM patients their incidence 
was only 2.7 per 1,000. Diagnoses were IBM (n = 7), familial OPMD-DM (n = 
1), rigid spine syndrome (n = 1), acid maltase deficiency (n = 1), and amyloid 
neuropathy (n = 1). 
For clinico-pathological features, diagnosis, and the frequency of the filaments 
in individual patients see Tables 1 and 3; for illustrations see Figure 3A-F. 
Apart from the IBM patients, a combination of RBV and filamentous inclusions 
was observed in the patient with familial OPMD-DM, and in the patient with 
rigid spine syndrome. Moreover, familial OPMD-DM patient had a RBV-fiber 
density comparable to that of IBM patients (26.4). 
Table 3 Clinical and pathological characteristics of patients with 15 - 21 nm filamen­
tous inclusions on electron microscopy and absence of rimmed basophilic vacuoles on 
light microscopy. 
Pt Age Age Clinical Pathological Filamentous Diagnosis 
Biopsy Onset Features Features Inclusions 
В 46 31 Hip girdle Myopathic, С + Acid Maltase 
weakness glycogen* Deficiency 
JR 48 46 Sensorimotor Neurogenic, С + Amyloid 
polyneuropathy amyloid ** Neuropathy 
* Quadriceps muscle 
** Soleus muscle 
C, cytoplasmic 
+,}ew to mederate 
Discussion 
In this quantitative study we demonstrated that in IBM patients the density of 
RBV-positive fibers ranged from about 10 to 65 per 10 mm 2 cross section. The 
under limit of this range -1 per mm 2 - fairly corresponds to the observation of 
Lotz et al., who studied 48 patients with light microscopic evidence of IBM and 
found at least 1 RBV-positive fiber per low-power field in IBM [3]. In addition, 
we demonstrated that the density of RBV-positive fibers in IBM is significant­
ly higher than in RBV-positive patients with neurogenic disorders or LGMD. 
Moreover, values did not overlap, making that in the presence of RBV quanti­
tation of RBV-positive fibers may be helpful in differentiating IBM from these 
two categories of neuromuscular disorders. 
It can be argued that RBV-fiber densities might vary between different mus­
cles. Indeed, in the rigid spine patient the absence of RBV in the quadriceps 
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Figure 3A-F Filamentous inclusions in muscle fibers from patient В (acid maltase defi­
ciency) (Figure Α-B), patient D (rigid spine sysndrome) (Figure C-D), and patient JR 
(amyloid neuropathy) (Figure Ε-F) in the sarcoplasm (FigureA, Figure B-F) or nucleus 
(Figure C). Figure B: transverse section of the filaments in Figure A. Figure E: fila­
mentous inclusions (centre part) bordering myofibrils and membranous whorls (upper 
and lower part, respectively). Figure F: higher magnification of filaments in Figure E. 
N = nucleus; bar = 1 ¿urn, except in Figure B: 0.1 ¿urn. 
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muscles strongly contrasted to the abundance of RBV-positive fibers in the 
erector spinae, suggesting that in a given muscle the RBV-fiber density may 
relate to the degree of clinical involvement. If so, the involvement of proximal 
muscles could explain that in the IBM group RBV-densities did not differ 
between quadriceps and deltoid muscle. On the other hand, in patients with 
neurogenic disorders, the soleus muscle revealed only few RBV-positive mus-
cle fibers, in spite of the distal weakness. Our data do neither exclude the pos-
sibility that the differences in RBV-fiber densities between IBM and neuroge-
nic disorders migth to some degree relate to the different sites of the biopies, 
irrespective of the degree of pathology or of clinical involvement. 
The RBV-fiber density in a patient with sporadic distal myopathy and in a 
patient with OPMD-DM were in the same range as in IBM. Previously, not-
quantified observations have been reported on RBV in familial distal myopa-
thy of the Welander type [15,19] and in OPMD [10]. Our findings indicate that 
quantitation of RBV-positive fibers does not contribute to the differentiation 
between distal myopathy and OPMD-DM on the one hand, and IBM on the 
other. Since the RBV-fiber density we found in a patient with sporadic distal 
myopathy lays well within the range of values for IBM patients, we suggest 
that the supposed entity of non-inflammatory inclusion body myopathy [17] 
may be identical to sporadic distal myopathy. 
As has been known, the simultaneous occurrence of rimmed vacuoles and fila-
mentous inclusions is highly suggestive of IBM [2,3]. Our results are in agree-
ment with those of Lotz et al., who found filamentous inclusions in 93% of 
patients with light microscopic evidence of IBM [3]. Yet, in our series filamen-
tous inclusions and rimmed vacuoles also coexisted in a patient with rigid 
spine syndrome and in a patient with familial OPMD-DM. Others made simi-
lar observations in familial distal myopathy of the Welander type [15] and in 
oculopharyngeal muscular dystrophy [7]. As to rigid spine syndrome, the 
abundance of RBV-positive fibers in the erector spinae muscle may facilitate its 
morphological differentiaton from IBM. 
We demonstrated that the incidence of rimmed vacuoles in non-IBM disorders 
as a whole is very low - approximately 9 per 1,000 -, and that they seem to occur 
preferentially in neurogenic disorders and muscular dystrophies. In fact, we 
found RBV in patients with various types of peripheral neuropathy, not having 
IBM; even half of our RBV-positive non-IBM patients had a neurogenic disea-
se without coexisting myopathy. However, in not one of these patients RBV-
positive fibers were as numerous as in IBM. Previous reports described RBV in 
spinal muscular atrophy [5] and in muscular atrophy after poliomyelitis [14], 
suggesting that motor neuron dysfunction may induce the development of 
rimmed vacuoles. Remarkably, coexisting neuropathies have been reported in 
up to 25 % of IBM patients [3,20], and combined morphological and electro-
physiological studies revealed peripheral nerve involvement in established 
IBM [21]. In some IBM patients clinical, electrophysiological and morphologi-
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cal features even suggest a neurogenic origin of the disease [22]. Our findings 
seem to support this view. 
It has been known that 15 to 21 nm filamentous inclusions not only occur in 
IBM, but in a wide range of neuromuscular disorders [5-16,19,23]. We found 
these inclusions in an even more heterogenous group of disorders, ranging 
from muscular dystrophies - including the limb-girdle type - to lateral sclero­
sis. Interestingly, the diseases in 6 of the 14 non-IBM patients with RBV, and in 
2 of the 4 non-IBM patients with filamentous inclusions are thougth to have a 
genetic origin: muscular dystrophies, spinal muscular atrophy, lateral sclero­
sis, and acid maltase deficiency. Thereabove, rimmed vacuoles and/or fila­
mentous inclusions occur in various familial diseases, like familial OPMD-DM 
[11], familial myopathy with periventricular leukencephalopathy [9], and 
familial distal myopathy [6,15,16,19]. A familial form of IBM has also been 
described, possibly representing the same entity as the familial rimmed vacuo­
le myopathy sparing the quadriceps [23,24]. These observations may be cir­
cumstantial evidence for a genetic causation of IBM itself. Only very recently 
Oldfors et al. showed that mtDNA deletions may be involved in the pathoge­
nesis of IBM and cause respiratory chain dysfunction [25]. 
In conclusion, on retrospective analysis of light microscopic findings in 1600 
muscle biopsies, and of electron microscopic findings in 750 biopsies the follo­
wing was found. Firstly, RBV as well as 15-21 nm filamentous inclusions are 
rare in non-IBM neuromuscular disorders: 8.8 per 1,000 and 2.7 per 1,000, 
respectively. Secondly, RBV and filamentous inclusions may coexist in familial 
OPMD-DM and rigid spine syndrome. Thirdly, non-IBM RBV preferentially 
occur in neurogenic disorders and muscular dystrophies, and the RBV-fiber 
density may help to discriminate these cases from IBM. 
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Introduction 
The idiopathic inflammatory myopathies polymyositis (PM) and dermatomy-
ositis (DM) are clinically characterized by a progressive bilateral weakness of 
proximal muscles and elevation of serum creatinine kinase (CK) levels [1-3]. 
Immunologic and immunohistochemical data strongly suggest an autoimmu­
ne pathogenesis [4-6]. Association with other autoimmune pathology fre­
quently conforms to one of the well-defined connective tissue diseases [1,6]. In 
an immunoelectronmicroscopic study in PM patients Arahata and Engel 
showed in morphologically normal fibers CD8+ cells and macrophages, which 
may indicate that Τ cell-mediated injury of muscle fibers has a pathogenic role 
in PM [7]. 
Prednisone is generally accepted as the first-line treatment in PM and DM [6]. 
In patients not responding to prednisone or requiring high dosages for main­
tenance therapy, azathioprine [8,9], methotrexate [10,11], or cyclophosphami­
de [12,13] have been used succesfully. Some studies reported a beneficial effect 
of plasmapheresis in steroid-resistent patients [14,15]. However, approximate­
ly 50% of PM and DM patients do not respond sufficiently to conventional the­
rapy [16]. 
Cyclosporine (Cs) has potent immunosuppressive properties as demonstrated 
in clinical organ transplantation [17]. Cs probably interferes with Τ cell-media­
ted autoimmune responses [18]. It inhibits the activation of Τ helper cells and 
the subsequent amplification of Τ helper cell-dependent responses [18]. 
Therapeutic results of Cs, 3 to 10 mg/kg/d, have been reported in patients 
with acute PM and DM resistant to conventional immunosuppressive therapy 
[19-23]. One patient had a complete remission for 1 year on a maintenance dose 
of 5 mg/kg/d [23]. 
Recently, three patients attending our neuromuscular outpatient clinic with 
chronic slowly progressive PM showed persistent disease activity not respon­
ding to prednisone, azathioprine, and plasmapheresis. In view of the favorable 
reports on Cs in acute PM and DM and the suspected pathogenetic role of Τ 
cell-mediated fiber injury in PM, we treated these patients with Cs in combi­
nation with low doses of prednisone. In this report we present the clinical 
results. 
Patients and Methods 
Patients 
Three male patients, A, B, and C, 68, 50, and 45 years old, respectively, had a 
history of subacute PM followed by a chronic progressive course for 20,5, and 
3 years, respectively. At the onset of their disease all patients had progressive 
bilateral weakness of proximal muscles, raised serum levels of CK (690, 400, 
and 1,900 U/l, respectively), and myopathic changes with high-frequency dis-
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charges on electromyography. Dermatologie features were absent. On histolo-
gical examination of quadriceps muscle tissue obtained by needle biopsy, infil-
tration of mononuclear cells and necrosis of muscle fibers were present in 
every patient. On electron microscopy, inclusion body myositis could be exclu-
ded. Hematologic, biochemical, and radiological examinations ruled out neo-
plastic, metabolic, endocrinologie, and associated inflammatory or autoimmu-
ne disease, except for patient B, who had a history of rheumatoid arthritis for 
14 years. But when the myositis became apparent, his rheumatic disease was 
not active, and he was taking no medication. Family histories were negative for 
neuromuscular disorders. On the basis of these findings, definite PM was diag-
nosed in every patient according to the criteria of Whitaker [2]. 
In patient A 1 mg prednisone/kg/d resulted in a marked improvement, but 
when receiving maintenance doses of 15 to 40 mg/d , continuous slow progres-
sion was seen. In patient B, azathioprine 150 m g / d gave no improvement. 
When receiving prednisone, 1 m g / k g / d , serum CK levels normalized, but 
there was no increase in muscle force. Tapering the prednisone dosage to 17.5 
mg /d was followed by a rise in serum CK levels to 180 U/ l . In patient C, serum 
CK levels decreased to 500 U/ l on a regimen of prednisone 1 m g / k g / d wit-
hout an increase in muscle strength. In this patient prednisone treatment was 
continued at a dose of 35 m g / d for 6 months without clinical improvement. At 
that time a spontaneous impression fracture of the third lumbar vertebra 
occurred, and the patient was transferred to our neuromuscular outpatient cli-
nic. Prednisone therapy was discontinued. In both patient A and C, azathiop-
rine (150 mg/d) and plasmapheresis gave only a partial and shortlasting 
improvement. 
In these three patients with definite PM, persistent disease activity did not 
respond to conventional immunosuppression and resulted in a slowly 
progressive course of their signs and symptoms. 
Methods 
Before treatment muscular atrophy was assessed clinically. Dynamometry of 
proximal muscles by using a hand-held Hammersmith strain gauge dynamo-
meter included a bilateral measurement of the maximum voluntary contrac-
tion force (MVCF) of trapezius, biceps, triceps, and quadriceps muscles [24,25]. 
Criteria for selecting these muscles were easy testability and an absence of con-
tractures. Cs was given in a dosage of 6 mg /kg /d . Depending on Cs levels and 
side effects, the dose was adjusted during the treatment period. Measurement 
of serum CK levels and screening for side effects and toxicity of Cs were per-
formed every other day for the first 2 weeks and every month in the period the-
reafter. Treatment monitoring included hematologic and biochemical evalu-
ation, control of blood pressure and body weight, and determination of Cs 
trough levels in whole blood by using a radioimmunoassay. The range of 200 
to 800 ng/ml whole blood was considered therapeutic. From systolic and dia-
stolic blood pressures the mean arterial pressure (MAP) was calculated. 
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Clinical evaluation was performed after 6 and 30 weeks of treatment and inclu­
ded a measurement of serum CK levels and dynamometry of proximal mus­
cles as mentioned earlier. Normalization of serum CK levels, objective increa­
se of MVCF in at least 6 muscles, and subjective improvement in the activities 
of daily living (ADL) were considered criteria for successful therapy. 
Results 
Pretreatment examination showed severe bilateral atrophy of the shoulder and 
upper arm muscles in all patients. Severe atrophy of upper leg muscles and a 
moderate atrophy of trunk muscles were seen in patient A. The upper leg mus­
cles in patients В and С were moderately atrophic. 
Serum CK levels and results of dynamometry are given in Table 1. Cs levels, 
serum creatinine concentrations, and MAP are shown in Table 2. 
Table 1 Serum CK levels and maximum voluntan/ contraction force (MVCF) on bila­
teral dynamometry before and after 6 and 30 weeks ofCs treatment 
CK (U/l) 
MVCF (N) 
Trapezius 
Biceps 
Triceps 
Quadriceps 
Patient A 
0 6wk 
674 881 
58/58* 60/55 
90/82 85/80 
60/60 50/45 
70/70 72/68 
30wk 
105 
72/72 
90/90 
72/68 
80/80 
Patient В 
0 
226 
46/48 
58/62 
28/30 
65/62 
6wk 
256 
40/60 
50/78 
32/38 
62/68 
30wk 
208 
50/52 
52/68 
42/42 
68/80 
0 
134 
40/41 
50/49 
22/25 
61/55 
Patient С 
6wk 
149 
68/ 68 
52/ 38 
54/ 58 
110/110 
30wk 
175 
90/ 90 
48/ 42 
80/ 80 
115/115 
* Right/Left 
N, Newton 
Table 2 Cs trough levels, mean arterial pressure (MAP), and serum creatinine levels 
after 6 and 30 weeks 
Cs levels (ng/ml) 
Serum creatinine 
MAP 
Patient A 
6wk 
63 
+21 
+23 
30wk 
800 
+154 
+ 23 
6wk 
250 
+10 
+10 
Patient В 
30wk 
150 
+58 
+16 
6wk 
225 
+23 
+ 5 
Patient С 
30wk 
228 
+ 2 
+10 
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atient A noticed an increased fatigability and a decreased proximal muscle 
force in the first 6 weeks. In this period low Cs blood levels were found, and 
therefore the daily dosage was raised to 7 mg/kg. A gradual improvement 
started thereafter, and after 30 weeks he had subjectively recovered his pretre­
atment condition. Patient В noticed a stabilization of his condition. Weakness, 
fatigability, and disability remained unchanged compared with the pretreat­
ment situation. Patient С noticed a gradual increase of muscle force and impro­
ved walking. At the same time the back pain decreased and additional radio­
logical examinations showed healing of the lumbar disk fracture. At 25 weeks 
the Cs dosage was lowered to 5 mg/kg/d in patient В because of progressive 
renal dysfunction. At 12 weeks the Cs dosage in patient С was lowered to 4 
mg/kg/d because of hypertension. In all patients hypertension occurred wit­
hin 6 weeks and necessitated atenolol medication, 100 mg/d. 
After 30 weeks Cs therapy was discontinued in patient A because of progres­
sive renal dysfunction and a lack of subjective improvement. In patient В the 
persistent elevation of CK levels and the absence of subjective improvement in 
the presence of serious side effects like hypertension and nephrotoxicity neces­
sitated discontinuation of Cs therapy. Because the pretreatment pathology of 
the lumbar vertebra had probably interfered with a maximal performance on 
quadriceps dynamometry, the marked increase in quadriceps MVCF in patient 
С was not considered a result of decreased muscle disease. The slight increase 
in the serum CK level during treatment was in support of this explanation, and 
at 30 weeks Cs therapy was discontinued. 
Discussion 
In this paper we present the clinical results of Cs in a dose of 5 to 7 mg/kg/d 
in three patients with chronic slowly progressive PM and proven resistance to 
prednisone, azathioprine, and plasmapheresis. To our knowledge this is the 
first study on Cs in this clinical type of PM. There are several reports on the use 
of Cs with a dose of 3 to 10 mg/kg/d in patients with acute onset or exacerba­
ting PM and DM resistant to conventional immunosuppression who show 
improvement within 1 to 3 weeks [19-23]. In a recent preliminary report posi­
tive results were claimed in nine patients with idiopathic inflammatory myo­
pathies [26]. The types of disease and results on dynamometry, however, were 
not reported. In one patient with acute PM a complete remission for 1 year was 
achieved on a maintenance dose of 5 mg/kg/d [23]. 
The serum CK level and degree of muscle weakness are accepted disease para­
meters in PM and DM. Normalization of CK level and improvement in muscle 
force with an ensuing increase in ADL seem solid criteria to assess the effecti­
veness of a certain therapy. At 30 weeks the CK level in patient A had practi­
cally normalized, whereas in patients В and С CK levels had not changed, 
which suggests persistence of disease activity. In patients with acute and seve-
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re disease a valid assessment of muscle force can be made by MRC grading. In 
patients with chronic progressive disease, however, the therapy-induced chan­
ges in muscle force are expected to be small, and dynamometry seems war­
ranted. The validity and sensitivity of the Hammersmith strain gauge dyna­
mometer we used has been demonstrated [24,27]. Learning effects are known 
to be small and cannot explain the increased MVCF we found [27]. At 30 weeks 
all patients showed an increase in the MVCF in at least six of eight proximal 
muscles, thus indicating improved proximal strength and suggesting decre­
ased disease activity. Seven muscles improved in patient A, who also showed 
a normalization of the CK value. ADL improvement, however, was only seen 
in patient C, and had, in part, to be attributed to healing of the lumbar verte­
bra. In conclusion, at 30 weeks none of the three patients showed improvement 
in all three parameters: subjective improvement, normalization of CK levels, 
and improved proximal muscle force as detected by dynamometry. In explai­
ning these partly discordant findings one must consider that in patients with 
long-lasting disease activity the extensive loss of muscle tissue may preclude a 
clinically impressive increase in strength on a relatively short term. 
The side effects we observed in patient A and, to a lesser extent, in patient В 
were progressive renal dysfunction and hypertension (see Table 2). They were 
serious and necessitated discontinuation of Cs treatment. After cessation of Cs 
therapy, serum creatinine levels and blood pressure normalized. In patient A 
the high Cs through levels at 7 mg/kg/d might have had a causative relation 
to the occurrence of these side effects. But the value of trough level monitoring 
in their prevention is uncertain because even at the lower therapeutic range of 
200 ng/ml nephrotoxicity has been reported [28,29]. 
In the absence of subjective improvement in ADL (patient A and B) or norma­
lization of CK levels (patients В and C) we feel that the moderate increase in 
proximal muscle force as detected by dynamometry did not outweigh the side 
effects of Cs. On the basis of our observations it is questionable whether Cs 
may be useful in the chronic progressive type of PM in contrast to the positive 
results obtained in acute and exacerbating PM and DM [19-23]. Jones et al. 
reported two cases in which patients with intractable exacerbations of PM and 
DM did not benefit from treatment with Cs [30]. The authors do not, however, 
mention whether inclusion body myositis had been excluded in the PM 
patient. This could be of importance in view of the poor results of immuno­
suppression in this type of myositis [6]. 
Further studies using dosages aiming at trough levels in the lower therapeutic 
range are needed to elucidate the possible benefits of Cs in patients with acute 
and exacerbating PM and DM. In view of the serious side effects that may 
occur, careful monitoring is mandatory. Therefore, in our opinion Cs therapy 
should only be instituted in centers with experience in this field, if possible 
cooperating in the framework of a well-designed clinical trial. 
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Chapter 12 
Inclusion body myositis responding to longterm 
chlorambucil treatment 
PJH Jongen, HJ ter Laak, LBA van de Putte 
(Journal of Rheumatology 1995;22:576-578) 
CHAPTER 12 
Introduction 
Inclusion body myositis (IBM) is known for its poor response to immunosup­
pression [1-5]. Yet, recent retrospective studies indicate that some patients may 
benefit from prolonged treatment with methotrexate, azathioprine, or cyclo­
s p o r i n (Cs) in combination with prednisone [6,7]. In a patient with IBM, who 
was resistant to these immunosuppressive drugs, we prospectively studied for 
3 years the effects of chlorambucil and low-dose prednisone. 
Patient and treatment 
Our patient, a 53 yrs-old woman, noticed a slowly progressive weakness of 
legs and arms in 1987. Examination showed proximal weakness of both legs. 
Rheumatological and dermatological evaluation was normal. Serum creatine 
kinase (CK) concentration was 5200 U/l. Electromyography suggested an inf­
lammatory myopathy. Light microscopy of paraffine-embedded sections of 
quadriceps muscle biopsy showed atrophic fibers, necrosis, mononuclear cell 
infiltration, and vacuoles without basophilia. Polymyositis was diagnosed and 
prednisone (1 mg/kg/day) was given for 6 weeks and then tapered. Because 
of further progression she was transferred to our hospital. We found a sym­
metric weakness (Medical Research Council, MRC) grade 4.5 of all four limbs, 
proximal and distal. A steroid-resistant polymyositis was diagnosed. For sub­
sequent treatments and serum CK values see Figure 1. Addition of azathiopri­
ne (150-250 mg/day) or methotrexate (20-30 mg/week) to prednisone (20 
mg/day) did not stop the slow progression. Cs (4-6 mg/kg/day), with pred­
nisone (20 mg/day), did stabilise her muscle strength for 1 month, but had to 
be discontinued after 5 weeks because of intractable side effects. She under­
went lymphapheresis (2/week) with methotrexate (30-35 mg/week) and pred­
nisone (20 mg/day) for 10 weeks, but muscle force and activities of daily living 
were impaired further. Light microscopy of a 2nd quadriceps muscle biopsy 
(haematoxylin-eosin stained fresh-frozen transverse 8 μιτι sections) showed 
lymphocyte infiltrations, necrotic muscle fibres, myophagia, and rimmed bas­
ophilic vacuoles. Electron microscopy showed scarce 16 nm filaments in the 
cytoplasm, close to glycogen and lysosomes. IBM was diagnosed. 
Cyclophosphamide (500-1000 mg/week i.V., for 12 weeks), gave an initial sta­
bilisation, but muscle weakness worsened in the 2nd month. On a 2nd trial of 
prednisone (80-45 mg/day for 6 months) serum CK levels decreased to 1500 
U/l, but clinical deterioration continued. 
At that time, August 1990, we started chlorambucil 0.1 mg/kg/day (8 
mg/day). Prednisone dose (30 mg/day) was lowered by 2.5 mg/month. 
Before and during this treatment muscles with MRC grade 4 had the maximal 
voluntary contraction force (MVCF) measured on a hand-held strain-gauge 
dynamometer [8]. Addition of MVCF values yielded the muscle force sum 
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score. For MRC grade 3 muscles, not quantifiable on dynamometry, the MRC 
mean value was calculated. 
Results 
Chlorambucil was well tolerated. After 2 months the patient and her family 
noticed a slight improvement of walking. For this reason we continued chlor-
ambucil and after 7 months, when the prednisone dose was 20 mg/day, she 
had a more stable gait, could rise from a high chair without assistance, and was 
capable of some housekeeping and driving a car. Improvement continued 
slowly for the next 8 months; during this period prednisone was tapered to 10 
mg/day. Then her condition stabilised. After 1 year chlorambucil was lowered 
to 6 mg/day. During the 3rd year it was decreased by 2 mg/day per 4 months. 
After 3 years chlorambucil was stopped. Until now her condition is unchan-
ged. Results of muscle testing are given in Table 1. 
Discussion 
We think that chlorambucil contributed essentially to this patient's improve-
ment, since the changes were temporally related to the administration of chlor-
ambucil. Although the serum CK concentrations decreased during the regimen 
of high-dose prednisone, they did not reach normal values. Moreover, in myo-
sitis a decrease of CK values during prednisone does not imply a steroid-
responsiveness of the inflammation [9], and indeed in our patient CK levels 
remained elevated, indicating ongoing disease activity. The last high-dose 
prednisone trial might have led to a steroid-myopathy. If so, the improvement 
on chlorambucil could have resulted from prednisone taper. However, the ste-
ady deteriotation in muscle strength before and during high dose prednisone 
argues against this explanation. 
Vacuolar myopathy may have various causes [10]. Although the findings on 
electron microscopy were not typical [11], we think that IBM diagnosis ist most 
probable, given the resistance to previous immunosuppression and the char-
acteristic findings on light microscopy [3]. In fact, filamentous inclusions may 
be absent in as much as 25% to 70% of IBM patients [2]. 
Recently, a retrospective study reported that 12 of 28 patients, having received 
some sort of immunosuppression, experienced delayed progression and 3 
exhibited longterm improvement [6]. The responding patients were treated 
with methotrexate, azathioprine, or Cs, in combination with prednisone. In our 
patient the clearly positive effects of chlorambucil appeared after 7 months. 
Perhaps azathioprine or methotrexate would also have been effective, if given 
for more than 3 months. For, in one patient normalization of muscle force and 
CK concentration occurred at 2 years of azathioprine and low dose prednisone 
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[12]. Our observation confirms the view that, given the chronicity and the slow 
progression in IBM, trials of 3 months may be not long enough to yield clinical 
results [3]. Therefore, we judge it reasonable in progressive IBM to consider a 
longterm trial with a cytotoxic agent, such as chlorambucil, possibly m combi­
nation with low-dose prednisone. 
Table 1 Results ofMRC grading of muscle strength (MRC mean) and of dynamo-
metry (muscle force sum score, MFSS), and daily doses of chlorambucil and predniso­
ne. 
Pre treatment 
After 1 yr 
2yrs 
3yrs 
MRC mean 1) 
2 6 ± 0 5 
3 0 ± 0 6 * 
3 0 ± 0 7 * 
3 1 ± 0 7 * 
MFSS 2) 
88 5 ± 38 1 
9 4 4 ± 4 2 0 
9 6 3 ± 4 7 4 
99 4 ± 52 6 
Chlorambucil 
(mg) 
-
8 
6 
-
Prednisone 
(mg) 
35 
15 
-
-
1) Left and right deltoid, subscapular, triceps, iliopsoas, gluteus, adductor, obturator, and rectus abdominis 
muscles 
2) Left and right sternocleidomastoideus, trapezius, infraspinatus, biceps, and quadriceps femorts muscles 
* Ρ <0 04 compared to pretreatment value (Wilcoxon test for matched pairs) 
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Summary and conclusions 
The studies on inflammatory muscle disease presented in this thesis concen-
trate on Coxsackie Bl virus-induced murine myositis on the one hand, and on 
human polymyositis, dermatomyositis, and inclusion body myositis on the 
other. 
Murine studies 
Inoculation of the Tucson strain of Coxsackie Bl virus (CB1) in newborn CD1 
Swiss mice induces a chronic myositis of proximal hindlimb muscles (CB1 
myositis). In view of its clinical, electromyographic, and histopathological 
similarities to polymyositis, CB1 myositis has been known as a model for poly-
myositis. In our studies on CB1 myositis we elaborated upon the following 
questions: (a) Does persistence of viral RNA play a pathogenic role in CB1 
myositis ? (b) Which humoral and cellular immune mechanisms are involved 
in CB1 myositis ? 
At the start we investigated the persistence of Coxsackie viral RNA in mice 
with CB1 myositis. Hamstring muscle samples of diseased mice obtained at 
various times after inoculation were examined for the presence of infectious 
virus, viral RNA and histopathological abnormalities. Viral RNA was detected 
up to 4 weeks after infection, whereas virus could be isolated from hamstring 
muscles for up to 2 weeks. After 2 weeks no sign of infection was demonstra-
ted although histological abnormalities, including inflammation, remained 
present for the entire observation period of 16 weeks. The observation that 
viral RNA was detectable for only 2 more weeks after tissues became negative 
for infectious virus suggests that the infection slowly wanes rather than per-
sistence of viral RNA. We concluded that CB1 does play an essential role in the 
initiation of CB1 myositis but not in the maintenance of the chronic phase 
(Chapter 1). 
Then we studied the role of the virus dose and of antiviral antibodies in the 
development of CB1 myositis. Groups of newborn mice were infected with 6 
CB1 doses and after 4 and 8 weeks we quantified morbidity, antiviral antibody 
titer, and histopathological changes. At 4 weeks, morbidity and mononuclear 
cell infiltration differed significantly for the various groups, with most promi-
nent changes in animals infected with 300 plaque forming units (pfu). At 4 and 
at 8 weeks diseased animals had significantly higher antibody titers than clini-
cally unaffected animals, and at 4 weeks myopathic and infiltrative changes 
correlated positively with the serum antibody titer. We concluded that the 
virus dose does play a pathogenic role in CB1 myositis, and that humoral 
immune mechanisms might well play a role in the early phase of CB1 myositis 
(Chapter 2). 
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Thereafter we investigated the role of humoral factors in the pathogenesis of 
CB1 myositis in more detail. At 2, 4 and 8 weeks after inoculation serum was 
studied for circulating immune complexes (CIC) (Raji-cell assay), haemolytic 
complement activity (CH50 titer) and anticytoplasmic autoantibodies 
(Western blotting, immunoprecipitation) in relation to degree of mononuclear 
cell infiltration and muscle fiber necrosis. At 2, 4 and 8 weeks cell infiltration 
correlated positively to muscle fiber necrosis. From 2 weeks on moderate quan­
tities of CIC were found in nearly all CB1 inoculated mice, however, without 
correlation to histological changes. Except for a positive correlation of CH50 
titer to muscle necrosis at 4 weeks (r = 0.60; Ρ = 0.02), CH50 titers did not cor­
relate to muscle lesions. Moreover, anticytoplasmic and other known autoan­
tibody specificities were absent. We concluded that in spite of the occurrence 
of CIC in CB1 myositis from 2 weeks on, that there was no correlative eviden­
ce for their involvemenent in pathogenesis, nor for that of complement or anti­
cytoplasmic autoantibodies. In addition, the positive correlation between cell 
infiltration and muscle necrosis underscored the importance of cellular mecha­
nisms. In all, these data did not support, nor conclusively excluded a role for 
humoral processes in CB1 myositis (Chapter 3). 
To obtain histological clues regarding pathogenesis in CB1 myositis we stu­
died characteristics, severity and duration of muscle changes. We qualitative­
ly and quantitatively examined transverse sections of hamstring, quadriceps 
and gluteus muscles at 1,2,4, 8, and 16 weeks after inoculation. Mononuclear 
cell infiltration, muscle fibre necrosis, fibre atrophy, and fibres with central 
nuclei were quantified. Findings in acute viral myositis (1-2 weeks) were com­
pared to those in CB1 myositis (4 -16 weeks). Qualitatively, abnormalities were 
essentially the same from 1 to 16 weeks: mononuclear cell infiltration, muscle 
fiber necrosis, fiber atrophy, fascicular involvement, and perifascicular atro­
phy. Mononuclear cells invaded necrotic and non-necrotic fibers, but necrotic 
invaded fibers were clearly more frequent than non-necrotic fibers. 
Quantitative examination showed the following: hamstring muscles were in all 
respects more severely affected than quadriceps and gluteus muscles; infiltra­
tion and necrosis at 4, 8, and 16 weeks were less than at 1 and 2 weeks; and on 
equidistant sections abnormal fascicles were involved at their full length, with 
only small intramuscular variations. From these findings we concluded that 
CB1 myositis has chronic low-grade disease activity for at least 16 weeks, and 
that the presence of inflammatory cells and fibre necrosis justifies the designa­
tion of myositis. The histopathological features of CB1 myositis apparently 
bear more resemblance to those in human dermatomyositis than to those in 
polymyositis. Finally, the histological similarities between CB1 myositis and 
the preceding phase of viral myositis may reflect common or closely related 
pathogenic process(es) (Chapter 4). 
To clarify the immunopathology in CB1 myositis on tissue level, we immu-
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nophenotyped subsets of mononuclear cells by using monoclonal antibodies 
and looked for immunoglobulin and complement deposits using polyclonal 
antibodies. After inoculation of neonatal CD1 Swiss mice with 300 pfu CB1, 
hamstring muscle of affected animals were examined at 1, 2, 4, and 8 weeks. 
Consecutive mid-portion sections were stained for desmin, vimentin, СЗс, IgG, 
IgM, CD4, CD8a, CD3, CD45R, and CD25. At all time points CD4+ cells were 
the predominant Τ cell type, at times invading muscle fibers. Necrotic invaded 
fibers were more frequent than non-necrotic ones. At 2 and 4 weeks the CD4+ 
cell proportion was higher at endomysial than at perivascular sites. In endo-
mysial infiltrates the proportion of CD8a+ cells increased as the inflammation 
became more chronic, and in perivascular infiltrates the proportion of CD8a+ 
cells at 4 weeks was higher than at 2 weeks. Once an IgM+ positive venule was 
observed. We concluded that CD4+ Τ cells, and not CD8a+ Τ cells, most likely 
play a decisive role in muscle fiber injury. Thereabove, our data suggested that 
immune-mediated vasculopathy might contribute to ischaemic necrosis 
(Chapter 5). 
To establish more firmly the suggested existence of predominant right leg 
involvement in CB1 myositis we regularly observed inoculated mice for pos­
ture, mobility and gait. After 2 and 4 weeks motor dysfunction of right and left 
leg were compared quantitatively (asymmetry score), and on light microscopy 
we quantified mononuclear cell infiltration and muscle fiber necrosis in bila­
teral hamstring muscles. Motor asymmetries were seen during acute viral 
myositis as soon as hind leg dysfunction appeared, and animals with a predo­
minant dysfunction of one leg preserved that preference throughout the obser­
vation period. At 2 weeks, mice with predominant right leg dysfunction signi­
ficantly outnumbered those with predominant left leg dysfunction (P = 0.01). 
At 2 and 4 weeks, infiltration and necrosis in hamstrings from legs with pre­
dominant dysfunction were not higher than in those from contralateral legs; 
and infiltration in right-sided hamstrings was not higher than in left-sided 
ones, nor was infiltration at 4 weeks. At 4 weeks right-sided muscles were 
more necrotic (mean ± SD, 1.8 ± 1.5) than left-sided muscles (1.1 ± 1.2; P=0.03). 
In the absence of a predominant inflammatory disease of the right leg, we inter­
preted the hind leg asymmetry as a preferential use of the left leg, due to left-
leggedness, and suggested that in CD1 Swiss mice left-leggednes is associated 
with increased susceptibility to CB1 myositis (Chapter 6). 
At the end of this section we reviewed the available data on CB1 myositis, dis­
cussed possible pathogenic mechanisms, and reconsidered the use of CB1 
myositis as a model for human inflammatory muscle disease. We concluded 
that there is little support for the notion that CB1 myositis is a model for poly­
myositis, but that there is evidence for the use of CB1 myositis as a model for 
dermatomyositis. Thereabove, we suggested that the value to be gained from 
studying CB1 myositis may lie in its heuristic potential regarding various 
aspects of inflammatory muscle disease in general (Chapter 7) 
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Human studies 
In a study on aetio pathogenesis we investigated the possibility of viral persis­
tence in human idiopathic inflammatory muscle disease. Muscle tissue was 
obtained from 10 patients with polymyositis and five patients with dermato-
myositis, all with adult-onset and active disease. We performed a polymerase 
chain reaction (PCR) using primers with high specificity for enterovirus and 
encephalomyocarditis (EMC) virus RNA, followed by Southern blot hybridi­
sation with an oligonucleotide probe directed against the internal portion of 
the amplified product. PCR directed against the Abelson tyrosine kinase 
mRNA served as an internal control for the presence and quality of RNA. In 
none of the muscle biopsy specimens could a specific amplification be obser­
ved for enterovirus or for EMC, despite a sensitivity of approximately 30 pfu 
for enterovirus and of 100 pfu for EMC. Southern blot hybridisation confirmed 
the results, in that positive controls hybridized with the oligonucleotide probe 
but no signal was obtained with the muscle specimens. So, using a sensitive 
and specific PCR technique we found no evidence for the presence of enter­
ovirus or EMC RNA in muscle from patients with polymyositis or dermato-
myositis. We concluded that these data do not support the notion that viral 
RNA persistence plays a role in polymyositis or dermatomyositis (Chapter 8). 
In the next two chapters we described two diagnostic studies. First a study that 
assessed the diagnostic yield of automatic decomposition electromyography 
(ADEMG) in idiopathic inflammatory muscle disease. ADEMG is a commer­
cially available software package with installed reference values that enables 
the objective measurement of motor unit action potentials (MUAPs). We per­
formed biceps brachii ADEMG in patients with polymyositis, dermatomyosi-
tis, and inclusion body myositis. Results were compared with those in controls, 
and with the results of conventional EMG of the biceps and other muscles. 
Decreased mean values for MUAP duration occurred significantly more fre­
quently in idiopathic myositis than in controls; other MUAP characteristics did 
not differ. In the idiopathic myositis patients, decreased mean amplitude and 
increased mean number of turns occurred significantly less frequently on 
ADEMG than did corresponding abnormalities on conventional biceps EMG. 
Decreased mean values for duration and amplitude, and increased mean valu­
es for number of turns were seen significantly less often on ADEMG, than cor­
responding abnormalities on conventional EMG of 4 different, individually 
chosen muscles. Overall evaluation of ADEMG resulted in diagnosis of 'possi­
ble myopathy' in 1 and 'probable myopathy' in 8 patients, whereas overall eva­
luation of conventional EMG led to diagnosis 'suggestive of ИМ' in 13 patients. 
We concluded that, although measurement of mean MUAP duration might be 
valuable in diagnosis of idiopathic myositis, our results did not favour the use 
of biceps brachii ADEMG and the installed reference values in diagnosis of 
myositis. We suggested modifications to improve ADEMG's applicability 
(Chapter 9). 
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Then we described our study on the incidence of rimmed basophilic vacuoles 
(RBV) and 15-21 nm filamentous inclusions in neuromuscular disorders, other 
than inclusion body myositis (IBM), and determined the diagnostic value of 
RBV quantitation in the differential diagnosis of IBM. To that end we reviewed 
1600 muscle biopsies for RBV and 750 biopsies for filamentous inclusions. The 
number of RBV-positive fibers per 10 mm2 - the RBV-fiber density - was deter-
mined. The incidence of RBV in non-IBM biopsies was 8.8 per 1000. Major dia-
gnostic categories were neurogenic disorders (n = 7) and limb girdle muscular 
dystrophies (LGMD) (n = 3). In IBM (n = 7) the RBV-fiber density ranged from 
10.4 to 63.1 and was significantly higher than in neurogenic disorders (0.9 - 4.4) 
and LGMD (1.1 - 2.7). The highest value was found in rigid spine syndrome 
(205.8). Filamentous inclusions were seen in 2.7 per 1000 non-IBM biopsies, 
including familial oculopharyngeal muscular dystrophy with distal myopathy 
(OPMD-DM), rigid spine syndrome, acid maltase deficiency and amyloid neu-
ropathy. RBV and filamentous inclusions coexisted in rigid spine syndrome 
and in familial OPMD-DM. We concluded that RBV as well as filamentous 
inclusions have a very low incidence, in non-IBM disorders, and that the RBV-
fiber density may help to discriminate neurogenic disorders and LGMD from 
IBM (chapter 10). 
Finally, we performed two therapeutic studies in patients with idiopathic inf-
lammatory muscle disease and irresponsiveness to conventional immunosup-
pression. In the first study, three patients with slowly progressive polymyosi-
tis, insufficient or temporary benefit from prednisone, azathioprine or 
plasmapheresis, and clinical (progressive weakness) and biochemical (incre-
ased serum CK levels) signs of disease activity, were treated with cyclosporine 
A, 6 mg/kg/day , in combination with low doses of prednisone. Light micro-
scopy and electron microscopy had given no evidence for inclusion body myo-
sitis. At 30 weeks of treatment the CK level had practically normalized in one 
patient, whereas in the two other patients serum CK had not changed; all three 
patients showed an increase of the maximum voluntary contraction force on 
dynamometry in at least 6 out of 8 proximal muscles, but there was no impro-
vement of activities of daily living (ADL) attributable to the drug treatment. 
Serious side effects were progressive renal dysfunction and hypertension, 
necessitating discontinuation of cyclosporine A treatment in 2 patients. In the 
absence of subjective improvement (ADL) or of normalization of CK concen-
trations we felt that the moderate increase in proximal muscle strength, as 
detected by dynamometry, did not outweigh the side effects of cyclosporine A, 
and we questioned wether cyclosporine A may be usefull in the treatment of 
chronic polymyositis (Chapter 11). 
In the second therapeutic study we described a 56 year old woman with clini-
cally progressive inclusion body myositis and proven resistance to metho-
trexate, azathioprine, cyclosporine A, lymphapheresis, and cyclophosphami-
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de. We administered a 3 year-treatment with chlorambucil 8 to 2 mg daily, with 
continuation of lowdose prednisone for one year. Seven months after the start 
of chlorambucil the progressive course of the disease stopped and the serum 
CK concentrations clearly decreased. At 1 year there was a subjective impro-
vement of motor functions, a significant increase of muscle strength on MRC 
grading, and a further decrease of the serum CK concentration. After 3 years of 
chlorambucil treatment, subjective motor functioning and performance on 
MRC grading were unchanged compared to 1 year, and the serum CK concen-
tration had almost reached normal values. The positive results of long-term 
chlorambucil treatment in this patient confirmed the view that, given the chro-
nicity and slow progression of inclusion body myositis, trials of 3 months may 
not be long enough to obtain clinical results. Therefore, we judged it reasona-
ble in patients with inclusion body myositis and evident clinical progression to 
consider a long-term trial with a cytotoxic agent, such as chlormabucil 
(Chapter 12). 
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Samenvatting en conclusies 
Ontstekingen in de skeletspieren en daaruit voortvloeiende spierzwakte vor-
men de klinisch-pathologische essentie van de inflammatoire spierziekten, de 
myositiden. Vanouds worden zij onderverdeeld in die aandoeningen die ver-
band houden met blootstelling aan omgevingsinvloeden (virussen, bacterieèn, 
geneesmiddelen) en die, waarbij dat niet het geval is, de zg. idiopathische myo-
sitiden. Polymyositis, dermatomyositis en inclusion body myositis zijn de 
meest frequent voorkomende syndromen in deze laatste groep. Hoewel ze 
kunnen worden voorafgegaan door blootstelling aan uitwendige agentia, met 
name virussen, bestaat vooralsnog geen duidelijke oorzaak-gevolg relatie tus-
sen blootstelling en het ontstaan van de onsteking. 
Verschillende soorten gegevens wijzen erop dat de idiopathische myositiden 
een gevolg zijn van een autoimmuunstoomis: aanwezigheid van verschillende 
autoantilichamen, door Τ lymphocyten gemedieerde cytotoxiciteit (polymyo­
sitis) of door complement gemedieerde micro-angiopathie (dermatomyositis), 
de vaak gunstige reactie op immunosuppressieve of immuunmodulerende 
behandeling, en het feit dat ze geassocieerd voorkomen met ziekten waarvan 
het autoimmuun karakter met meer zekerheid is vastgesteld. Men is het erover 
eens dat bij polymyositis cytotoxische Τ lymphocyten, reagerend met een tot 
nu toe onbekend antigen, een pathogène rol spelen. De mogelijke bijdrage van 
humorale mechanismen aan spierbeschadiging is veel minder duidelijk. 
Serologische studies wijzen erop dat de enterovirus en cardiovirus subgroepen 
van de picornavirussen betrokken zijn bij het op gang brengen van de autoim-
muunprocessen. Het is gesuggereerd dat bij poly- en dermatomyositis viraal 
RNA in de spieren persisteert, conform de hypothese van virus-geinduceerde 
autoimmuniteit. 
Nu is het is bekend dat virussen bij muizen autoimmuniteit kunnen opwekken. 
Inoculane van verschillende serotypes Coxsackie В (CB) virus kan uiteenlo­
pende chronische orgaan-specifieke ontstekingsziekten te weeg brengen, zoals 
СВЗ-geinduceerde myocarditis en CB4-geinduceerde diabetes. Inoculatie van 
de Tucson stam van CB1 virus in pasgeboren CD1 Swiss muizen induceert een 
chronische ontsteking van de achterpootspieren, leidend tot progressieve 
spierzwakte: CBl-geinduceerde myositis (CB1 myositis). Daar in de chroni­
sche fase het virus niet meer uit zieke spieren kan worden geïsoleerd, wordt 
CB1 myositis beschouwd als een door het virus geïnduceerde autoimmuun-
stoomis. Het feit dat CB1 myositis niet ontstaat in afwezigheid van Τ lympho­
cyten suggereert dat Τ cel gemedieerde mechanismen in het spel zijn. Vanwege 
het progressieve karakter van de achterpootzwakte en de electromyographi-
sche en histologische afwijkingen wordt CB1 myositis beschouwd als een 
model voor polymyositis. 
Het eerste deel van dit proefschrif beschrijft experimenten waarbij we CB1 
myositis gebruikten om de rol te bestuderen van virale persistentie en virus-
geinduceerde humorale en cellulaire immuunreacties bij het ontstaan van 
chronische inflammatoire spierziekte. 
De in het tweede deel beschreven studies concentreren zich op bij de mens 
166 
voorkomende chronische inflammatoire spierziekten: polymyositis, dermato-
myositis en inclusion body myositis. In deze eeuw zijn neurologen, reumato-
logen, internisten, dermatologen en kinderartsen getuige geweest van een 
belangrijke toename in de kennis omtrent deze vormen van myositis. Toch 
weten we fundamentele vragen vaak niet te beantwoorden, bijv. tegen welke 
antigen(en) de immuunresponsen gericht zijn. Evenzo kunnen behandelende 
artsen vaak geen passende oplossing vinden voor specifieke diagnostische of 
therapeutische problemen. Derhalve concentreren de hier beschreven klini-
sche studies zich op (a) de mogelijke rol van persisterend viraal RNA als anti-
gene trigger in polymyositis en dermatomyositis, (b) een verdere verfijning 
van het diagnostisch instrumentarium, en (c) nieuwe medicamenteuze thera-
pieën bij patiënten die onvoldoende baat hebben bij bestaande immunosup-
presieve behandeling. 
Studies bij de muis 
Bij onze studies van CB1 myositis gingen we nader in op de volgende vragen: 
(a) Speelt virale persistentie, het aanwezig blijven van viraal RNA, een rol bij 
CB1 myositis ? (b) Welke humorale en cellulaire afweermechanismen zijn bij 
CB1 myositis betrokken ? 
Om te beginnen onderzochten we of Coxsackievirus RNA persisteert in spie-
ren met CB1 myositis. Daartoe werden stukjes hamstringspieren, verkregen op 
verschillende tijdstippen na inoculatie, onderzocht op de aanwezigheid van 
infectieus virus, viraal RNA en histologische afwijkingen. Viraal RNA werd 
aangetoond tot en met 4 weken na inoculatie, terwijl infectieuze virusdeeltjes 
tot en met 2 weken uit hamstringspieren konden worden geïsoleerd. 
Gedurende de hele observatieperiode van 16 weken bleven histologische 
afwijkingen aanwezig, waaronder ontsteking. Het feit dat viraal RNA slechts 2 
weken langer aantoonbaar was dan dat infectieuze viruspartikels uit het spier-
weefsel kon worden geïsoleerd, suggereert dat de infectie langzaam afneemt, 
en niet zozeer dat viraal RNA aanwezig blijft. We concludeerden dat CB1 wel 
een cruciale rol speelt bij het begin van CB1 myositis, maar niet bij het onder-
houden van de ontsteking (Hoofdstuk 1). 
Daarna bestudeerden we de rol van de hoeveelheid geinoculeerd virus (dosis) 
en van tegen het virus gerichte antilichamen bij het onstaan van CB1 myositis. 
Groepen pasgeboren muizen werden met 6 hoeveelheden CB1 virus geinocu-
leerd en na 4 en 8 weken kwantificeerden we morbiditeit (percentage zieke die-
ren), concentratie van antivirale antilichamen in het serum (titer) en histologi-
sche veranderingen in hamstring spieren. Vier weken na inoculatie waren 
zowel morbiditeit als hoeveelheid ontstekingscellen statistisch significant ver-
schillend voor de verschillende doses, met de meest uitgesproken veranderin-
gen in dieren die met 300 plaque-vormende eenheden (plaque forming units, 
pfu) waren ingespoten. Na 4 en 8 weken hadden zieke muizen significant 
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hogere antilichaamtiters dan dieren met normale motoriek. Bovendien corre­
leerden na 4 weken de veranderingen van de spiervezels en de hoeveelheid 
ontstekingscellen positief met de antilichaamtiter. We concludeerden dat de 
virus dosis een rol speelt bij CB1 myositis en dat humorale factoren mogelij­
kerwijs een rol spelen in de vroege fase van CB1 myositis (Hoofdstuk 2). 
Vervolgens bestudeerden we de rol van humorale immuunmechanismen meer 
in detail. Twee, 4 en 8 weken na inoculatie werd serum onderzocht op aanwe­
zigheid van circulerende immuuncomplexen (Raji cel test), hemoly tische com­
plement activiteit (CH50 titer) en anticytoplasmatische autoantilichamen 
(Western blotting en immunoprecipitatie) in relatie tot de hoeveelheid ontste­
kingscellen en de hoeveelheid necrotische spiervezels. Na 2,4 en 8 weken was 
er een positieve correlatie tussen hoeveelheid necrotische spiervezels en hoe­
veelheid ontstekingscellen. Vanaf 2 weken konden we matige hoeveelheden 
circulerende immuuncomplexen vaststellen in bijna alle geinoculeerde dieren, 
echter zonder correlatie met histologische veranderingen. Behalve een positie­
ve correlatie tussen CH50 titer en spiervezelnecrose (r = 0.60; Ρ = 0.02) na 4 
weken was er geen verband tussen CH50 titer en veranderingen aan de spier­
vezels. Bovendien ware anticytoplasmatische en andere autoantilichamen 
afwezig. We concludeerden dat er geen correlatici bewijs was voor de betrok­
kenheid van deze complexen bij de pathogenese, noch voor een rol van com­
plement of anticytoplasmatische antilichamen. De positieve correlatie tussen 
hoeveelheid ontstekingscellen en hoevelheid necrotische spiervezels onder­
streept het belang van cellulaire mechanismen (Hoofdstuk 3). 
Teneinde nadere aanwijzingen omtrent de pathogenese van CB1 myositis te 
verkrijgen, verrichtten we een gedetailleerde kwalitatieve en kwantitatieve 
analyse van histologische afwijkingen in dwarsdoorsnedes van hamstring-, 
quadriceps- en gluteusspieren 1, 2, 4, 8 en 16 weken na inoculatie. Het aantal 
mononucléaire ontstekingscellcn, necrotische spiervezels, atrofische vezels en 
vezels met centrale kernen werd gekwantificeerd, en de bevindingen tijdens 
acute virale myositis (1 en 2 weken) werden vergeleken met die tijdens CB1 
myositis (4 tot 16 weken). In kwalitatief opzicht waren de afwijkingen in wezen 
ongewijzigd van 1 tot 16 weken: binnendringen (infiltratie) van mononucléai-
re ontstekingscellen, spiervezelnecrose, vezelatrofie, fascikelgewijs voorko-
men van afwijkingen en perifasciculaire atrofie. Mononucléaire ontstekings-
cellen drongen zowel necrotische als normaal ogende vezels binnen, maar 
necrotische vezels beduidend vaker. Bij kwantitatief onderzoek bleek dat ham-
stringspieren in alle opzichten erger waren aangedaan dan quadriceps- of glu-
teusspieren. Ook waren na 4,8 en 16 weken infiltrarne van mononucléaire cel-
len en necrose significant minder dan na 1 en 2 weken. Op equidistante 
doorsnedes bleek dat abnormale spierfascikels over hun hele lengte afwijkend 
waren, met slechts kleine variaties in het verloop van de spier. Op grond van 
deze bevindingen concludeerden we dat CB1 myositis inderdaad een chroni-
sche aandoening is met een minimale duur van 16 weken, en dat de aanwe-
zigheid van ontstekingscellen en vezelnecrose de benaming 'myositis' recht-
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vaardigt, zij het met laag-gradige ziekteactiviteit. De histopathologische ken-
merken van CB1 myositis vertonen meer overeenkomst met die van dermato-
myositis dan met die van polymyositis. Daarenboven suggereren de histopa-
thologische overeenkomsten tussen CB1 myositis en de voorafgaande fase van 
virale myositis dat gemeenschappelijke of nauw verwante processen werk-
zaam zijn (Hoofdstuk 4). 
Om de pathogenese op weefselniveau te verduidelijken, werden in een immu-
nohistochemische studie met behulp van monoclonale antilichamen de infil-
trerende ontstekingscellen nader gekarakerterizeerd en werd met behulp van 
polyclonale antilichamen gezocht naar neerslagen van immuunglobulines en 
complement. Na inoculatie van 300 pfu werden bij zieke dieren hamstring-
spieren verwijderd na 1,2,4 en 8 weken. Dwarsdoorsnedes werden achtereen-
volgens gekleurd op C3c, IgG, IgM, CD4, CD8a, CD3, CD45R, en CD25. Op alle 
tijdstippen waren veel meer CD4+ cellen aanwezig dan CD8a+ cellen, met 
navenant lage CD4+/CD8a+ ratio's. Alleen CD4+ cellen invadeerden spierve-
zels, necrotische vaker dan niet-necrotische. Na 2 en 4 weken was het percen-
tage CD4+ cellen in endomysiale infiltra ten groter dan in perivasculaire Infilt-
raten, hoewel in endomysiale infiltraten het percentage CD8a+ cellen naarmate 
de ontsteking meer chronisch werd. In perivasculaire infiltraten was na 4 
weken het percentage CD8a+ cellen hoger dan na 2 weken. Eenmaal werd een 
venule gezien met IgM positieve neerslag in de wand. We concludeerden dat 
zeer waarschijnlijk CD4+ cellen, en niet CD8a+ cellen, een doorslaggevende rol 
spelen bij spiervezelbeschadiging, en dat mogelijk een immunologisch geme-
dieerde afwijking van kleine bloedvaten (mede) tot ischaemie en necrose leidt 
(Hoofdstuk 5). 
Op grond van niet gekwantificeerde observaties werd door anderen aangeno-
men dat bij CB1 myositis de rechter achterpoot vaker en ernstiger was aange-
daan dan de linker. Om nu deze vermeende asymmetrie met meer zekerheid 
aan te tonen, observeerden we in een volgend experiment houding, beweeg-
lijkheid en gang van geinoculeerde muizen. Na 2 en 4 weken werd per dier de 
motorische stoornis van de rechter achterpoot kwantitatief vergeleken met die 
van de linker (asymmetriescore), en kwantificeerden we in beide hamstring-
spieren cellulaire infiltratie en spiervezelnecrose. Motorische asymmetrieen 
werden reeds gezien tijdens de fase van acute myositis, zodra een stoornis van 
de achterpootfunctie optrad, en dieren met een asymmetrische functiestoornis 
behielden die asymmetrie gedurende de hele observatieperiode. Twee weken 
na inoculatie was het aantal muizen met een overwegend rechtszijdige achter-
pootstoomis significant hoger dan dat met een overwegend linkszijdige stoor-
nis. Echter, op de tijdstippen twee en vier weken waren infiltratie en necrose in 
spieren uit achterpoten met de overwegende motorische stoornis niet hoger 
dan in spieren van de contralaterale achterpoten; evenmin was de infiltratie in 
rechtszijdige spieren hoger dan in linkszijdige, noch necrose op tijdstip vier 
weken. Wel waren op tijdstip vier weken rechtszijdige spieren meer necrotisch 
dan linkszijdige. Op grond van deze bevindingen concludeerden wij dat de 
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asymmetrische functiestoornis van de achterpoten niet berust op een ernstiger 
ontsteking van de spieren aan de rechter zijde, maar wellicht op een preferent 
gebruik van de linker achterpoot, ten gevolge van 'linkspotigheid'van de CD1 
Swiss muis. Wij suggereerden dat in de Swiss muis linkspotigheid is geasso-
cieerd met verhoogde vatbaarheid voor CB1 myositis (Hoofdstuk 6). 
In het laatste hoofdstuk van dit deel gaven wij een review van de momenteel 
beschikbare gegevens over CB1 myositis, bespraken wij mogelijke pathogène 
mechanismen en onderwierpen we de rol van CB1 myositis als model voor inf-
lammatoire myopathieen aan een kritische beschouwing. We stelden vast dat 
er weinig argumenten zijn om CB1 myositis te beschouwen als model voor 
polymyositis, maar dat het veeleer als model voor dermatomyositis kan wor-
den gebruikt. Wij suggereerden dat de waarde van CB1 myositis vooral gele-
gen kan zijn in het vermogen om verschillende aspecten van inflammatoire 
spierziekten in het algemeen te onderzoeken. 
Studies bij de mens 
In een onderzoek betreffende de etiopathogenese van polymyositis en derma-
tomyositis bestudeerden we virale persistentie. Met een PCR techniek zochten 
we naar viraal RNA in spieren van 10 volwassen patiënten met polymyositis 
en 5 met dermatomyositis, allen met actieve ziekte. Bij de PCR werden primers 
gebruikt met een hoge specificiteit voor enterovirus en encephalomyocarditis-
virus (EMC) RNA, gevolgd door Southern-blot hybridisatie met een oligonu-
cleotide probe gericht tegen het interne deel van het geamplificeerde product. 
PCR gericht tegen het Abelson tyrosine kinase mRNA diende als interne con-
trole voor de aanwezigheid en kwaliteit van het RNA. In geen enkele spier-
biopsie kon specifieke amplificatie van enterovirus of EMC RNA worden vast-
gesteld, ondanks een gevoeligheid van ongeveer 30 pfu voor enterovirus en 
100 pfu voor EMC. Southern-blot hybridisatie bevestigde de resultaten: posi-
tieve controles hybridiseerden wel met de oligonucleotide probe, maar geen 
signaal werd verkregen bij spierweefsel. Wij konden dus geen enterovirus of 
EMC RNA aantonen in spieren van patiënten met actieve polymyositis en der-
matomyositis. Deze bevindingen gaven geen steun aan de opvatting dat per-
sistentie van viraal RNA een rol speelt bij polymyositis of dermatomyositis 
(Hoofdstuk 8). 
In de volgende twee hoofdstukken beschreven we een tweetal diagnostische 
studies. Ten eerste onderzochten we de diagnostische opbrengst van automa-
tische decompositie-electromyografie (automatic decomposition electromyo-
graphy, ADEMG) bij patiënten met polymyositis, dermatomyositis en inclu-
sion body myositis. ADEMG is een commercieel verkrijgbaar software pakket 
met bijgeleverde referentiewaarden dat de objectieve meting van motor unit 
actiepotentialen (MUAPs) mogelijk maakt. Wij verrichtten ADEMG in de 
biceps brachii-spier en vergeleken de resultaten met die van controle personen 
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en met de resultaten van conventioneel EMG van biceps en andere spieren. 
Verlaagde gemiddelde waarden voor de duur van de MUAPs kwamen vaker 
voor bij patiënten met myositis dan bij controles; de overige MUAP kenmerken 
verschilden niet. Bij de myositis-patienten kwamen verlaagde gemiddelde 
waarden voor amplitude en verhoogde waarden voor het aantal 'turns' min-
der vaak voor op ADEMG, dan corresponderende waarden op conventioneel 
biceps EMG. Verlaagde gemiddelde waarden voor duur en amplitude, en ver-
hoogde gemiddelde waarden voor het aantal 'turns' kwamen minder vaak 
voor op ADEMG, dan corresponderende afwijkingen op conventioneel EMG 
van vier per individu gekozen spieren. De algehele beoordeling van het 
ADEMG resulteerde in de diagnose 'mogelijke myopathie' bij 1 patient en 
'waarschijnlijke myopathie' bij 8 patiënten, terwijl de algehele beoordeling van 
het conventioneel EMG leidde tot de diagnose 'verdacht voor myositis' bij 13 
patiënten. Wij concludeerden dat, hoewel meting van gemiddelde MUAP 
duur kan bijdragen tot het stellen van de diagnose myositis, onze resultaten 
niet pleiten voor het gebruik van biceps brachii ADEMG en de bijgeleverde 
referentiewaarden bij de diagnostiek van inflammatoire spierziekten 
(Hoofdstuk 9). 
Daarna beschreven we ons onderzoek naar de incidentie van zg. 'rimmed' 
basofiele vacuolen (RBV) en 15-21 nm filamenteuze insluitsels (filamentous 
inclusions) bij neuromusculaire aandoeningen, anders dan inclusion body 
myositis (IBM), en bepaalden we de diagnostische waarde van RBV kwantifi-
katie bij de differentiële diagnose van IBM. Daartoe bekeken we de verslagen 
van 1600 spierbiopten op de vermelding van RBV en 750 biopsieverslagen op 
de vermelding van filamenteuze insluitsels. Het aantal RBV-positieve vezels 
per 10 mm2 - the RBV-vezel dichtheid - werd bepaald. De incidentie bij niet-
IBM spierbiopten bedroeg 8,8 per 1000. De meest voorkomende diagnostische 
categorieën waren neurogene aandoeningen en limb girdle spierdystrofie. Bij 
de IBM patiënten lag de RBV-vezeldichtheid tussen 10,4 en 63,1 en was hoger 
dan bij neurogene aandoeningen (0,9 tot 4,4) en limb girdle spierdystrofie (1,1 
tot 2,7). De hoogste waarde werd gezien bij een patient met rigid spine syn-
droom (205,8). Filamenteuze insluitsels kwamen voor bij 2,7 per 1000 niet-IBM 
biopten, waaronder familiaire oculofaryngeale spierdystrofie met distale myo-
pathie (OSD-DM), rigid spine syndroom, zure maltase deficiëntie en amyloid 
neuropathie. RBV en filamenteuze insluitsels samen kwamen voor in rigid 
spine syndroom en familiaire OSD-DM. Aldus bleek zowel voor RBV als voor 
filamenteuze insluitsels een zeer lage incidentie in niet-IBM neuromusculaire 
aandoeningen. De RBV-vezeldichtheid kan bijdragen tot de differentiatie van 
IBM ten opzichte van andere neurogene aandoeningen en limb girdle spierdy-
strofie. 
Tenslotte verrichtten we twee therapeutische studies bij patiënten met idiopat-
hische spierontsteking en onvoldoende verbetering na conventionele immu-
nosuppressieve behandeling. Het eerste onderzoek betreft drie patiënten met 
langzaam progressieve polymyositis en onvoldoende of slechts tijdelijke 
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respons op prednison, azathioprine of plasmaferese, en toenemende spier-
zwakte en verhoogde serumconcentraties van creatine kinase (CK). Wij behan-
delden hen met cyclosporine A, 6 mg/kg /dag , in combinatie met lage dosis 
prednison. Er waren geen licht- of electronenmicroscopische aanwijzingen 
voor IBM. Na 30 weken was bij een patient de CK concentratie nagenoeg 
genormalizeerd, terwijl die bij de andere twee ongewijzigd was. Alle drie 
patiënten lieten bij handdynamometrie een matige toename van de maximale 
spierkracht in 6 van 8 proximale spieren zien, maar subjectieve verbetering van 
ADL-functies (activiteiten van het dagelijks leven), die kon worden toege-
schreven aan de medicatie, was er niet. Ernstige bijwerkingen waren progres-
sieve nierfunctiestoomis en hoge bloeddruk, waardoor bij 2 patiënten cyclo-
sporine A moest worden gestaakt. We concludeerden dat de matige toename 
van de maximale kracht in de proximale spieren niet opwoog tegen de bijwer-
kingen. 
In de tweede therapeutische studie beschreven we een 56-jarige vrouw met kli-
nisch progressieve IBM, die niet of nauwelijks baat had bij prednison, metho-
trexaat, azathioprine, cyclosporine A, lymfaferese en cyclofosfamide. We 
gaven gedurende 3 jaar chlorambucil, 8 tot 2 mg/dag, onder voortzetting van 
prednison gedurende 1 jaar (15 mg/dag). Na zeven maanden was de toene-
mende verslechtering gestopt en waren de CK concentraties duidelijk gedaald. 
Na 1 jaar was er een subjectieve verbetering van de motorische functies, een 
significante toename van de spierkracht volgens de MRC-methode (Medical 
Research Council), en een verdere daling van de serum CK concentratie. Na 3 
jaar chlorambucilbehandeling waren de motorische functies en spierkracht 
(MRC) ongewijzigd in vergelijking tot 1 jaar therapie, en was de CK concen-
tratie nagenoeg genormalizeerd. De gunstige resultaten van lange-termijnbe-
handeling bij deze patient met IBM bevestigt de opvatting dat gezien de lang-
zame progressie van IBM immunosuppressieve behandeling van 3 maanden te 
kort kan zijn om klinisch waarneembare resultaten te boeken. Wij vinden het 
daarom aangewezen om bij IBM patiënten met duidelijke klinische verslechte-
ring een lang termijnbehandeling met een cytotoxisch middel zoals chloram-
bucil te overwegen. 
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